CA2512479A1

CA2512479A1 - Secreted and transmembrane polypeptides and nucleic acids encoding the same

Info

Publication number: CA2512479A1
Application number: CA002512479A
Authority: CA
Inventors: Luc Desnoyers; Dan L. Eaton; Audrey Goddard; Paul J. Godowski; Austin L. Gurney; James Pan; Timothy A. Stewart; Colin K.. Watanabe; William I. Wood; Zemin Zhang
Original assignee: Individual
Current assignee: Genentech Inc
Priority date: 1999-03-23
Filing date: 2000-03-01
Publication date: 2000-09-28
Also published as: CA2510806A1; CA2510797C; CA2510797A1; CA2510931A1; CA2512291A1; CA2510982A1

Abstract

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heteralogous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention,

Description

SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE
SAME
FIELD OF THE INVENTION
The present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides.
BACKGROUND OF THE INVENTION
Extracellular proteins play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of action in the extracellular environment.
Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors. Most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins.
Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic agents. Efforts are being undertaken by both industry and academia to identify new, native secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., Proc. Natl. Acad. Sri. 93:7108-7113 (1996); U.S. Patent No. 5,536,637)].
Membrane-bound proteins and receptors can play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins.
Such membrane-bound proteins and cell receptors include; but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesin molecules like selectins and integrins. For instance, transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and nerve growth factor receptor.

Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.
Efforts are being undertaken by both industry and academia to identify new, native receptor or membrane-bound proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor or membrane-bound proteins.
1. PR01484 Adipose differentiation is accompanied by changes in cellular morphology, a dramatic accumulation of intracellular lipid and activation of a specific program of gene expression (Liang et al., J. Biol. Chem.
271:10697-10703 ( 1996)). Adipose complement-related protein is a protein whose expression is highly induced during adipocyte differentiation and which shares significant homology with subunits of complement factor Clq, collagen alpha 1(x) and the brain-specific facto cerebellin (Scherer et al., J. Biol. Chem. 270:26746-26749 ( 1995)). While the function of adipocyte complement-related protein is presently unlatown, the tissue-specific expression thereof suggests that this protein functions as a novel signaling molecule for adipose tissue. As such, there is significant interest in identifying and characterizing novel polypeptides having homology to adipocyte complement-related protein. We herein describe the identification and characterization of novel polypeptides having homology to adipocyte complement-related protein, designated herein as PR01484 polypeptides.

2. PR04334 Plasma cell membrane glycoprotein PC-1 is of interest. The cloning of PC-1 is described in the art, i.e., see Buckley, et al., J. Biol. Chem., 265(29):17506-11 (1990) and W09519570-A. W09519570-A
describes the human insulin receptor tyrosine kinase inhibitor PC-1. It is reported that PC-1 is useful in the diagnosis and treatment of diseases involving inappropriate insulin receptor tyrosine kinase inhibitor expression such as non-insulin dependent raellitus. Thus, proteins having homology to PC-1 are of interest.

3. PROI122 It has been reported that the cytokine interleukin 17 (IL-17) stimulates epithelial, endothelial, and fibroblastic cells to secrete cytokines such as IL-6, IL-8, and granulocyte-colony-stimulating factor, as well as prostaglandin E2. Moreover, it has been shown that when cultured in the presence of IL-17, fibroblasts could sustain proliferation of CD34+ preferential maturation into neutrophils. Thus it has been suggested that IL-17 constitutes an early initiator of the T cell-dependent inflammatory reaction and/or an element of the cytokine network that bridges the immune system to hematopoiesis. See, Yao, et al., J.
Immunol., 155(12):5483-5486 (1995); Fossiez, et al., J. Exp. Med., 183(6):2593-2603 (1996); Kennedy, et al., J. Interferon Cytokine Res., 16(8):611-617 (1996). Thus, proteins related to IL-17, including CTLA-8, which has been mistaken for IL-17 (see Kennedy, su ra are of interest.

Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.
Efforts are being undertaken by both industry and academia to identify new, native receptor or membrane-bound proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor or membrane-bound proteins.
1. PR01484 Adipose differentiation is accompanied by changes in cellular morphology, a dramatic accumulation of intracellular lipid and activation of a specific program of gene expression (Liang et al., J. Biol. Chem.
271:10697-10703 (1996)). Adipose complement-related protein is a protein whose expression is highly induced during adipocyte differentiation and which shares significant homology with subunits of complement factor C 1 q, collagen alpha 1(x) and the brain-specific facto cerebellin (Scherer et al., J. Biol. Chem. 270:26746-26749 (1995)). While the function of adipocyte complement-related protein is presently unlrnown, the tissue-specific expression thereof suggests that this protein functions as a novel signaling molecule for adipose tissue. As such, there is significant interest in identifying and characterizing novel polypeptides having homology to adipocyte complement-related protein. We herein describe the identification and characterization of novel polypeptides having homology to adipocyte complement-related protein, designated herein as PR01484 polypeptides.
2. PR04334 Plasma cell membrane glycoprotein PC-1 is of interest. The cloning of PC-1 is described in the art, i.e., see Buckley, et al., J. Biol. Chem., 265(29):17506-11 (1990) and W09519570-A. W09519570-A
describes the human insulin receptor tyrosine kinase inhibitor PC-1. It is reported that PC-1 is useful in the diagnosis and treatment of diseases involving inappropriate insulin receptor tyrosine kinase inhibitor expression such as non-insulin dependent mellitus. Thus, proteins having homology to PC-1 are of interest.
3. PROI122 It has been reported that the cytokine interleukin 17 (IL-17) stimulates epithelial, endothelial, and fibroblastic cells to secrete cytokines such as IL-6, IL-8, and granulocyte-colony-stimulating factor, as well as prostaglandin E2. Moreover, it has been shown that when cultured in the presence of IL-17, fibroblasts could sustain proliferation of CD34+ preferential maturation into neutrophils. Thus it has been suggested that IL-17 constitutes an early initiator of the T cell-dependent inflammatory reaction and/or an element of the cytokine network that bridges the immune system to hematopoiesis. See, Yao, et al., J.
Immunol., 155(12):5483-5486 (1995); Fossiez, et al., J. Exp. Med., 183(6):2593-2603 (1996); Kennedy, et al., J. Interferon Cytokine Res., 16(8):611-617 (1996). Thus, proteins related to IL-17, including CTLA-8, which has been mistaken for IL-17 (see Kennedy, supra) are of interest.

4. PR01889 E48 antigen protein is a cysteine-rich GPI-anchored membrane protein that belongs to the LY-6 family of human proteins (see, e.g., WO 96/35808). The E48 antigen serves as a marker for squamous cells, exhibits biological activity of cell-cell/cell-matrix adhesion and is a target for antibody-based immunotherapy. The amino acid sequence of the E48 antigen protein has previously been deduced from a cDNA clone which was obtained from a squamous cell carcinoma of the head and neck. As such, the E48 antigen serves as a potential target for the treatment of squamous cell cancer.
We herein describe the identification and characterization of novel polypeptides having homology to E48 antigen protein, designated herein as PR01889 polypeptides.

5. PROl 90 The recognition of carbohydrates by lectins has been found to play an important role in various aspects of eukaryotic physiology. A number of different animal and plant lectin families exist, but it is the calcium dependent, or type C, lectins that have recently garnered the most attention.
For example, the recognition of carbohydrate residues on either endothelial cells or leukocytes by the selectin family of calcium dependent lectins has been found to be of profound importance to the trafficking of leukocytes to inflammatory sites. Lasky, L., Ann. Rev. Biochem., 64 113-139 (1995). The biophysical analysis of these adhesive interactions has suggested that lectin-carbohydrate binding evolved in this case to allow for the adhesion between leukocytes and the endothelium under the high shear conditions of the vasculature. Thus, the rapid on rates of carbohydrate recognition by such lectins allows for a hasty acquisition of ligand, a necessity under the high shear of the vascular flow. The physiological use of type C lectins in this case is also supported by the relatively low affinities of these interactions, a requirement for the leukocyte rolling phenomenon that has been observed to occur at sites of acute inflammation. The crystal structures of the mannose binding protein (Weir et al. , cienc 254, 1608-1615 [1991]; Weis et al., Nature 360127-134 [1992]) and E-selectin (Graves et al., Nature 367(6463), 532-538 [1994]), together with various mutagenesis analyses (Erbe et al., J. Cell.
Biol. 11 (1), 215-227 (1992];
Drickamer, Nature 360, 183-186 [1992]; Iobst et al., J. Biol. Chem. 169(22), 15505-1551I (1994]; Kogan et al., J. Biol. Chem. 270(23), 14047-14055 [1995]), is consistent with the supposition that the type C lectins are, in general, involved with the rapid recognition of clustered carbohydrates.
Together, these data suggest that type C lectins perform a number of critical physiological phenomena through the rapid, relatively low affinity recognition of carbohydrates.
Given the obvious importance of the lectin proteins in numerous biological processes, efforts are currently being trade to identify novel lectin proteins or proteins having sequence homology to lectin proteins.
We herein describe the identification and characterization of novel polypeptides having homology to a l~tin protein, designated herein as PR01890 polypeptides.

6. PR01887 Enzymatic proteins play important roles in the chemical reactions involved in the digestion of foods, the biosynthesis of macromolecules, the controlled release and utilization of chemical energy, and other processes necessary to sustain life. Enzymes have also been shown to play important roles in combating various diseases and disorders. For example, liver carboxylesterases have been reported to assist in sensitizing human tumor cells to the cancer prodrugs. Danks et al., report that stable expression of the cDNA encoding a carboxylesterase in Rh30 human rhabdomyosarcoma cells increased the sensitivity of the cells to the CPT-11 cancer prodrug 8.1-fold. Cancer Res. (1998) 58(1):20-22. The authors propose that this prodivg/enzyme combination could be exploited therapeutically in a manner analogous to approaches currently under investigation with the combinations of ganciclovir/herpes simplex virus thymidine Itinase and 5-fiuorocytosinelcytosine deaminase.
van Pelt et al. demonstrated that a 55 kD human liver carboxylesterase inhibits the invasion of Plasmodium falciparum malaria sporozoites into primary human hepatocytes in culture. J
Hepatol (1997) 27(4):688-698.
Carboxylesterases have also been found to be of importance in the detoxification of drugs, pesticides and other xenobiotics. Purified human liver carboxylesterases have been shown to be involved in the metabolism of various drugs including cocaine and heroin. Prindel et al. describe the purification and cloning of a broad substrate specificity human l fiver carboxylesterase which catalyzes the hydrolysis of cocaine and heroin and which may play an important role in the degradation of these drugs in human tissues.
J. BioI. Chem. (1997) 6:272(23):14769-14775. Brzenzinski et al. describe a spectrophotometric competitive inhibition assay used to IS identify drug or environmental esters that are metabolized by carboxylesterases. Drug Metab Dispos (1997) 25(9):1089-1096.
As additional background information on carboxyIesterases, Kroetz et al.
(Biochemistry, (1993) 32(43):11606-17) reported the cDNA cloning and characterization of human liver carboxylesterases. Aida et al.
(Biochim Biophys Acta (1993) 1174(1):72-4) reported the cDNA cloning and characterization of a male-predominant carboxylesterase in mouse liver carboxylesterases.
In light of the important physiological roles played by carboxylesterases, efforts are being undertaken by both industry and academia to identify new, native carboxylesterase homologs. We herein describe the identification and characterization of a novel polypeptide having homology to carboxylesterase.

7. PR01785 Antioxidant enzymes are thought to play a crucial role in the survival of the parasite, Schistosoma mansoni, during its migration through the tissues of a definitive host.
Recently, one such enzyme, glutathione peroxidase was cloned. Roche, et al., Gene, 138:149-152 (1994), accession number GSHC SCHMA.
Glutathione perxodiases are further described in FR2689906-A. Thus, glutathione peroxidases, and the nucleic acids which encode them are useful as diagnostic reagents, vaccines and in assays to find modulators of antioxidant enzymes.

8. PR04353 Semaphorins comprise a large family of proteins implicated in axonal guidance during development.
Semaphorin Y may be used to inhibit peripheral nerve growth. Semaphorin Z is useful as a central nerve extension inhibitor. Semaphorin Z inhibitors can be used as promoters of central nerve regeneration. Thus semaphorins and regulators of semaphorins are of great interest. Kikuchi, et al., Brain Res Mol Brain Res., 51(1-2):229-37 (1997); Shoji, et al., Development, 125(7):1275-83 (1998).
9. PR 4357 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. We herein describe the identification and characterization of novel secreted polypeptides, designated herein as PR04357 polypeptides.

10. PR04405 Efforts are being undertaken by both industry and academia to identify new, native transmembrane receptor proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel transmembrane receptor proteins. We herein describe the identification and characterization of novel transmembrane polypeptides, designated herein as PR04405 polypeptides.

11. PR04356 Glycosylphosphatidylinositol (GPn anchored proteoglycans are generally localized to the cell surface and are thus known to be involved in the regulation of responses of cells to numerous growth factors, cell adhesion molecules and extracelluiar matrix components. The metastasis-associated GPI-anchored protein (MAGPIAP) is one of these cell surface proteins which appears to be involved in metastasis. Metastasis is the form of cancer wherein the transformed or malignant cells are traveling and spreading the cancer from one site to another. Therefore, identifying the polypeptides related to metastasis and MAGPIAP is of interest.

12. PR04352 Cadherins are a large family of transmembrane proteins. Cadherins comprise a family of calcium-dependent glycoproteins that function in mediating cell-cell adhesion in virtually alt solid tissues of multicellular organisms. At least cadherins 1-13 as well as types B, E, EP, M, N, P and R
have been characterized. Among the functions cadherins are known for, with some exceptions, cadherins participate in cell aggregation and are associated with cell-cell adhesion sites. Recently, it has been reported that while all cadherins share multiple repeats of a cadherin specific motif believed to correspond to folding of extracellular domains, members of the cadherin superfamily have divergent structures and, possibly, functions. In particular it has been reported that members of the cadherin superfamily are involved in signal transduction. See, Suzuki, J. Cell Biochem., 61(4):531-542 (1996). Cadherins are further described in Tanihara, et al., J.
Cell Sci., 107(6):1697-1704 (1994), Aberie, et al., J. Cell Biochem., 61(4):514-523 (1996), Obata, et al., Cell Adhes. Commun., 6(4):323-33 (1998) and Tanihara, et al., Cell Adhes. Commun., 2(1):15-26 (1994).
Protocadherins are members of the cadherin superfamily which are highly expressed in the brain. In some studies, protocadherins have shown cell adhesion activity. See, Sano, et al., EMBO J., 12(6):2249-2256 (1993). However, studies have also shown that some protocadherins, such as protocadherin 3 (also referred to as Pcdh3 or pc3), do not show strong calcium dependent cell aggregation activity. See, Sago, et al., Genomics, 29(3):631-640 (1995) for this study and further characteristics of Pcdh3.
Molecules related to pc3 are thus of great interest. Also of great interest is the subtype of desmosomal cadherin described in Koch, et al., Differentiation, 47(1):29-36 (1991).
Of particular interest are proteins having a sequence with homology to that described in Amagai, et al., Cell, 67(5):869-77 (1991). This study describes antibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Also of interest are full-length cadherins. Additionally, proteins having homology to the fat tumor suppressor gene which are novel cadherins are of interest.

13. PR04380 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. We herein describe the identification and characterization of novel secreted polypeptides, designated herein as PR04380 polypeptides.

14. PR04354 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. We herein describe the identification and characterization of novel secreted polypeptides, designated herein as PR04354 polypeptides.

15. PR04408 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. We herein describe the identification and characterization of novel secreted polypeptides, designated herein as PR04408 polypeptides.

16. PR 5737 Interleukin-1 refers to two proteins (IL-1 a and IL-1 (3) which play a key role early in the inflammatory response (for a review, see Dinarello, Blood, 87: 2095-2147 ( 1996) and references therein). Both proteins are made as intracellular precursor proteins which are cleaved upon secretion to yield mature carboxy-terminal 17 kDa fragments which are biologically active. In the case of IL-1(3, this cleavage involves an intracellular cysteine protease, known as ICE, which is required to release the active fragment from the inactive precursor.
The precursor of IL-la is active.
These two proteins act by binding to cell surface receptors found on almost all cell types and triggering a range of responses either alone or in concert with other secreted factors.
These range from effects on proliferation (e.g. fibroblasts, T cells) apoptosis (e.g. A375 melanoma cells), cytokine induction (e.g. of TNF, IL-1, IL-8), receptor activation (e.g. E-selectin), eicosanoid production (e.g. PGE2) and the secretion of degradative enzymes (e.g. collagenase). To achieve these effects, IL-1 activates transcription factors such as NF-KB and AP-I . Several of the activities of IL-1 action on target cells are believed to be mediated through activation of kinase cascades that have also been associated with cellular stresses, such as the stress activated MAP kinase JNK/SAPK and p38.
A third member of the IL-1 family was subsequently discovered which acts as a natural antagonist of IL-la and IL-1(3 by binding to the IL-1 receptor but not transducing an intracellular signal or a biological response. The protein is called IL-1Ra (for IL-1 receptor antagonist) or IRAP
(for IL-1 receptor antagonist protein). At least three alternatively spliced forms of IL-1Ra exist: one encodes secreted protein, and the other two encode intracellular proteins. IL-la, IL-1(i and IL-1Ra exhibit approximately 25-3036 sequence identity with each other and share a similar three dimensional structure consisting of twelve ~i-strands folded into a (i-barrel, with an internal thrice repeated structural motif.
There are three known IL-1 receptor suburuts. The active receptor complex consists of the type I
receptor and IL-1 accessory protein (IL-lltAcP). The type I receptor is responsible for binding of the IL-la, IL-1/3 and IL-IRa ligands, and is able to do so in the absence of the IL-IRAcP. However, signal transduction requires the interaction of IL-la or IL-lei with the IL-IRAcP. IL-IRa does not interact with the IL-IRAcP and hence cannot induce signal transduction. A third receptor subunit, the type II
receptor, binds IL-1 a and IL-1 ~i but cannot transduce signal due its lack of an intracellular domain. Instead, the type II receptor either acts as a decoy in its membrane bound form or as an IL-1 antagonist in a processed, secreted form, and hence inhibits IL-1 activity. The type II receptor weakly binds to IL-lRa.
Many studies using IL-lRa, soluble IL-1R derived from the extracellular domain of the type I IL-I
receptor, antibodies to IL-1 a or IL-1 p, and transgenic knockout mice for these genes have shown that IL-1 plays a role in a number of pathophysiologies (for a review, see Dinarello, Blood, 87: 2095-2147 (1996)). For example, IL-IRa has been shown to be effective in animal models of septic shock, rheumatoid arthritis, graft-versus-host disease (GVHD), stroke, cardiac ischemia, psoriasis, inflammatory bowel disease, and asthma.
In addition, IL-1Ra has demonsuated efficacy in clinical trials for rheumatoid arthritis and GVHD, and is also in clinical trials for inflammatory bowel disease, asthma and psoriasis.
More recently, interleukin-18 (IL-18) was placed in the IL-1 family (for a review, see Dinarello et al, J. Leukocyte Biol., 63: 658-664 (1998)). IL-18 shares the ~i-pleated, barrel-like form of IL-la and IL-lei. In addition, IL-18 is the natural ligand for the IL-1 receptor family member formerly known as IL-1R-related protein (IL-IRrp) (now known as the IL-18 receptor (IL-I8R)). IL-18 has been shown to initiate the inflammatory cytokine cascade in a mixed population of peripheral blood mononuclear cells (PBMCs) by triggering the constitutive IL-18 receptors on lymphocytes and NK cells, inducing TNF production in the activated cells. TNF, in turn, stimulates IL-1 and IL-8 production in CD14+
cells. Because of its ability to induce TNF, IL-i, and both C-C and C-X-C chemokines, and because IL-18 induces Fas ligand as well as nuclear translocation of nuclear factor 6B (NF-6B), IL-18 ranks with other pro-inflammatory cytokines as a likely contributor to systemic and local inflammation.

WO 00/56$89 PCT/US00/OSfi01 17. PRO 25 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. We herein describe the identification and characterization of novel secreted polypeptides, designated herein as PR04425 polypeptides.

18. PR05990 The secretogranin proteins (e.g. secretogranin I and II) are found in secretory granules in a variety of endocrine cells and neurons. Schimmel, A. et al., FEBS Lett. 314(3):375-80 (1992); Gerdes, H. H. et al., ~
Biol. Chem. 264(20): 12009-15. A possible function of the secretogranin proteins is the packaging of secretory products, including regulatory peptides. Chanat, E. et al., FEBS IxttLeft.
351(2):225-30 (1994); Rosa, P. et al., J. Cell. Biol. 101(5):1999-2011 (1985); Gotr, S. U. et al., Am. J. PhvsioI.
257(2):E247-54 (1989).
Secretogranins have been successfully used as biological markers in a number of contexts. For example, secretogranin II has gained importance as an immunohistochemical marker for endocrine neoplasms. See Fischer-Colbrie, R. et al., J. Biol. Chem. 265(16):9208-13 (1990). Eder et al, found that the ratio of secretogranin I1 to chromogranins was remarkably constant within patient populations, and suggest that the ratio may be used as a parameter to standardize CSF levels of other peptides, such as neuropeptides. Eder, U., et al., J. Neural Transm., 105(1):39-51 (1998).
We herein describe the identification and characterization of novel polypeptides having sequence similarity to secretogranin, designated herein as PR05990 polypeptides.

19. PR06030 Efforts are being undertaken by both industry and academia to identify new, native transmembrane receptor proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel transmembrane receptor proteins. We herein describe the identification and characterization of novel transmembrane polypeptides, designated herein as PR06030 polypeptides.

20. PR04424 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. We herein describe the identification and characterization of novel secreted polypeptides, designated herein as PR04424 polypeptides.

21. PR04422 Lysozyme is a protein which is widely distributed in several human tissues and secretions including milk, tears and saliva. It has been demonstrated to hydrolyze linkages between N-acetylglucosamines. It has been demonstrated to be an inhibitor of chemotaxis and of the production of toxic oxygen free radicals and may also have some role in the calcification process. As such, there is substantial interest in identifying novel WO 00/56889 Ptr'f/(JS00/05601 polypeptides having homology to lysoryme. Nakano and Graf, Biochim. Biophys Acta, 1090(2):273-6 (1991).

22. - PR04430 Efforts are being undertaken by both industry and academia to identify new, native secreted proteins.
Many of these efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. We herein describe the identification and characterization of novel secreted polypeptides, designated herein as PR04430 polypeptides.

23. PR04499 Efforts are being undertaken by both industry and academia to identify new, native transmembrane receptor proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel transmembrane receptor proteins. We herein describe the identification and characterization of novel transmembrane polypeptides, designated herein as PR04499 polypeptides.
SUMMARY OF THE INVENTION
1. PR01484 A cDNA clone (DNA44686-1653) has been identified, having homology to nucleic acid encoding adipocyte complement-related protein that encodes a novel poiypeptide, designated in the present application as "PR01484".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01484 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at Ieast about 80~ sequence identity, preferably at least about 8530 sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 ~ sequence identity to (a) a DNA molecule encoding a PR01484 polypeptide having the sequence of amino acid residues from about 1 or about 23 to about 246, inclusive of Figure 2 (SEQ ID
N0:2), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR01484 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 77 or about 143 and about 814, inclusive, of Figure 1 (SEQ ID NO:1). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80'~ sequence identity, preferably at least about 8596 sequence identity, more preferably at least about 90q6 sequence identity, most preferably at least about 95:~ sequence identity to (a) a DNA mol~ule encoding the same mature polypeptide encoded by the human protein eDNA in ATCC
Deposit No. 203581 (DNA44686-1653) or (b) the complement of the nucleic acid molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203581 (DNA44686-1653).

In still a further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 23 to about 246, inclusive of Figure 2 (SEQ ID N0:2), or (b) the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least 600 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA
molecule encoding a PR01484 polypeptide having the sequence of amino acid residues from 1 or about 23 to about 246, inclusive of Figure 2 (SEQ ID N0:2), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85 % sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01484 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 22 in the sequence of Figure 2 (SEQ
ID N0:2).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85 % positives, more preferably at least about 90% positives, most preferably at least about 95%
positives when compared with the amino acid sequence of residues 1 or about 23 to about 246, inclusive of Figure 2 (SEQ ID N0:2), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR01484 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 1 (SEQ ID NO:1).
In another embodiment, the invention provides isolated PR01484 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
In a specific aspect, the invention provides isolated native sequence PR01484 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 23 to about 246 of Figure 2 (SEQ ID N0:2).
In another aspect, the invention concerns an isolated PR01484 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 23 to about 246, inclusive of Figure 2 (SEQ ID N0:2).
In a further aspect, the invention concerns an isolated PR01484 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85 %
positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 23 to about 246, inclusive of Figure 2 (SEQ 1D N0:2).
In yet another aspect, the invention concerns an isolated PR01484 polypeptide, comprising the sequence of amino acid residues 1 or about 23 to about 246, inclusive of Figure 2 (SEQ
ID N0:2), or a fragment thereof sufficient to provide a binding site for an anti-PR01484 antibody. Preferably, the PR01484 fragment retains a qualitative biological activity of a native PR01484 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR01484 polypeptide having the sequence of amino acid residues from about 1 or about 23 to about 246, inclusive of Figure 2 (SEQ ID NO:
3), or (b) the complement of the DNA molecule of (a), and if the test DNA
molecule has at least about an 80%
sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90%
sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
2. PR04334 A cDNA clone (DNA59608-2577) has been identified that encodes a novel polypeptide having homology to PC-1 and designated in the present application as "PR04334".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04334 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04334 polypeptide having the sequence of amino acid residues from 1 or about 23 to about 440, inclusive of Figure 4 (SEQ ID N0:9), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04334 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 150 and about 1403, inclusive, of Figure 3 (SEQ ID N0:8). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80 °6 sequence identity, preferably at least about 85 ~
sequence identity, more preferably at least about 90 % sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203870 (DNA59608-2577), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203870 (DNA59608-2577).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 9096 sequence identity, most preferably at least about 95 % sequence identity to the sequence of amino acid residues from about 23 to about 440, inclusive of Figure 4 (SEQ ID
N0:9), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nuchtides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04334 polypeptide having the sequence of amino acid residues from about 23 to about 440, inclusive of Figure 4 (SEQ ID
N0:9), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 %
positives when compared with the amino acid sequence of residues 23 to about 440, inclusive of Figure 4 (SEQ ID
N0:9), or (b) the complement of the DNA of (a).
IS Another embodiment is directed to fragments of a PR04334 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04334 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04334 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 23 through 440 of Figure 4 (SEQ ID
N0:9).
In another aspect, the invention concerns an isolated PR04334 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 23 to about 440, inclusive of Figure 4 (SEQ ID
N0:9).
In a further aspect, the invention concerns an isolated PR04334 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 %
positives, more preferably at least about 90°'o positives, most preferably at least about 9596 positives when compared with the amino acid sequence of residues 23 through 440 of Figure 4 (SEQ ID N0:9).
In yet another aspect, the invention concerns an isolated PR04334 polypeptide, comprising the sequence of amino acid residues 23 to about 440, inclusive of Figure 4 (SEQ ID N0:9), or a fragment thereof sufficient to provide a binding site for an anti-PR04334 antibody. Preferably, the PR04334 fragment retains a qualitative biological activity of a native PR04334 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04334 polypeptide having the sequence of amino acid residues from about 23 to about 440, inclusive of Figure 4 (SEQ ID N0:9), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80~ sequence identity, preferably at least about an 85~ sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 ~ sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
3. PR01122 A cDNA clone (DNA62377-1381) has been identified, having sequence identity with CTLA-8 that encodes a novel polypeptide, designated in the present application as "PR01122."
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01122 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80°.& sequence identity, preferably at least about 85 ~ sequence identity, more preferably at least about 90 % sequence identity, most preferably at least about 95 q& sequence identity to (a) a DNA molecule encoding a PR01122 polypeptide having the sequence of amino acid residues from 1 or about 19 to about 197, inclusive of Figure 6 (SEQ ID NO:11), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR01122 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 104 and about 640, inclusive, of Figure 5 (SEQ ID NO:10). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80 °6 sequence identity, preferably at least about 85 %
sequence identity, more preferably at least about 90~ sequence identity, most preferably at least about 95~ sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203552 (DNA62377-1381), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203552 (DNA62377-1381).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80~ sequence identity, preferably at least about 85~ sequence identity, more preferably at least about 90 ~ sequence identity, most preferably at least about 95 ~O sequence identity to the sequence of amino acid residues from about 19 to about 197, inclusive of Figure 6 (SEQ ID
NO:11), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01122 polypeptide having the sequence of amino acid residues from about 19 to about 197, inclusive of Figure 6 (SEQ ID NO:11), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 90 sequence identity, preferably at least about an 85 ~ sequence identity, more preferably at least about a 90 ~

sequence identity, most preferably at least about a 95~ sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80 ~ positives, preferably at least about 85 °6 positives, more preferably at least about 9096 positives, most preferably at least about 95 ~
positives when compared with the amino acid sequence of residues I9 to about 197, inclusive of Figure 6 (SEQ ID
NO:11 ), or (b) the complement of the DNA of (a).
In another embodiment, the invention provides isolated PR01122 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR01122 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 19 through 197 of Figure 6 (SEQ ID
NO:11).
In another aspect, the invention concerns an isolated PR01122 polypeptide, comprising an amino acid sequence having at least about 800 sequence identity, preferably at least about 85% sequence identity, more preferably at least about 909b sequence identity, most preferably at least about 9596 sequence identity to the sequence of amino acid residues 19 to about I97, inclusive of Figure 6 (SEQ ID
NO:I1).
In a further aspect, the invention concerns an isolated PRO 1122 polypeptide, comprising an amino acid sequence scoring at least about 80~ positives, preferably at least about 85 ~
positives, more preferably at least about 9096 positives, most preferably at least about 95 ~ positives when compared with the amino acid sequence of residues 19 through 197 of Figure 6 (SEQ ID NO:11).
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR01122 polypeptide having the sequence of amino acid residues from about 19 to about 197, inclusive of Figure 6 (SEQ ID NO:11), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80~ sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 9096 sequence identity, most preferably at least about a 95~ sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
4. PR 1889 A cDNA clone (DNA77623-2524) has been identified, having homology to nucleic acid encoding E48 antigen protein, that encodes a novel polypeptide, designated in the present application as "PROI889".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01889 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 8090 sequence identity, preferably at least about 85~ sequence identity, more preferably at Least about 909b sequence identity, most preferably at least about 95 ~ sequence identity to (a) a DNA molecule encoding a PRO 1889 poIypeptide having the sequence of amino acid residues from about 1 or about 21 to about 97, inclusive of Figure 8 (SEQ ID

N0:16), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR01889 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 39 or about 99 and about 329, inclusive, of Figure 7 (SEQ ID N0:15). Preferably, hybridization occurs under stringent hybridization and wash conditions.
Tn a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90 % sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203546 (DNA77623-2524) or (b) the complement of the nucleic acid molecule of (a). In a preferred embodiment, the IO nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203546 (DNA77623-2524).
In still a further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85 ~ sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues I or about 21 to about 97, inclusive of Figure 8 (SEQ ID N0:16), or (b) the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least 315 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA
molecule encoding a PR01889 polypeptide having the sequence of amino acid residues from 1 or about 21 to about 97, inclusive of Figure 8 (SEQ 1D N0:16), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80% sequence identity, prefereably at least about an 859 sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 959'o sequence identity to (a) or (b), isolating the test DNA molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01889 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 20 in the sequence of Figure 8 (SEQ
ID N0:16).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80 % positives, preferably at least about $5 9~o positives, more preferably at least about 90:~ positives, most preferably at least about 95 %
positives when compared with the amino acid sequence of residues I or about 21 to about 97, inclusive of Figure 8 (SEQ ID N0:16), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PRO 1889 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 7 (SEQ ID NO:15).
In another embodiment, the invention provides isolated PR01889 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
In a specific aspect, the invention provides isolated native sequence PR01889 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 21 to about 97 of Figure 8 (SEQ ID N0:16).
In another aspect, the invention concerns an isolated PR01889 polypeptide, comprising an amino acid sequence having at least about 80 i6 sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 1 or about 21 to about 97, inclusive of Figure 8 (SEQ ID N0:16).
In a further aspect, the invention concerns an isolated PR01889 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85%
positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 1 or about 21 to about 97, inclusive of Figure 8 (SEQ ID N0:16).
In yet another aspect, the invention concerns an isolated PR01889 polypeptide, comprising the sequence of amino acid residues 1 or about 21 to about 97, inclusive of Figure 8 (SEQ
ID N0:16), or a fragment thereof sufficient to provide a binding site for an anti-PR01889 antibody. Preferably, the PR01889 fragment retains a qualitative biological activity of a native PR018$9 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR01889 polypeptide having the sequence of anuno acid residues from about 1 or about 21 to about 97, inclusive of Figure 8 (SEQ ID N0:16), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 8096 sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 9096 sequence identity, most preferably at least about a 9596 sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
In another embodiment, the invention concerns a method for determining the presence of a PR01889 polypeptide comprising exposing a cell suspected of containing the polypeptide to an anti-PRO 1889 antibody and determining binding of the antibody to the cell.
In yet another embodiment, the present invention relates to a method of diagnosing the presence of a cancerous cell in a mammal, comprising detecting the level of expression of a gene encoding a PROI889 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of lrnown normal tissue cells of the same cell type, wherein a higher expression level in the test sample indicates the presence of a cancerous cell, particularly a cancerous squamous cell, in the mammal.
A further embodiment is a method for identifying a compound capable of inhibiting the expression and/or activity of a PR01889 polypeptide by contacting a candidate compound with a PR01889 polypeptide under conditions and for time sufficient to allow these two compounds to interact. In a specific aspect, either the candidate compound or the PR01889 polypeptide is immobilized on a solid support. In another aspect, the non-immobilized component carries a detectable label.
In a further embodiment, the present invention provides a method of diagnosing tumor in a mammal, comprising detecting the level of expression of a gene encoding a PR01889 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher expression level in the test sample indicates the presence of tumor in the mammal from which the test tissue cells were obtained.
In another embodiment, the present invention provides a method of diagnosing tumor in a mammal, comprising (a) contacting an anti-PROI889 antibody with a test sample of the tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the anti-PR01889 and the PR01889 polypeptide in the test sample. The detection may be qualitative or quantitative, and may be performed in comparison with monitoring the complex formation in a control sample of known normal tissue cells of the same cell type. A
larger quantity of complexes formed in the test sample indicates the presence of tumor in the mammal from which the test tissue cells were obtained. The antibody preferably carries a detectable label. Complex formation can be monitored, for example, by light microscopy, flow cytometry, fluorimetry, or other techniques known in the art. Preferably, the test sample is obtained from an individual mammal suspected to have neoplastic cell growth or proliferation (e.g., cancerous cells).
In another embodiment, the present invention provides a cancer diagnostic kit, comprising an anti-PR01889 antibody and a carrier (e.g. a buffer) in suitable packaging. The kit preferably contains instructions for using the antibody to detect the PR01889 polypeptide.
1n yet another embodiment, the invention provides a method for inhibiting the growth of tumor cells comprising exposing a cell which overexpresses a PR01889 polypeptide to an effective amount of an agent inhibiting the expression and/or activity of the PR01889 polypeptide. The agent preferably is an anti-PR01889 polypeptide, a small organic and inorganic peptide, phosphopeptide, antisense or ribozyme molecule, or a triple helix molecule. In a specific aspect, the agent, e.g., anti-PR01889 antibody induces cell death. In a further aspect, the tumor cells are further exposed to radiation treaanent and/or a cytotoxic or chemotherapeutic agent.
In a further embodiment, the invention concerns an article of manufacture, comprising:
a container;
a label on the container, and a composition comprising an active agent contained within the container;
wherein the composition is effective for inhibiting the growth of tumor cells, the label on the container indicates that the composition can be used for treating conditions characterized by overexpression of a PR01889 polypeptide, and the active agent in the composition is an agent inhibiting the expression and/or activity of the PR01889 polypeptide. In a preferred aspect, the active agent is an anti-PROI889 antibody.
5. PR01890 A cDNA clone (DNA79230-2525) has been identified, having homology to nucleic acid encoding a lectin protein that encodes a novel polypepdde, designated in the present application as "PR01890".

In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01890 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 8536 sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR01890 polypeptide having the sequence of amino acid residues from about 1 or about 22 to about 273, inclusive of Figure 10 (SEQ ID
N0:18), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR01890 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about nucleotides 378 or about 441 and about 1196, inclusive, of Figure 9 (SEQ ID N0:17).
Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203549 IS (DNA79230-2525) or (b) the complement of the nucleic acid molecule of (a).
In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No. 203549 (DNA79230-2525).
In still a further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80 % sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues I or about 22 to about 273, inclusive of Figure 10 (SEQ ID
N0:18), or (b) the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least 475 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA
molecule encoding a PR01890 polypeptide having the sequence of amino acid residues from 1 or about 22 to about 273, inclusive of Figure 10 (SEQ ID N0:18), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, prefereably at least about an 85% sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01890 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e., transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 21 in the sequence of Figure 10 (SEQ
ID N0:18). The transmembrane domain has been tentatively identified as extending from about amino acid position 214 to about amino acid position 235 in the PR01890 amino acid sequence (Figure 10, SEQ ID N0:18).

In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 8096 positives, preferably at least about 8596 positives, more preferably at least about 90 ~O positives, most preferably at least about 95 %
positives when compared with the amino acid sequence of residues 1 or about 22 to about 273, inclusive of Figure 10 (SEQ ID N0:18), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR01890 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length and most preferably from about 20 to about 40 nucleotides in length and may be derived from the nucleotide sequence shown in Figure 9 (SEQ ID N0:17).
In another embodiment, the invention provides isolated PR01890 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
In a specific aspect, the invention provides isolated native sequence PR01890 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues 1 or about 22 to about 273 of Figure 10 (SEQ ID N0:18).
In another aspect, the invention concerns an isolated PR01890 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 9536 sequence identity to the sequence of amino acid residues I or about 22 to about 273, inclusive of Figure 10 (SEQ ID N0:18).
In a further aspect, the invention concerns an isolated PRO 1890 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 %
positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 1 or about 22 to about 273, inclusive of Figure 10 (SEQ ID N0:18).
In yet another aspect, the invention concerns an isolated PR01890 polypeptide, comprising the sequence of amino acid residues 1 or about 22 to about 273, inclusive of Figure 10 (SEQ
ID NO:18), or a fragment thereof sufficient to provide a binding site for an anti-PR01890 antibody.
Preferably, the PR01890 fragment retains a qualitative biological activity of a native PROI890 poIypeptide.
In a still further aspect, the invention provides a polypeptide produced by (l) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR01890 polypeptide having the sequence of amino acid residues from about 1 or about 22 to about 273, inclusive of Figure 10 (SEQ ID
N0:18), or (b) the complement of the DNA molecule of (a), and if the test DNA
molecule has at least about an 80 % sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90%
sequence identity, most preferably at least about a 9596 sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

6. PR01887 A cDNA clone (DNA79862-2522) has been identified that encodes a novel polypeptide having homology to carboxylesterases and designated in the present application as "PR01887".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01887 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR01887 polypeptide having the sequence of amino acid residues from 1 or about 28 to about 571, inclusive of Figure 12 (SEQ ID N0:23), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR01887 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 87 and about 1718, inclusive, of Figure 11 (SEQ ID N0:22). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203550 (DNA79862-2522), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203550 (DNA79862-2522).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 8096 sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 28 to about 571, inclusive of Figure 12 (SEQ ID
N0:23), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01887 polypeptide having the sequence of amino acid residues from about 28 to about 571, inclusive of Figure 12 (SEQ ID
N0:23), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 Y6 sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01887 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble variants (i.e. transmembrane domain deleted or inactivated), or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 27 in the sequence of Figure I2 (SEQ ID
N0:23). The transmembrane WO 00/56889 PC'f/US00/05601 domain has been tentatively identified as extending from about amino acid position 226 to about amino acid position 24S in the PR01887 amino acid sequence (Figure 12, SEQ ID N0:23).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 8086 positives, preferably at least about 8S% positives, more preferably at least about 9096 positives, most preferably at least about 95 ~
positives when compared with the amino acid sequence of residues 28 to about 571, inclusive of Figure 12 (SEQ
ID N0:23), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PRO 1887 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about 50 nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR01887 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR01887 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 28 to 571 of Figure 12 (SEQ ID N0:23).
In another aspect, the invention concerns an isolated PR01887 polypeptide, comprising an amino acid sequence having at least about 80~ sequence identity, preferably at least about 8S & sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 9S% sequence identity to the sequence of amino acid residues 28 to about 571, inclusive of Figure 12 (SEQ
ID N0:23).
In a further aspect, the invention concerns an isolated PR01887 polypeptide, comprising an amino acid sequence scoring at least about 80 ~ positives, preferably at least about 85 %
positives, more preferably at least about 90'~ positives, most preferably at least about 95 ~ positives when compared with the amino acid sequence of residues 28 to 571 of Figure 12 (SEQ ID N0:23).
In yet another aspect, the invention concerns an isolated PROI 887 polypeptide, comprising the sequence of amino acid residues 28 to about S71, inclusive of Figure 12 (SEQ ID N0:23), or a fragment thereof sufficient to provide a binding site for an anti-PR01887 antibody. Preferably, the PRO
1887 fragment retains a qualitative biological activity of a native PR01887 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR01887 polypeptide having the sequence of amino acid residues from about 28 to about 571, inclusive of Figure 12 (SEQ ID N0:23), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80~ sequence identity, preferably at least about an 8596 sequence identity, more preferably at least about a 90Rb sequence identity, most preferably at least about a 95 ~ sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

7. PRO 785 A cDNA clone (DNA80136-2503) has been identified that encodes a novel polypeptide having sequence identity with peroxidases and designated in the present application as "PR01785.
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01785 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR01785 polypeptide having the sequence of amino acid residues from 1 or about 32 to about 209, inclusive of Figure 14 (SEQ ID N0:29), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR01785 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 95 and about 628, inclusive, of Figure 13 (SEQ ID N0:28). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203541 (DNA80136-2503), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the say mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203541 (DNA80136-2503).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 9096 sequence identity, most preferably at least about 95°6 sequence identity to the sequence of amino acid residues from about 32 to about 209, inclusive of Figure 14 (SEQ ID
N0:29), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about SO
nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR01785 polypeptide having the sequence of amino acid residues from about 32 to about 209, inclusive of Figure 14 (SEQ ID
N0:29), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably at least about an 85'~ sequence identity, more preferably at least about a 90'~ sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR01785 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble, i.e. transmembrane domain deleted or inactivated variants, or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 31 in the sequence of Figure 14 (SEQ ID
N0:29). The transmembrane domain has been tentatively identified as extending from about amino acid position 18 through about amino acid position 37 in the PR01785 amino acid sequence (Figure 14, SEQ ID N0:29).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80~ positives, preferably at least about 85~ positives, more preferably at least about 9096 positives, most preferably at least about 95 ~
positives when compared with the amino acid sequence of residues 32 to about 209, inclusive of Figure 14 (SEQ
ID N0:29), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR01785 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 to about 80 nucleotides in length, preferably from about 20 to about 60 nucleotides in length, more preferably from about 20 to about SO
nucleotides in length, and most preferably from about 20 to about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR01785 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR01785 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 32 through 209 of Figure 14 (SEQ ID
N0:29).
In another aspect, the invention concerns an isolated PR01785 polypeptide, comprising an amino acid sequence having at least about 80°6 sequence identity, preferably at least about 85~ sequence identity, more preferably at least about 90Yb sequence identity, most preferably at least about 95 ~ sequence identity to the sequence of amino acid residues 32 to about 209, inclusive of Figure 14 (SEQ
ID N0:29).
In a further aspect, the invention concerns an isolated PR01785 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 ~
positives, more preferably at least about 90 ~ positives, most preferably at least about 95 ~ positives when compared with the amino acid sequence of residues 32 through 209 of Figure 14 (SEQ ID N0:29).
In yet another aspect, the invention concerns an isolated PR01785 polypeptide, comprising the sequence of amino acid residues 32 to about 209, inclusive of Figure 14 (SEQ ID N0:29), or a fragment thereof sufficient to provide a binding site for an anti-PR01785 antibody. Preferably, the PR01785 fragment retains a qualitative biological activity of a native PR01785 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (t) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR01785 polypeptide having the sequence of amino acid residues from about 32 to about 209, inclusive of Figure 14 (SEQ ID N0:29), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80~ sequence identity, preferably at least about an 85~ sequence identity, more preferably at least about a 90'Y sequence identity, most preferably at least about a 95 ~ sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

8. PR 4353 A cDNA clone (DNA80145-2594) has been identified that encodes a novel polypeptide having homology to semaphorin Z and designated in the present application as "PR04353°.
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04353 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04353 polypeptide having the sequence of amino acid residues from 1 or about 26 to about 888, inclusive of Figure 16 (SEQ ID N0:35), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04353 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 94 and about 2682, inclusive, of Figure 15 (SEQ ID N0:34). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 204-PTA
(DNA80145-2594), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 204-PTA (DNA8014S-2594).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 26 to about 888, inclusive of Figure 16 (SEQ ID
N0:35), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04353 polypeptide having the sequence of amino acid residues from about 26 to about 888, inclusive of Figure 16 (SEQ ID
N0:35), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA
molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04353 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble variants (i.e. transmembrane domain deleted or inactivated), or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 25 in the sequence of Figure 16 (SEQ ID
N0:35). The transmembrane domains have been tentatively identified as extending from about amino acid positions 318-339 and 598-617 (Figure 16, SEQ ID N0:35).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95%
positives when compared with the S amino acid sequence of residues 26 to about 888, inclusive of Figure 16 (SEQ
ID N0:35), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR04353 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04353 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04353 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 26 through 888 of Figure 16 (SEQ ID
N0:35).
In another aspect, the invention concerns an isolated PR04353 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 26 to about 888, inclusive of Figure 16 (SEQ
ID N0:35).
In a further aspect, the invention concerns an isolated PR04353 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 %
positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 26 through 888 of Figure 16 (SEQ ID N0:35).
In yet another aspect, the invention concerns an isolated PR04353 polypeptide, comprising the sequence of amino acid residues 26 to about 888, inclusive of Figure 16 (SEQ ID N0:35), or a fragment thereof sufficient to provide a binding site for an anti-PR04353 antibody. Preferably, the PR04353 fragment retains a qualitative biological activity of a native PR04353 polypeptide.
In a still fitrther aspect, the invention provides a polypeptide produced by (t) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04353 polypeptide having the sequence of amino acid residues from about 26 to about 888, inclusive of Figure 16 (SEQ ID N0:35), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 8096 sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 9096 sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

9. PR04 7 A cDNA clone (DNA84917-2597) has been identified that encodes a novel polypeptide having homology to "BK158 1" and designated in the present application as "PR04357".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04357 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at Least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04357 polypeptide having the sequence of amino acid residues from 1 or about 18 to about 502, inclusive of Figure 18 (SEQ ID N0:40), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04357 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 337 and about 1791, inclusive, of Figure 17 (SEQ ID N0:39). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203863 (DNA84917-2597), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203863 (DNA84917-2597).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 9096 sequence identity, most preferably at least about 9596 sequence identity to the sequence of amino acid residues from about 18 to about 502, inclusive of Figure 18 (SEQ ID
N0:40), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04357 polypeptide having the sequence of amino acid residues from about 18 to about 502, inclusive of Figure 18 (SEQ ID
N0:40), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80~
sequence identity, preferably at least about an 85 9~ sequence identity, more preferably at least about a 90 9b sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95%
positives when compared with the amino acid sequence of residues 18 to about 502, inclusive of Figure 18 (SEQ
ID N0:40), or (b) the complement of the DNA of (a).

WO 00/56889 PC'f/US00/05601 Another embodiment is directed to fragments of a PR04357 polypeptide coding sequence that may fmd use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04357 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04357 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 18 through 502 of Figure 18 (SEQ ID
N0:40).
In another aspect, the invention concerns an isolated PR04357 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 18 to about 502, inclusive of Figure 18 (SEQ
ID N0:40).
In a further aspect, the invention concerns an isolated PR04357 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 %
positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 18 through 502 of Figure 18 (SEQ ID N0:40).
In yet another aspect, the invention concerns an isolated PR04357 polypeptide, comprising the sequence of amino acid residues 18 to about 502, inclusive of Figure 18 (SEQ ID N0:40), or a fragment thereof sufficient to provide a binding site for an anti-PR04357 antibody. Preferably, the PR04357 fragment retains a qualitative biological activity of a native PR04357 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04357 polypeptide having the sequence of amino acid residues from about 18 to about 502, inclusive of Figure 18 (SEQ ID N0:40), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
10. PR 440 A cDNA clone (DNA84920-2614) has been identified that encodes a novel polypeptide designated in the present application as "PR04405".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04405 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 8096 sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04405 polypeptide having the sequence of amino acid residues from 1 or about 35 to about 310, inclusive of Figure 20 (SEQ ID N0:45), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04405 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 181 and about 1008, inclusive, of Figure 19 (SEQ ID N0:44). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95~& sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203966 (DNA84920-2614), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203966 (DNA84920-2614).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 35 to about 310, inclusive of Figure 20 (SEQ ID
N0:45), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04405 polypeptide having the sequence of amino acid residues from about 35 to about 310, inclusive of Figure 20 (SEQ ID
N0:45), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90%
sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04405 polypepdde, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble variants (i.e. transmembrane domain deleted or inactivated), or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 34 in the sequence of Figure 20 (SEQ ID
N0:45). The transmembrane domain has been tentatively identified as extending from about amino acid position 58 through about amino acid position 76 in the PR04405 amino acid sequence (Figure 20, SEQ ID N0:45) and may be a type II
transmembrane domain.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95%
positives when compared with the amino acid sequence of residues 35 to about 310, inclusive of Figure 20 (SEQ
ID N0:45), or (b) the complement of the DNA of (a).

Another embodiment is directed to fragments of a PR04405 polypeptide coding sequence that may find use as hybridization pmbes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04405 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04405 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 35 through 310 of Figure 20 (SEQ ID
N0:45).
In another aspect, the invention concerns an isolated PR04405 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85'~ sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 35 to about 310, inclusive of Figure 20 (SEQ
ID N0:45).
In a further aspect, the invention concerns an isolated PR04405 polypeptide, comprising an amino acid sequence scoring at least about 80~ positives, preferably at least about 85 ~
positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 35 through 310 of Figure 20 (SEQ ID N0:45).
In yet another aspect, the invention concerns an isolated PR04405 polypeptide, comprising the sequence of amino acid residues 35 to about 310, inclusive of Figure 20 (SEQ ID N0:45), or a fragment thereof sufficient to provide a binding site for an anti-PR04405 antibody. Preferably, the PR04405 fragment retains a qualitative biological activity of a native PR04405 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (t) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04405 polypeptide having the sequence of amino acid residues from about 35 to about 310, inclusive of Figure 20 (SEQ ID N0:45), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85~ sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 ~ sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the poIypeptide, and (iii) recovering the polypeptide from the cell culture.
11. PRO 56 A cDNA clone (DNA86576-2595) has been identified that encodes a novel polypeptide having homology to MAGPIAP and designated in the present application as "PR04356".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04356 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04356 polypeptide having the sequence of amino acid residues from 1 or about 20 to about 251, inclusive of Figure 22 (SEQ ID NO:50), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04356 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues I I2 and about 807, inclusive, of Figure 21 (SEQ ID N0:49). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203868 (DNA86576-2595), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203868 (DNA86576-2595).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 20 to about 251, inclusive of Figure 22 (SEQ ID
NO:50), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04356 polypeptide having the sequence of amino acid residues from about 20 to about 251, inclusive of Figure 22 (SEQ ID
NO:50), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04356 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble variants (i.e. transmembrane domain deleted or inactivated), or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from amino acid position I through about amino acid position 19 in the sequence of Figure 22 (SEQ ID
NO:50). The transmembrane domain has been tentatively identified as extending from about amino acid position 233 through about amino acid position 251 in the PR04356 amino acid sequence (Figure 22, SEQ ID NO:50).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 8096 positives, preferably at least about 8596 positives, more preferably at least about 9096 positives, most preferably at least about 9596 positives when compared with the amino acid sequence of residues 20 to about 251, inclusive of Figure 22 (SEQ
ID NO:50), or (b) the complement of the DNA of (a).

Another embodiment is directed to fragments of a PR04356 polypeptide coding sequence that may fmd use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04356 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04356 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 20 through 251 of Figure 22 (SEQ ID
N0:50).
In another aspect, the invention concerns an isolated PR04356 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 20 to about 251, inclusive of Figure 22 (SEQ
ID N0:50).
In a further aspect, the invention concerns an isolated PR04356 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 %
positives, more preferably at least about 90% positives, most preferably at least about 95% positives when compared with the amino acid sequence of residues 20 through 251 of Figure 22 (SEQ ID N0:50).
In yet another aspect, the invention concerns an isolated PR04356 potypeptide, comprising the sequence of amino acid residues 20 to about 251, inclusive of Figure 22 (SEQ ID N0:50), or a fragment thereof sufficient to provide a binding site for an anti-PR04356 antibody. Preferably, the PR04356 fragment retains a qualitative biological activity of a native PR04356 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (l) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04356 polypeptide having the sequence of amino acid residues from about 20 to about 251, inclusive of Figure 22 (SEQ ID N0:50), or (b) the complement of the DNA molecule of {a), and if the test DNA molecule has at least about an 8096 sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
12. PR04352 A cDNA clone (DNA87976-2593) has been identified that encodes a novel polypeptide having homology to protocadherin pc3 designated in the present application as "PR04352".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04352 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 809b sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04352 polypeptide having the sequence of amino acid residues from 1 or about 27 to about 800, inclusive of Figure 24 (SEQ ID N0:52), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04352 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 257 and about 2578, inclusive, of Figure 23 (SEQ ID NO:51). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 9086 sequence identity, most preferably at least about 9596 sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203888 (DNA87976-2593), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203888 (DNA87976-2593).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 27 to about 800, inclusive of Figure 24 (SEQ 1D
N0:52), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04352 polypeptide having the sequence of amino acid residues from about 27 to about 800, inclusive of Figure 24 (SEQ ID
N0:52), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95% sequence identity to (a) or (b), isolating the test DNA
molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04352 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble variants (i.e. uansmembrane domain deleted or inactivated), or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 26 in the sequence of Figure 24 (SEQ ID
N0:52). The transmembrane domain has been tentatively identified as extending from about amino acid position 687 through about amino acid position 711 in the PR04352 amino acid sequence (Figure 24, SEQ ID N0:52).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 %
positives when compared with the amino acid sequence of residues 27 to about 800, inclusive of Figure 24 (SEQ
ID N0:52), or (b) the complement of the DNA of (a).

WO 00/56889 PC'T/US00/0560I
Another embodiment is directed to fragments of a PR04352 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04352 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04352 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 27 through 800 of Figure 24 (SEQ ID
N0:52).
In another aspect, the invention concerns an isolated PR04352 polypeptide, comprising an amino acid sequence having at Ieast about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at Least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 27 to about 800, inclusive of Figure 24 (SEQ
ID N0:52).
In a further aspect, the invention concerns an isolated PR04352 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85 %
positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 27 through 800 of Figure 24 (SEQ ID N0:52).
In yet another aspect, the invention concerns an isolated PR04352 polypeptide, comprising the sequence of amino acid residues 27 to about 800, inclusive of Figure 24 (SEQ ID N0:52), or a fragment thereof sufficient to provide a binding site for an anti-PR04352 antibody. Preferably, the PR04352 fragment retains a qualitative biological activity of a native PR04352 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (t) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04352 polypeptide having the sequence of amino acid residues from about 27 to about 800, inclusive of Figure 24 (SEQ ID N0:52), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 800 sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
13. PR04380 A cDNA clone (DNA92234-2602) has been identified that encodes a novel polypeptide designated in the present application as "PR04380".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04380 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80 % sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90 % sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04380 polypeptide having the sequence of amino acid residues from 1 or about 27 to about 507, inclusive of Figure 26 (SEQ ID N0:57), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04380 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 279 and about 1721, inclusive, of Figure 25 (SEQ ID N0:56). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80 Yo sequence identity, preferably at least about 85 %
sequence identity, more preferably at least about 90 % sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203948 (DNA92234-2602), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203948 (DNA92234-2602).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 27 to about 507, inclusive of Figure 26 (SEQ ID
N0:57), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04380 polypeptide having the sequence of amino acid residues from about 27 to about 507, inclusive of Figure 26 (SEQ ID
N0:57), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04380 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble variants (i.e. transmembrane domain deleted or inactivated), or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from amino acid position 1 through about amino acid position 26 in the sequence of Figure 26 (SEQ ID
N0:57). The transmembrane domain has been tentatively identified as extending from about amino acid position 273 through about amino acid position 292 in the PR04380 amino acid sequence (Figure 26, SEQ ID N0:57).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95%
positives when compared with the amino acid sequence of residues 27 to about 507, inclusive of Figure 26 (SEQ
ID N0:57), or (b) the complement of the DNA of (a).

Another embodiment is directed to fragments of a PR04380 polypeptide coding sequence that may fmd use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04380 polypeptide encoded by any of the S isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04380 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 27 through 507 of Figure 26 (SEQ ID
N0:57).
In another aspect, the invention concerns an isolated PR04380 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 27 to about 507, inclusive of Figure 26 (SEQ
ID N0:57).
In a further aspect, the invention concerns an isolated PR04380 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85%
positives, more preferably at least 1S about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 27 through 507 of Figure 26 (SEQ ID N0:57).
In yet another aspect, the invention concerns an isolated PR04380 polypeptide, comprising the sequence of amino acid residues 27 to about 507, inclusive of Figure 26 (SEQ ID N0:57), or a fragment thereof sufficient to provide a binding site for an aati-PR04380 antibody. Preferably, the PR04380 fragment retains a qualitative biological activity of a native PR04380 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (l) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04380 polypeptide having the sequence of amino acid residues from about 27 to about 507, inclusive of Figure 26 (SEQ 1D N0:57), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence 2S identity, preferably at least about an 85% sequence identity, more preferably at least about a 90'Y sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
14. 804354 A cDNA clone (DNA92256-2596) has been identified that encodes a novel polypeptide designated in the present application as "P804354".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04354 polypeptide.
3S In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 909b sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04354 polypeptide having the sequence of amino acid residues from about 22 to about 248, inclusive of Figure 28 (SEQ ID N0:59), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04354 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 171 and about 851, inclusive, of Figure 27 (SEQ ID N0:58). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203891 (DNA92256-2596), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203891 (DNA92256-2596).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 22 to about 248, inclusive of Figure 28 (SEQ ID
N0:59), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04354 polypeptide having the sequence of amino acid residues from about 22 to about 248, inclusive of Figure 28 (SEQ ID
N0:59), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90 % positives, most preferably at least about 95 %
positives when compared with the amino acid sequence of residues 22 to about 248, inclusive of Figure 28 (SEQ
ID N0:59), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR04354 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04354 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04354 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 22 through 248 of Figure 28 (SEQ ID

N0:59).
In another aspect, the invention concerns an isolated PR04354 polypeptide, comprising an amino acid sequence having at least about 80 °~ sequence identity, preferably at least about 85 °b sequence identity, more preferably at least about 90~ sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 22 to about 248, inclusive of Figure 28 (SEQ
ID N0:59).
In a further aspect, the invention concerns an isolated PR04354 polypeptide, comprising an amino acid sequence scoring at least about 80°6 positives, preferably at least about 85 % positives, more preferably at least about 90 ~ positives, most preferably at least about 95 ~ positives when compared with the amino acid sequence of residues 22 through 248 of Figure 28 (SEQ ID N0:59).
In yet another aspect, the invention concerns an isolated PR04354 polypeptide, comprising the sequence of amino acid residues 22 to about 248, inclusive of Figure 28 (SEQ ID N0:59), or a fragment thereof sufficient to provide a binding site for an anti-PR04354 antibody. Preferably, the PR04354 fragment retains a qualitative biological activity of a native PR04354 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04354 polypeptide having the sequence of amino acid residues from about 22 to about 248, inclusive of Figure 28 (SEQ ID N0:59), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 8030 sequence identity, preferably at least about an 8590 sequence identity, more preferably at least about a 90~ sequence identity, most preferably at least about a 95 ~ sequence identity to (a) or (b), (ii) culruring a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
15. PR04408 A cDNA clone (DNA92274-2617) has been identified that encodes a novel polypeptide designated in the present application as "PR04408".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04408 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80'~ sequence identity, preferably at least about 8596 sequence identity, more preferably at least about 9096 sequence identity, most preferably at least about 95.°6 sequence identity to (a) a DNA molecule encoding a PR04408 polypeptide having the sequence of amino acid residues from about 23 to about 223, inclusive of Figure 30 (SEQ ID N0:61), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04408 polypeptide comprising DNA hybridizing to the complement of the nucieic acid between about residues 155 and about 757, inclusive, of Figure 29 (SEQ ID N0:60). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 8090 sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203971 (DNA92274-2617), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203971 (DNA92274-2617).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 23 to about 223, inclusive of Figure 30 (SEQ ID
N0:61), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04408 polypeptide having the sequence of amino acid residues from about 23 to about 223, inclusive of Figure 30 (SEQ ID
N0:61), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90%
sequence identity, most preferably at least about a 9S % sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80 % positives, preferably at least about 8S % positives, more preferably at least about 90 % positives, most preferably at least about 95 %
positives when compared with the amino acid sequence of residues 23 to about 223, inclusive of Figure 30 (SEQ
ID N0:61), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR04408 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nuchtides in Length, preferably from about 20 through about 60 nuchtides in length, more preferably from about 20 through about SO nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04408 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04408 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 23 through 223 of Figure 30 (SEQ ID
N0:61).
In another aspect, the invention concerns an isolated PR04408 polypeptide, comprising an amino acid sequence having at least about 8096 sequence identity, preferably at least about 8516 sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to the sequence of amino acid residues 23 to about 223, inclusive of Figure 30 (SEQ
ID N0:61).
In a further aspect, the invention concerns an isolated PR04408 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 %
positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 23 through 223 of Figure 30 (SEQ ID N0:61).
In yet another aspect, the invention concerns an isolated PR04408 polypeptide, comprising the sequence of amino acid residues 23 to about 223, inclusive of Figure 30 (SEQ ID N0:61), or a fragment thereof sufficient to provide a binding site for an anti-PR04408 antibody. Preferably, the PR04408 fragment retains a qualitative biological activity of a native PR04408 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04408 polypeptide having the sequence of amino acid residues from about 23 to about 223, inclusive of Figure 30 (SEQ ID NO:61), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
16. PR05737 A cDNA clone (DNA92929-2534) has been identified that encodes a novel polypeptide having homology to IL-1 and is designated in the present application as "PR05737".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR05737 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR05737 polypeptide having the sequence of amino acid residues from 1 or about 18 to about 134, inclusive of Figure 32 (SEQ ID N0:63), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR05737 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 96 or about 147 and about 497, inclusive, of Figure 31 (SEQ ID N0:62). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80 % sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203586 (DNA92929-2534), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203586 (DNA92929-2534).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90 % sequence identity, most preferably at least about 95 % sequence identity to the sequence of amino acid residues from about 18 to about 134, inclusive of Figure 32 (SEQ ID
N0:63), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR05737 polypeptide having the sequence of amino acid residues from about 18 to about 134, inclusive of Figure 32 (SEQ ID
N0:63), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 %
positives when compared with the amino acid sequence of residues 18 to about 134, inclusive of Figure 32 (SEQ
ID N0:63), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR05737 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR05737 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR05737 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 18 through 134 of Figure 32 (SEQ ID
N0:63).
In another aspect, the invention concerns an isolated PR05737 polypeptide, comprising an amino acid sequence having at least about 80 % sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to the sequence of amino acid residues 18 to about 134, inclusive of Figure 32 (SEQ
ID N0:63).
In a further aspect, the invention concerns an isolated PR05737 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 %
positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 18 through 134 of Figure 32 (SEQ ID N0:63).
In yet another aspect, the invention concerns an isolated PR05737 polypeptide, comprising the sequence of amino acid residues 18 to about 134, inclusive of Figure 32 (SEQ ID N0:63), or a fragment thereof sufficient to provide a binding site for an anti-PR05737 antibody. Preferably, the PR05737 fragment retains a qualitative biological activity of a native PR05737 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR05737 polypeptide having the sequence of amino acid residues from about 18 to about 134, inclusive of Figure 32 (SEQ ID N0:63), or (b) v.a~ Vc_avlcGl GVV1-VO-V.J

the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
17. PR04425 A cDNA clone (DNA93011-2637) has been identified that encodes a novel polypeptide having homology to a protein in GenBank, accession number HGS RE295, and designated in the present application as "PR04425".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04425 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90 % sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04425 polypeptide having the sequence of amino acid residues from 1 OR about 20 to about 136, inclusive of Figure 34 (SEQ ID N0:65), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04425 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 84 and about 434, inclusive, of Figure 33 (SEQ ID N0:64). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 20-PTA
(DNA93011-2637), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 20-PTA (DNA93011-2637).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 20 to about 136, inclusive of Figure 34 (SEQ ID
N0:65), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04425 polypeptide having the sequence of amino acid residues from about 20 to about 136, inclusive of Figure 34 (SEQ ID
N0:65), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80%
sequence identity, preferably *-trademark 41 at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95 %
positives when compared with the amino acid sequence of residues 20 to about 136, inclusive of Figure 34 (SEQ
ID N0:65), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR04425 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04425 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04425 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 20 through 136 of Figure 34 (SEQ ID
N0:65).
In another aspect, the invention concerns an isolated PR04425 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 20 to about 136, inclusive of Figure 34 (SEQ
ID N0:65).
In a further aspect, the invention concerns an isolated PR04425 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 85 %
positives, more preferably at least about 90% positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 20 through 136 of Figure 34 (SEQ ID N0:65).
In yet another aspect, the invention concerns an isolated PR04425 polypeptide, comprising the sequence of amino acid residues 20 to about 136, inclusive of Figure 34 (SEQ ID N0:65), or a fragment thereof sufficient to provide a binding site for an anti-PR04425 antibody. Preferably, the PR04425 fragment retains a qualitative biological activity of a native PR04425 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04425 polypeptide having the sequence of amino acid residues from about 20 to about I36, inclusive of Figure 34 (SEQ ID N0:65), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity; most preferably at least about a 95 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

18. PR 990 A cDNA clone (designated herein as DNA96042-2682) has been identified that has homology to nucleic acid encoding secretogranin and that encodes a novel polypeptide, designated in the present application as "PR05990".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PR05990 polypeptide.
In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81% sequence identity, more preferably at least about 82%
sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88 % sequence identity, yet more preferably at least about 89 %
sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 %
sequence identity, yet more preferably at least about 92 % sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at least about 99%
sequence identity to (a) a DNA molecule encoding a PR05990 polypeptide having the sequence of amino acid residues from about 1 or about 22 to about 468, inclusive, of Figure 36 (SEQ
ID N0:67), or (b) the complement of the DNA molecule of (a).
In another aspect, the isolated nucleic acid molecule comprises (a) a nucleotide sequence encoding a PR05990 polypeptide having the sequence of amino acid residues from about 1 or about 22 to about 468, inclusive, of Figure 36 (SEQ ID N0:67), or (b) the complement of the nucleotide sequence of (a).
In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82%
sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88 % sequence identity, yet more preferably at least about 89 %
sequence identity, yet more preferably at least about 90 % sequence identity, yet more preferably at least about 91 %
sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at least about 99%
sequence identity to (a) a DNA molecule having the sequence of nucleotides from about 265 or about 328 to about 1668, inclusive, of Figure 35 (SEQ ID N0:66), or (b) the complement of the DNA molecule of (a).
In another aspect, the isolated nucleic acid molecule comprises (a) the nucleotide sequence of from about 265 or about 328 to about 1668, inclusive, of Figure 35 (SEQ ID N0:66), or (b) the complement of the nucleotide sequence of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89%
sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96 %
sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98%
sequence identity and yet more preferably at least about 99 % sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by the human protein cDNA deposited with the ATCC on July 20, 1999 under ATCC Deposit No. 382-PTA (DNA96042-2682) or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the isolated nucleic acid molecule comprises (a) a nucleotide sequence encoding the same mature polypeptide encoded by the human protein cDNA deposited with the ATCC on July 20, 1999 under ATCC Deposit No. 382-PTA (DNA96042-2682) or (b) the complement of the nucleotide sequence of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89%
sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96 %
sequence identity, yet more preferably at least about 97 % sequence identity, yet more preferably at least about 98 %
sequence identity and yet more preferably at least about 99% sequence identity to (a) the full-length polypeptide coding sequence of the human protein cDNA deposited with the ATCC on July 20, 1999 under ATCC Deposit No.
382-PTA (DNA96042-2682) or (b) the complement of the nucleotide sequence of (a). In a preferred embodiment, the isolated nucleic acid molecule comprises (a) the full-length polypeptide coding sequence of the DNA deposited with the ATCC
on July 20, 1999 under ATCC Deposit No. 382-PTA (DNA96042-2682) or (b) the complement of the nucleotide sequence of(a).
In another aspect, the invention concerns an isolated nucleic acid molecule which encodes an active PR05990 polypeptide as defined below comprising a nucleotide sequence that hybridizes to the complement of a nucleic acid sequence that encodes amino acids 1 or about 22 to about 468, inclusive, of Figure 36 (SEQ ID

N0:67). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In yet another asp~t, the invention concerns an isolated nucleic acid molecule which encodes an active PR05990 polypeptide as defined below comprising a nucleotide sequence that hybridizes to the complement of the nucleic acid sequence between about nucleotides 265 or about 328 and about 1668, inclusive, of Figure 35 (SEQ ID N0:66). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 1301 nucleotides and which is produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR05990 polypeptide having the sequence of amino acid residues from about 1 or about 22 to about 468, inclusive, of Figure 36 (SEQ ID N0:67), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 81 % sequence identity, more preferably at least about an 82% sequence identity, yet more preferably at least about an 83 % sequence identity, yet more preferably at least about an 84 %
sequence identity, yet more preferably at least about an 85 % sequence identity, yet more preferably at least about an 86 % sequence identity, yet more preferably at least about an 87 ~ sequence identity, yet more preferably at least about an 88 % sequence identity, yet more preferably at least about an 89% sequence identity, yet more preferably at least about a 90%
sequence identity, yet more preferably at least about a 91 % sequence identity, yet more preferably at least about a 92 % sequence identity, yet more preferably at least about a 93 % sequence identity, yet more preferably at least about a 94 % sequence identity, yet more preferably at least about a 95 %
sequence identity, yet more preferably at least about a 96:6 sequence identity, yet more preferably at least about a 97% sequence identity, yet more preferably at least about a 98 % sequence identity and yet more preferably at least about a 99 R6 sequence identity to (a) or (b), and isolating the test DNA molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) a nuchtide sequence encoding a polypeptide scoring at least about 80% positives, preferably at least about 81 % positives, more preferably at least about 82% positives, yet more preferably at least about 83% positives, yet more preferably at least about 84 % positives, yet more preferably at least about 85 % positives, yet more preferably at least about 869b positives, yet more preferably at least about 87 %
positives, yet more preferably at least about 88% positives, yet more preferably at least about 89'J~ positives, yet more preferably at least about 9096 positives, yet more preferably at least about 91 % positives, yet more preferably at least about 92% positives, yet more preferably at least about 9396 positive, yet more preferably at least about 949 positives, yet more preferably at least about 9596 positives, yet more preferably at least about 96% positives, yet more preferably at least about 9796 positives, yet more preferably at least about 98 %
positives and yet more preferably at least about 999b positives when compared with the amino acid sequence of residues about 1 or about 22 to 468, inclusive, of Figure 36 (SEQ ID N0:67), or (b) the complement of the nucleotide sequence of (a).
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR05990 polypeptide without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 21 in the sequence of Figure 36 (SEQ
ID N0:67). It is noted, however, that the C-terminal boundary of the signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Pro .
Ene. 10:1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, $ resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding them, are contemplated by the present invention. As such, for purposes of the present application, the signal peptide of the PR05990 polypeptide shown in Figure 36 (SEQ ID N0:67) extends from amino acids 1 to X of Figure 36 (SEQ ID N0:67), wherein X is any amino acid from 16 to 26 of Figure 36 (SEQ ID
N0:67). Therefore, mature forms of the PR05990 polypeptide which are encompassed by the present invention include those comprising amino acids X to 468 of Figure 36 (SEQ ID N0:67), wherein X is any amino acid from 16 to 26 of Figure 36 (SEQ ID N0:67) and variants thereof as described below. Isolated nucleic acid molecules encoding these polypeptides are also contemplated.
Another embodiment is directed to fragments of a PR05990 polypeptide coding sequence that may find use as, for example, hybridization probes or for encoding fragments of a PR05990 polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PR05990 antibody. Such nucleic acid fragments are usually at least about 20 nucleotides in length, preferably at least about 30 nucleotides in length, more preferably at least about 40 nucleotides in length, yet more preferably at least about 50 nucleotides in length, yet more preferably at least about 60 nucleotides in length, yet more preferably at least about 70 nucleotides in length, yet more preferably at least about 80 nucleotides in length, yet more preferably at least about 90 nucleotides in length, yet more preferably at least about I00 nucleotides in length, yet more preferably at least about 110 nucleotides in length, yet more preferably at least about 120 nucleotides in length, yet more preferably at least about 130 nucleotides in length, yet more preferably at least about 140 nucleotides in length, yet more preferably at least about 150 nucleotides in length, yet more preferably at least about I60 nucleotides in length, yet more preferably at least about 170 nucleotides in length, yet more preferably at least about 180 nucleotides in length, yet more preferably at least about 190 nucleotides in length, yet more preferably at least about 200 nucleotides in Length, yet more preferably at least about 250 nucleotides in length, yet more preferably at least about 300 nucleotides in length, yet more preferably at least about 350 nucleotides in length, yet more preferably at least about 400 nucleotides in length, yet more preferably at least about 450 nucleotides in length, yet more preferably at least about 500 nucleotides in length, yet more preferably at least about 600 nucleotides in length, yet more preferably at least about 700 nucleotides in length, yet more preferably at least about 800 nucleotides in length, yet more preferably at least about 900 nucleotides in length and yet more preferably at least about 1000 nucleotides in length, wherein in this context the term "about° means the referenced. nucleotide sequence length plus or minus 109 of that referenced length. In a preferred embodiment, the nucleotide sequence fragment is derived from any coding region of the nucleotide sequence shown in Figure 35 (SEQ ID
N0:66). It is noted that novel fragments of a PR05990 polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PR05990 polypeptide-encoding nucleotide sequence with other Irnown nucleotide sequences using any of a number of well lmown sequence alignment programs and deterntining which PR05990 polypeptide-encoding nucleotide sequence fragments) are novel.
All of such PR05990 polypeptide-encoding nucleotide sequences are contemplated herein and can be determined without undue experimentation. Also contemplated are the PR05990 polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PR05990 polypeptide fragments that comprise a binding site for an anti-PR05990 antibody.
In another embodiment, the invention provides isolated PR05990 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
In a specific aspect, the invention provides isolated native sequence PR05990 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues from about 1 or about 22 to about 468 of Figure 36 (SEQ ID N0:67).
In another aspect, the invention concerns an isolated PR05990 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82 % sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89%
sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96 %
sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98%
sequence identity and yet more preferably at least about 99% sequence identity to the sequence of amino acid residues from about 1 or about 22 to about 468, inclusive, of Figure 36 (SEQ ID N0:67).
In a further aspect, the invention concerns an isolated PR05990 polypeptide comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82 % sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89%
sequence identity, yet more preferably at least about 90 % sequence identity, yet more preferably si least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96 %
sequence identify, yet more preferably at least about 97 % sequence identity, yet more preferably at least about 98 %
sequence identity and yet more preferably at least about 99 % sequence identity to an amino acid sequence encoded by the human protein cDNA
deposited with the ATCC on July 20, 1999 under ATCC Deposit No. 382-PTA
(DNA96042-2682). In a preferred embodiment, the isolated PR05990 polypeptide comprises an amino acid sequence encoded by the human protein cDNA deposited with the ATCC on July 20, 1999 under ATCC Deposit No. 382-PTA

WO 00/56889 PC'f/US00/05601 (DNA96042-2682).
In a further aspect, the invention concerns an isolated PR05990 polypeptide comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 81 %
positives, more preferably at least about 82 % positives, yet more preferably at least about 83 % positives, yet more preferably at least about 84 positives, yet more preferably at least about 85% positives, yet more preferably at least about 86% positives, yet more preferably at least about 87% positives, yet more preferably at least about 88% positives, yet more preferably at least about 89% positives, yet more preferably at least about 90% positives, yet more preferably at least about 91 % positives, yet more preferably at least about 92 %
positives, yet more preferably at least about 93 % positives, yet more preferably at least about 94 % positives, yet more preferably at least about 95 positives, yet more preferably at least about 96% positives, yet more preferably at least about 97% positives, yet more preferably at least about 98% positives and yet more preferably at least about 99% positives when compared with the amino acid sequence of residues from about 1 or about 22 to about 468, inclusive, of Figure 36 (SEQ ID N0:67).
In a specific aspect, the invention provides an isolated PR05990 polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PR05990 polypeptide and recovering the PR05990 polypeptide from the cell culture.
In yet another aspect, the invention concerns an isolated PR05990 polypeptide, comprising the sequence of amino acid residues from about 1 or about 22 to about 468, inclusive, of Figure 36 (SEQ ID N0:67), or a fragment thereof which is biologically active or sufficient to provide a binding site for an anti-PR05990 antibody, wherein the identification of PR05990 polypeptide fragments that possess biological activity or provide a binding site for an anti-PR05990 antibody may be accomplished in a routine manner using techniques which are well latown in the art. Preferably, the PR05990 fragment retains a qualitative biological activity of a native PR05990 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR05990 polypeptide having the sequence of amino acid residues from about 1 or about 22 to about 468, inclusive, of Figure 36 (SEQ ID
N0:67), or (b) the complement of the DNA molecule of (a), and if the test DNA
molecule has at least about an 80% sequence identity, preferably at least about an 8I °6 sequence identity, more preferably at least about an 82 % sequence identity, yet more preferably at least about an 83 % sequence identity, yet more preferably at least about an 84% sequence identity, yet more preferably at least about an 85%
sequence identity, yet more preferably at least about an 86 % sequence identity, yet more preferably at least about an 87 % sequence identity, yet more preferably at least about an 88 % sequence identity, yet more preferably at least about an 89 % sequence identity, yet more preferably at least about a 90% sequence identity, yet more preferably at least about a 91 sequence identity, yet more preferably at least about a 92% sequence identity, yet more preferably at least about a 93 % sequence identity, yet more preferably at least about a 94 % sequence identity, yet more preferably at least about a 95 % sequence identity, yet more preferably at least about a 96%
sequence identity, yet more preferably at least about a 97 % sequence identity, yet more preferably at least about a 98 % sequence identity and yet more preferably at least about a 99 % sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA
molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
Another embodiment of the present invention is directed to the use of a PR05990 polypeptide, or an agonist or antagonist thereof as herein described, or an anti-PR05990 antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PR05990 polypeptide, an agonist or antagonist thereof or an anti-PR05990 antibody.
19. PR06030 A cDNA clone (designated herein as DNA96850-2705) has been identified that encodes a novel polypeptide, designated in the present application as "PR06030".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PR06030 polypeptide.
In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82%
sequence identity, yet more preferably at least about 83% sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85% sequence identity, yet more preferably at least about 86 % sequence identity, yet more preferably at least about 87 % sequence identity, yet more preferably at least about 88 % sequence identity, yet more preferably at least about 89 %
sequence identity, yet more preferably at least about 90 % sequence identity, yet more preferably at least about 91 %
sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93% sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at least about 99%
sequence identity to (a) a DNA molecule encoding a PR06030 polypeptide having the sequence of amino acid residues from about 1 or about 27 to about 322, inclusive, of Figure 38 (SEQ
ID N0:72), or (b) the complement of the DNA molecule of (a).
In another aspect, the isolated nucleic acid molecule comprises (a) a nucleotide sequence encoding a PR06030 polypeptide having the sequence of amino acid residues from about 1 or about 27 to about 322, inclusive, of Figure 38 (SEQ ID N0:72), or (b) the complement of the nucleotide sequence of (a).
In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80 % sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82 %
sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84% sequence identity, yet more preferably at least about 85% sequence identity, yet more preferably at least about 8b % sequence identity, yet more preferably at least about 87 % sequence identity, yet more preferably at least about 88 % sequence identity, yet more preferably at least about 89 %
sequence identity, yet more preferably at least about 90 % sequence identity, yet more preferably at least about 91 %
sequence identity, yet more preferably at least about 92 % sequence identity, yet more preferably at Ieast about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98% sequence identity and yet more preferably at least about 9996 sequence identity to (a) a DNA molecule having the sequence of nucleotides from about 60 or about 138 to about 1025, inclusive, of Figure 37 (SEQ ID N0:71), or (b) the complement of the DNA
molecule of (a).
In another aspect, the isolated nucleic acid molecule comprises (a) the nucleotide sequence of from about 60 or about 138 to about 1025, inclusive, of Figure 37 (SEQ ID N0:71), or (b) the complement of the nucleotide sequence of(a).
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% sequence identity, preferably at least about 81 %a sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 8356 sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 %a sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89%
sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96 %
sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 9896 sequence identity and yet more preferably at least about 99 % sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by the human protein cDNA deposited with the ATCC on August 3, 1999 under ATCC Deposit No.
479-PTA (DNA96850-2705) or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the isolated nucleic acid molecule comprises (a) a nucleotide sequence encoding the same mature polypeptide encoded by the human protein cDNA deposited with the ATCC on August 3, 1999 under ATCC Deposit No.
479-PTA (DNA9b850-2705) or (b) the complement of the nucleotide sequence of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% sequence identity, preferably at least about 819 sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 839 sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86% sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89%
sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 96 sequence identity, yet more preferably at least about 96 %
sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98%
sequence identity and yet more preferably at least about 99% sequence identity to (a) the full-length polypeptide coding sequence of the human protein cDNA deposited with the ATCC on August 3, 1999 under ATCC Deposit No.
479-PTA (DNA96850-2705) or (b) the complement of the nucleotide sequence of (a). In a preferred embodiment, the isolated nucleic acid molecule comprises (a) the full-length polypeptide coding sequence of the DNA deposited with the ATCC
on August 3, 1999 under ATCC Deposit No. 479-PTA (DNA96850-2705) or (b) the complement of the nucleotide sequence of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule which encodes an active PR06030 polypeptide as defined below comprising a nucleotide sequence that hybridizes to the complement of a nucleic acid sequence that encodes amino acids 1 or about 27 to about 322, inclusive, of Figure 38 (SEQ ID
N0:72). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In yet another aspect, the invention concerns an isolated nucleic acid molecule which encodes an active PR06030 polypeptide as defined below comprising a nucleotide sequence that hybridizes to the complement of the nucleic acid sequence between about nucleotides 60 or about 138 and about 1025, inclusive, of Figure 37 (SEQ ID N0:71). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 528 nucleotides and which is produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR06030 polypeptide having the sequence of amino acid residues from about 1 or about 27 to about 322, inclusive, of Figure 38 (SEQ ID N0:72), or (b) the complement of the DNA molecule of (a), and, if the test DNA molecule has at least about an 8096 sequence identity, preferably at least about an 81 % sequence identity, more preferably at least about an 82% sequence identity, yet more preferably at least about an 83 % sequence identity, yet more preferably at least about an 84 %
sequence identity, yet more preferably at least about an 8596 sequence identity, yet more preferably at least about an 86% sequence identity, yet more preferably at least about an 8796 sequence identity, yet more preferably at least about an 88% sequence identity, yet more preferably at least about an 89 % sequence identity, yet more preferably at least about a 90 %
sequence identity, yet more preferably at least about a 919b sequence identity, yet more preferably at least about a 92 % sequence identity, yet more preferably at least about a 93 % sequence identity, yet more preferably at least about a 94 9b sequence identity, yet more preferably at least about a 95 %
sequence identity, yet more preferably at least about a 9696 sequence identity, yet more preferably at least about a 97~ sequence identity, yet more preferably at least about a 98 °& sequence identity and yet more preferably at least about a 99 % sequence identity to (a) or (b), and isolating the test DNA molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) a nucleotide sequence encoding a polypeptide scoring at least about 80'~ positives, preferably at least about 81 % positives, more preferably at least about 82 % positives, yet more preferably at least about 83 % positives, yet more preferably at least about 84 % positives, yet more preferably at least about 85 % positives, yet more preferably at least about 86% positives, yet more preferably at least about 87%
positives, yet more preferably at least about 88% positives, yet more preferably at least about 8996 positives, yet more preferably at least about 90%
positives, yet more preferably at least about 91 % positives, yet more preferably at least about 92% positives, yet more preferably at least about 93 % positives, yet more preferably at least about 94 % positives, yet more preferably at least about 95 % positives, yet more preferably at least about 9696 positives, yet more preferably at least about 97 % positives, yet more preferably at least about 98 %
positives and yet more preferably at least about 99~ positives when compared with the amino acid sequence of residues about I or about 27 to 322, inclusive, of Figure 38 (SEQ ID N0:72), or (b) the complement of the nucleotide sequence of (a).
In a specific aspect, the inventionprovides an isolated nucleic acid molecule comprising DNA encoding a PR06030 polypeptide without the N-terminal signal sequence and/or the initiating methionine, or is complementary to such encoding nucleic acid molecule. The signal peptide has been tentatively identified as extending from about amino acid position 1 to about amino acid position 26 in the sequence of Figure 38 (SEQ
ID N0:72). It is noted, however, that the C-terminal boundary of the signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot.
EtlE. 10;1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucIeotides encoding them, are contemplated by the present invention. As such, for purposes of the present application, the signal peptide of the PR06030 polypeptide shown in Figure 38 (SEQ ID N0:72) extends from amino acids 1 to X of Figure 38 (SEQ ID N0:72), wherein X is any amino acid from Z1 to 31 of Figure 38 (SEQ ID
N0:72). Therefore, mature forms of the PR06030 polypeptide which are encompassed by the present invention include those comprising amino acids X to 322 of Figure 38 (SEQ ID N0:72), wherein X is any amino acid from 21 to 31 of Figure 38 (SEQ ID N0:72) and variants thereof as described below. Isolated nucleic acid molecules encoding these polypeptides are also contemplated.
Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PR06030 polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain has been tentatively identified as extending from about amino acid position 142 to about amino acid position I58 in the sequence of Figure 38 (SEQ ID N0:72). Therefore, soluble extracellular domains of the herein described PR06030 polypeptides are contemplated.
In this regard, another aspect of the present invention is directed to an isolated nucleic acid molecule which comprises a nucleotide sequence having at least about 8096 sequence identity, preferably at least about 8196 sequence identity, more preferably at least about 82 9b sequence identity, yet more preferably at least about 83 '& sequence identity, yet more preferably at least about 8490 sequence identity, yet more preferably at least about 8596 sequence identity, yet more preferably at least about 8696 sequence identity, yet more preferably at least about 87 ~ sequence identity, yet more preferably at least about 88 %
sequence identity, yet more preferably at least about 89k sequence identity, yet more preferably at least about 90%
sequence identity, yet more preferably at least about 91 ~ sequence identity, yet more preferably at least about 9296 sequence identity, yet more preferably at least about 93 ~ sequence identity, yet more preferably at least about 94 96 sequence identity, yet more preferably at least about 95% sequence identity, yet more preferably at least about 96~ sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98%
sequence identity and yet more preferably at least about 99 % sequence identity to (a) a DNA molecule encoding amino acids 1 to X of Figure 38 (SEQ ID N0:72), where X is any amino acid from 137 to 147 of Figure 38 (SEQ ID N0:72), or (b) the complement of the DNA molecule of (a). In a specific aspect, the isolated nucleic acid molecule comprises a nucleotide sequence which (a) encodes amino acids 1 to X of Figure 38 (SEQ ID
N0:72), where X is any amino acid from 137 to 147 of Figure 38 (SEQ ID N0:72), or (b) is the complement of the DNA molecule of (a).
In yet another aspect of the present invention, the isolated nucleic acid molecule (a) encodes a polypeptide scoring at least about 80% positives, preferably at least about 81 % positives, more preferably at least about 82% positives, yet more preferably at least about 83% positives, yet more preferably at least about 84%
positives, yet more preferably at least about 85 % positives, yet more preferably at least about 86 % positives, yet more preferably at least about 87% positives, yet more preferably at least about 88% positives, yet more preferably at least about 89% positives, yet more preferably at least about 90% positives, yet more preferably at least about 91 % positives, yet more preferably at least about 92 %
positives, yet more preferably at least about 93 % positives, yet more preferably at least about 94% positives, yet more preferably at least about 9S %
positives, yet more preferably at least about 96% positives, yet more preferably at least about 97% positives, yet more preferably at least about 98% positives and yet more preferably at least about 99% positives when compared with the amino acid sequence of residues about 1 to X of Figure 38 (SEQ ID N0:72), where X is any amino acid from 137 to 147 of Figure 38 (SEQ ID N0:72), or (b) is the complement of the DNA molecule of (a).
Another embodiment is directed to fragments of a PR06030 polypeptide coding sequence that may find use as, for example, hybridization probes or for encoding fragments of a PR06030 polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PR06030 antibody. Such nucleic acid fragments are usually at least about 20 nucleotides in length, preferably at least about 30 nucleotides in length, more preferably aL least about 40 nucleotides in length, yet more preferably at least about 50 nucleotides in length, yet more preferably at least about 60 nucleotides in length, yet more preferably at least about 70 nucleotides in length, yet more preferably at least about 80 nucleotides in length, yet more preferably at least about 90 nucleotides in length, yet more preferably at least about 100 nucleotides in length, yet more preferably at least about 110 nucleotides in length, yet more preferably at least about 120 nucleotides in length, yet more preferably at least about 130 nucleotides in length, yet more preferably at least about 140 nucleotides in length, yet more preferably at least about 150 nucleotides in length, yet more preferably at least about 160 nucleotides in length, yet more preferably at least about 170 nuchtides in length, yet more preferably at least about 180 nucleotides in length, yet more preferably at least about 190 nucleotides in length, yet more preferably at least about 200 nucleotides in length, yet more preferably at least about 250 nucleotides in length, yet more preferably at least about 300 nucleotides in length, yet more preferably at least about 350 nucleotides in length, yet more preferably at least about 400 nucleotides in length, yet more preferably at least about 450 nucleotides in length, -yet more preferably at least about 500 nucleotides in length, yet more preferably at least about 600 nucleotides in length, yet more preferably at least about 700 nucleotides in length, yet more preferably at least about 800 nucleotides in length, yet more preferably at least about 900 nucleotides in length and yet more preferably at least about 1000 nucleotides in length, wherein in this context the term °about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. In a preferred embodiment, the nucleotide sequence fragment is derived from any coding region of the nucleotide sequence shown in Figure 37 (SEQ ID
N0:71). It is noted that novel fragments of a PR06030 polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PR06030 polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PR06030 polypeptide-encoding nt~leotide sequence fragments) are novel.
All of such PR06030 polypeptide-encoding nucleotide sequences are contemplated herein and can be determined without undue experimentation. Also contemplated are the PR06030 polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PR06030 polypeptide fragments that comprise a binding site for an anti-PR06030 antibody.
In another embodiment, the invention provides isolated PR06030 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.
In a specific aspect, the invention provides isolated native sequence PR06030 polypeptide, which in certain embodiments, includes an amino acid sequence comprising residues from about 1 or about 27 to about 322 of Figure 38 (SEQ ID N0:72).
In another aspect, the invention concerns an isolated PR06030 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 8291; sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86q sequence identity, yet more preferably at least about 876 sequence identity, yet more preferably at least about 88% sequence identity, yet more preferably at least about 89%
sequence identity, yet more preferably at least about 90 % sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 9o sequence identity, yet more preferably at least about 94 %
sequence identity, yet more preferably at least about 95 9~ sequence identity, yet more preferably at least about 96 9o sequence identity, yet more preferably at least about 97 % sequence identity, yet more preferably at least about 98 %
sequence identity and yet more preferably at least about 99 % sequence identity to the sequence of amino acid residues from about 1 or about 27 to about 322, inclusive, of Figure 38 (SEQ ID N0:72).
In a further aspect, the invention concerns an isolated PR06030 polypeptide comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 8496 sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86 % sequence identity, yet more preferably at least about 87 Xo sequence identity, yet more preferably at least about 88%a sequence identity, yet more preferably at least about 89%
sequence identity, yet more preferably at least about 90% sequence identity, yet more preferably at least about 91 % sequence identity, yet more preferably at least about 92% sequence identity, yet more preferably at least about 93 % sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95 % sequence identity, yet more preferably at least about 96 %
sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98%
sequence identity and yet more preferably at least about 99 % sequence identity to an amino acid sequence encoded by the human protein cDNA
deposited with the ATCC on August 3, 1999 under ATCC Deposit No. 479-PTA
(DNA96850-2705). In a preferred embodiment, the isolated PR06030 polypeptide comprises an amino acid sequence encoded by the human protein cDNA deposited with the ATCC on August 3, 1999 under ATCC
Deposit No. 479-PTA
(DNA96850-2705).
In a further aspect, the invention concerns an isolated PR06030 polypeptide comprising an amino acid sequence scoring at least about 80% positives, preferably at least about 81 %
positives, more preferably at least about 82 % positives, yet more preferably at least about 83 % positives, yet more preferably at least about 84 %
positives, yet more preferably at least about 85% positives, yet more preferably at least about 86% positives, yet more preferably at least about 87% positives, yet more preferably at least about 88% positives, yet more preferably at least about 89% positives, yet more preferably at least about 90% positives, yet more preferably at least about 91 % positives, yet more preferably at least about 92 %
positives, yet more preferably at least about 93 % positives, yet more preferably at least about 94 % positives, yet more preferably at least about 95 %
positives, yet more preferably at least about 96% positives, yet more preferably at least about 97% positives, yet more preferably at Least about 98% positives and yet more preferably at least about 99% positives when compared with the amino acid sequence of residues from about 1 or about 27 to about 322, inclusive, of Figure 38 (SEQ ID N0:72).
In a specific aspect, the invention provides an isolated PR06030 polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PR06030 polypeptide and recovering the PR06030 polypeptide from the cell culture.
Another aspect the invention provides an isolated PR06030 polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also hecein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PR06030 polypeptide and recovering the PR06030 polypeptide from the cell culture.
As such, one aspect of the present invention is directed to an isolated soluble PR06030 polypeptide which comprises an amino acid sequence having at least about 80% sequence identity, preferably at least about 81 % sequence identity, more preferably at least about 82% sequence identity, yet more preferably at least about 83 % sequence identity, yet more preferably at least about 84 % sequence identity, yet more preferably at least about 85 % sequence identity, yet more preferably at least about 86 % sequence identity, yet more preferably at least about 87% sequence identity, yet more preferably at least about 88 %
sequence identity, yet more preferably at least about 89 % sequence identity, yet more preferably at least about 90 %
sequence identity, yet more SS

WO 00/56889 PC'T/US00/05601 preferably at least about 91 % sequence identity, yet more preferably at least about 92 % sequence identity, yet more preferably at least about 93 96 sequence identity, yet more preferably at least about 94 % sequence identity, yet more preferably at least about 95% sequence identity, yet more preferably at least about 96% sequence identity, yet more preferably at least about 97% sequence identity, yet more preferably at least about 98%
sequence identity and yet more preferably at least about 99?6 sequence identity to amino acids 1 to X of Figure 38 (SEQ ID N0:72), where X is any amino acid from 137 to 147 of Figure 38 (SEQ
ID N0:72). In a preferred aspect, the isolated soluble PR06030 polypeptide comprises amino acids 1 to X
of Figure 38 (SEQ ID N0:72), where X is any amino acid from 137 to 147 of Figure 38 (SEQ ID N0:72).
In yet another aspect of the present invention, the isolated soluble PR06030 polypeptide comprises an amino acid sequence which scores at least about 80% positives, preferably at least about 81 % positives, more preferably at least about 82 % positives, yet more preferably at least about 83 % positives, yet more preferably at least about 84 % positives, yet more preferably at least about 85 9I6 positives, yet more preferably at least about 86% positives, yet more preferably at least about 87% positives, yet more preferably at least about 88%
positives, yet more preferably at least about 89% positives, yet more preferably at least about 90% positives, yet more preferably at least about 91 % positives, yet more preferably at least about 92 % positives, yet more preferably at least about 93 % positives, yet more preferably at least about 94 % positives, yet more preferably at least about 95 % positives, yet more preferably at least about 96 %
positives, yet more preferably at least about 97% positives, yet more preferably at least about 98% positives and yet more preferably at least about 99%
positives when compared with the amino acid sequence of residues about 1 to X
of Figure 38 (SEQ ID N0:72), where X is any amino acid from 137 to 147 of Figure 38 (SEQ ID N0:72).
In yet another asp~t, the invention concerns an isolated PR06030 polypeptide, comprising the sequence of amino acid residues from about 1 or about 27 to about 322, inclusive, of Figure 38 (SEQ ID N0:72), or a fragment thereof which is biologically active or sufficient to provide a binding site for an anti-PR06030 antibody, wherein the identification of PR06030 polypeptide fragments that possess biological activity or provide a binding site for an anti-PR06030 antibody may be accomplished in a routine manner using techniques which are well lmown in the art. Preferably, the PR06030 fragment retains a qualitative biological activity of a native PR06030 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (l) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR06030 polypeptide having the sequence of amino acid residues from about 1 or about 27 to about 322, inclusive, of Figure 38 (SEQ ID
N0:72), or (b) the complement of the DNA molecule of (a), and if the test DNA
molecule has at least about an 80% sequence identity, preferably at least about an 81 % sequence identity, more preferably at least about an 8296 sequence identity, yet more preferably at least about an 83 96 sequence identity, yet more preferably at least about an 84% sequence identity, yet more preferably at least about an 85%
sequence identity, yet more preferably at least about an 86% sequence identity, yet more preferably at least about an 87'~ sequence identity, yet more preferably at least about an 88 % sequence identity, yet more preferably at least about an 89 % sequence identity, yet more preferably at least about a 90% sequence identity, yet more preferably at least about a 91 %
sequence identity, yet more preferably at least about a 929fo sequence identity, yet more preferably at least about a 93 ~ sequence identity, yet more preferably at least about a 949b sequence identity, yet more preferably at least about a 95 % sequence identity, yet more preferably at least about a 96 %
sequence identity, yet more preferably at least about a 97% sequence identity, yet more preferably at least about a 98% sequence identity and yet more preferably at least about a 99 ~ sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA
molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
In a still further embodiment, the invention concerns a composition of matter comprising a PR06030 polypeptide, or an agonist or antagonist of a PR06030 polypeptide as herein described, or an anti-PR06030 antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.
Another embodiment of the present invention is directed to the use of a PR06030 polypeptide, or an agonist or antagonist thereof as herein described, or an anti-PR06030 antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PR06030 polypeptide, an agonist or antagonist thereof or an anti-PR06030 antibody.
20. R
A cDNA clone (DNA96857-2636) has been identified that encodes a novel polypeptide having homology to a protein in GenBank, accession number HGS A135 and designated in the present application as "PR04424°.
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04424 poiypeptide, In one aspect, the isolated nucleic acid comprises DNA having at least about 80 % sequence identity, preferably at least about 85~ sequence identity, more preferably at least about 909 sequence identity, most preferably at least about 95 '~ sequence identity to (a) a DNA molecule encoding a PR04424 polypeptide having the sequence of amino acid residues from 1 or about 29 to about 221, inclusive of Figure 40 (SEQ ID N0:74), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04424 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 136 and about 714, inclusive, of Figure 39 (SEQ ID N0:73). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 809~o sequence identity, preferably at least about 85 ~
sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95~ sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 17-PTA
(DNA96857-2636), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 17-PTA (DNA96857-2636).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80~ sequence identity, preferably at least about 85% sequence identity, more preferably at least about 9096 sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 29 to about 221, inclusive of Figure 40 (SEQ ID
N0:74), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04424 polypeptide having the sequence of amino acid residues from about 29 to about 221, inclusive of Figure 40 (SEQ ID
N0:74), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85 96 sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80% positives, preferably at least about 85% positives, more preferably at least about 90% positives, most preferably at least about 95%
positives when compared with the amino acid sequence of residues 29 to about 221, inclusive of Figure 40 (SEQ
ID N0:74), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR04424 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and mast preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04424 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04424 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 29 through 221 of Figure 40 (SEQ ID
N0:74).
In another aspect, the invention concerns an isolated PR04424 polypeptide, comprising an amino acid sequence having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 9596 sequence identity to the sequence of amino acid residues 29 to about 221, inclusive of Figure 40 (SEQ
ID N0:74).
In a further aspect, the invention concerns an isolated PR04424 polypeptide, comprising an amino acid sequence scoring at least about 80 % positives, preferably at least about 85 %
positives, more preferably at least about 90 % positives, most preferably at least about 95 96 positives when compared with the amino acid sequence of residues 29 through 221 of Figure 40 (SEQ ID N0:74).
In yet another aspect, the invention concerns an isolated PR04424 polypeptide, comprising the sequence of amino acid residues 29 to about 221, inclusive of Figure 40 (SEQ ID N0:74), or a fragment thereof sufficient to provide a binding site for an anti-PR04424 antibody. Preferably, the PR04424 fragment retains a qualitative biological activity of a native PR04424 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04424 polypeptide having the sequence of amino acid residues from about 29 to about 221, inclusive of Figure 40 (SEQ ID N0:74), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 9b sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
21. PR04422 A cDNA clone (DNA96867-2620) has been identified that encodes a novel polypeptide having homology to lysozyme g and designated in the present application as "PR04422".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04422 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04422 polypeptide having the sequence of amino acid residues from 1 or about 20 to about 194, inclusive of Figure 42 (SEQ ID N0:76), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04422 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 375 and about 899, inclusive, of Figure 41 (SEQ ID N0:75). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85.°6 sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203972 (DNA96867-2620), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 203972 (DNA96867-2620).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 8596 sequence identity, more preferably at least about 9096 sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 20 to about 194, inclusive of Figure 42 (SEQ ID
N0:76), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04422 polypeptide having the sequence of amino acid residues from about 20 to about 194, inclusive of Figure 42 (SEQ ID
N0:76), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80°6 sequence identity, preferably at least about an 85 % sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 '~ sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 8096 positives, preferably at least about 85'~ positives, more preferably at least about 9096 positives, most preferably at least about 9596 positives when compared with the amino acid sequence of residues 20 to about 194, inclusive of Figure 42 (SEQ
ID N0:76), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR04422 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about SO nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04422 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04422 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 20 through 194 of Figure 42 (SEQ ID
N0:76).
In another aspect, the invention concerns an isolated PR04422 polypeptide, comprising an amino acid sequence having at least about 809b sequence identity, preferably at least about 85 ~ sequence identity, more preferably at least about 9096 sequence identity, most preferably at least about 95 '~ sequence identity to the .
sequence of amino acid residues 20 to about 194, inclusive of Figure 42 (SEQ
ID N0:76).
In a further aspect, the invention concerns an isolated PR04422 polypeptide, comprising an amino acid sequence scoring at least about 8096 positives, preferably at least about 8596 positives, more preferably at least about 90 ~ positives, most preferably at least about 95 '.~ positives when compared with the amino acid sequence of residues 20 through 194 of Figure 42 (SEQ ID N0:76).
In yet another aspect, the invention concerns an isolated PR04422 poiypeptide, comprising the sequence of amino acid residues 20 to about 194, inclusive of Figure 42 (SEQ ID NO;
76), or a fragment thereof sufficient to provide a binding site for an anti-PR04422 antibody. Preferably, the PR04422 fragment retains a qualitative biological activity of a native PR04422 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04422 polypeptide having the sequence of amino acid residues from about 20 to about 194, inclusive of Figure 42 (SEQ ID N0:76), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80~ sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90~ sequence identity, most preferably at least about a 95 ~ sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.

22. PR04430 A cDNA clone (DNA96878-2626) has been identified that encodes a novel polypeptide having homology to a protein in GenBank, accession number MMHC213L3 9, and designated in the present application as "PR04430".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04430 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04430 polypeptide having the sequence of amino acid residues from 1 or about 19 to about 125, inclusive of Figure 44 (SEQ ID N0:78), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04430 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 110 and about 430, inclusive, of Figure 43 (SEQ ID N0:77). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90 % sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 23-PTA
(DNA96878-2626), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 23-PTA (DNA~878-2626).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80 % sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 959 sequence identity to the sequence of amino acid residues from about 19 to about 125, inclusive of Figure 44 (SEQ ID
N0:78), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about 100 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04430 polypeptide having the sequence of amino acid residues from about 19 to about 125, inclusive of Figure 44 (SEQ ID
N0:78); or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 8095 sequence identity, preferably at least about an 85 '~ sequence identity, more preferably at least about a 90 9b sequence identity, most preferably at least about a 95 % sequence identity to (a) or (b), isolating the test DNA
molecule.
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80'.6 positives, preferably at least about 8556 positives, more preferably at least about 9096 positives, most preferably at least about 95 ~
positives when compared with the amino acid sequence of residues 19 to about 125, inclusive of Figure 44 (SEQ
ID N0:78), or (b) the complement of the DNA of (a).
Another embodiment is directed to fragments of a PR04430 poiypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04430 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04430 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 19 through 125 of Figure 44 (SEQ ID
N0:78).
In another aspect, the invention concerns an isolated PR04430 polypeptide, comprising an amino acid sequence having at least about 80 ~ sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90~ sequence identity, most preferably at least about 959E sequence identity to the sequence of amino acid residues 19 to about 125, inclusive of Figure 44 (SEQ
ID N0:78).
In a further aspect, the invention concerns an isolated PR04430 polypeptide, comprising an amino acid sequence scoring at least about 80 r~ positives, preferably at least about 85 ~O positives, more preferably at least about 90 ~ positives, most preferably at least about 95 ~ positives when compared with the amino acid sequence of residues 19 through 125 of Figure 44 (SEQ ID N0:78).
In yet another aspect, the invention concerns an isolated PR04430 polypeptide, comprising the sequence of amino acid residues 19 to about 125, inclusive of Figure 44 (SEQ ID N0:78), or a fragment thereof sufficient to provide a binding site for an anti-PR04430 antibody. Preferably, the PR04430 fragment retains a qualitative biological activity of a native PR04430 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04430 poiypeptide having the sequence of amino acid residues from about 19 to about 125, inclusive of Figure 44 (SEQ ID N0:78), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85 q6 sequence identity, more preferably at least about a 90:6 sequence identity, most preferably at least about a 95 96 sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
23. PR04499 A cDNA clone (DNA96889-2641) has been identified that encodes a novel polypeptide and designated in the present application as "PR04499".
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04499 polypeptide.
In one aspect, the isolated nucleic acid comprises DNA having at least about 80% sequence identity, preferably at least about 85 91; sequence identity, more preferably at least about 90 ~ sequence identity, most preferably at least about 95 % sequence identity to (a) a DNA molecule encoding a PR04499 polypeptide having the sequence of amino acid residues from 1 or about 31 to about 339, inclusive of Figure 46 (SEQ ID N0:80), or (b) the complement of the DNA molecule of (a).
In another aspect, the invention concerns an isolated nucleic acid molecule encoding a PR04499 polypeptide comprising DNA hybridizing to the complement of the nucleic acid between about residues 275 and about 1201, inclusive, of Figure 45 (SEQ ID N0:79). Preferably, hybridization occurs under stringent hybridization and wash conditions.
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising DNA having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90'Y sequence identity, most preferably at least about 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 119-PTA
(DNA96889-2641 ), or (b) the complement of the DNA molecule of (a). In a preferred embodiment, the nucleic acid comprises a DNA encoding the same mature polypeptide encoded by the human protein cDNA in ATCC
Deposit No. 119-PTA (DNA96889-2641).
In a still further aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide having at least about 80% sequence identity, preferably at least about 85% sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues from about 31 to about 339, inclusive of Figure 46 (SEQ ID
NO:80), or the complement of the DNA of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule having at least about 50 nucleotides, and preferably at least about I00 nucleotides and produced by hybridizing a test DNA molecule under stringent conditions with (a) a DNA molecule encoding a PR04499 polypeptide having the sequence of amino acid residues from about 31 to about 339, inclusive of Figure 46 (SEQ ID
N0:80), or (b) the complement of the DNA molecule of (a), and, if the DNA molecule has at least about an 80 % sequence identity, preferably at least about an 85 '~ sequence identity, more preferably at least about a 90 % sequence identity, most preferably at least about a 95 9b sequence identity to (a) or (b), isolating the test DNA
molecule.
In a specific aspect, the invention provides an isolated nucleic acid molecule comprising DNA encoding a PR04499 polypeptide, with or without the N-terminal signal sequence and/or the initiating methionine, and its soluble variants (i.e. transmembrane domain deleted or inactivated), or is complementary to such encoding nucleic acid molecule. The signal peptide has bin tentatively identified as extending from amino acid position 1 through about amino acid position 30 in the sequence of Figure 46 (SEQ ID
N0:80). The transmembrane domain has been tentatively identified as extending from about amino acid position 171 through about amino acid position 190 in the PR04499 amino acid sequence (Figure 46, SEQ ID N0:80).
In another aspect, the invention concerns an isolated nucleic acid molecule comprising (a) DNA
encoding a polypeptide scoring at least about 80 % positives, preferably at least about 85 % positives, more preferably at least about 90% positives, most preferably at least about 95%
positives when compared with the amino acid sequence of residues 31 to about 339, inclusive of Figure 46 (SEQ
ID N0:80), or (b) the complement of the DNA of (a).

Another embodiment is directed to fragments of a PR04499 polypeptide coding sequence that may find use as hybridization probes. Such nucleic acid fragments are from about 20 through about 80 nucleotides in length, preferably from about 20 through about 60 nucleotides in length, more preferably from about 20 through about 50 nucleotides in length, and most preferably from about 20 through about 40 nucleotides in length.
In another embodiment, the invention provides isolated PR04499 polypeptide encoded by any of the isolated nucleic acid sequences hereinabove defined.
In a specific aspect, the invention provides isolated native sequence PR04499 polypeptide, which in one embodiment, includes an amino acid sequence comprising residues 31 through 339 of Figure 46 (SEQ ID
N0:80).
In another aspect, the invention concerns an isolated PR04499 polypeptide, comprising an amino acid sequence having at least about 80 % sequence identity, preferably at least about 85 % sequence identity, more preferably at least about 90% sequence identity, most preferably at least about 95% sequence identity to the sequence of amino acid residues 31 to about 339, inclusive of Figure 46 (SEQ
ID N0:80).
In a further aspect, the invention concerns an isolated PR04499 polypeptide, comprising an amino acid sequence scoring at least about 80% positives, preferably at teast about 85 %
positives, more preferably at least about 90 % positives, most preferably at least about 95 % positives when compared with the amino acid sequence of residues 31 through 339 of Figure 46 (SEQ ID N0:80).
In yet another aspect, the invention concerns an isolated PR04499 polypeptide, comprising the sequence of amino acid residues 31 to about 339, inclusive of Figure 46 (SEQ ID N0:80), or a fragment thereof sufficient to provide a binding site for an anti-PR04499 antibody. Preferably, the PR04499 fragment retains a qualitative biological activity of a native PR04499 polypeptide.
In a still further aspect, the invention provides a polypeptide produced by (i) hybridizing a test DNA
molecule under stringent conditions with (a) a DNA molecule encoding a PR04499 polypeptide having the sequence of amino acid residues from about 31 to about 339, inclusive of Figure 46 (SEQ 1D N0:80), or (b) the complement of the DNA molecule of (a), and if the test DNA molecule has at least about an 80% sequence identity, preferably at least about an 85% sequence identity, more preferably at least about a 90% sequence identity, most preferably at least about a 95 ro sequence identity to (a) or (b), (ii) culturing a host cell comprising the test DNA molecule under conditions suitable for expression of the polypeptide, and (iii) recovering the polypeptide from the cell culture.
24. Additional Embodiments In other embodiments of the present invention, the invention provides vectors comprising DNA
encoding any of the herein described polypeptides. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, E. coli, or yeast. A process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.
In other embodiments, the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence.
Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.
In another embodiment, the invention provides an antibody which specifically binds to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.
In yet other embodiments, the invention provides oligonucleotide probes useful for isolating genomic and cDNA nucleotide sequences or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide sequences.
In other embodiments, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.
In one aspect, the isolated nucleic acid molecule comprises a nuchtide sequence having at least about 80 ~ nucleic acid sequence identity, alternatively at least about 81 ~ nucleic acid sequence identity, alternatively at least about 82~ nucleic acid sequence identity, alternatively at least about 83 9'o nucleic acid sequence identity, alternatively at least about 84~ nucleic acid sequence identity, alternatively at least about 85~ nucleic acid sequence identity, alternatively at least about 86 ~ nucleic acid sequence identity, alternatively at feast about 87 ~
nucleic acid sequence identity, alternatively at least about 88 ~ nucleic acid sequence identity, alternatively at least about 89~ nucleic acid sequence identity, alternatively at least about 90~ nucleic acid sequence identity, alternatively at least about 91~ nucleic acid sequence identity, alternatively at least about 92'~ nucleic acid sequence identity, alternatively at least about 93 96 nucleic acid sequence identity, alternatively at least about 94 ~
nucleic acid sequence identity, alternatively at least about 95 '~ nucleic acid sequence identity, alternatively at least about 96~ nucleic acid sequence identity, alternatively at least about 97~ nucleic acid sequence identity, alternatively at least about 98~ nucleic acid sequence identity and alternatively at least about 99~ nucleic acid sequence identity to (a) a DNA molecule encoding a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).
In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80 ~ nucleic acid sequence identity, alternatively at least about 81 ~ nucleic acid sequence identity, alteruratively at least about 82 ~ nucleic acid sequence identity, alternatively at least about 83 ~ nucleic acid sequence identity, alternatively at least about 84 ~ nucleic acid sequence identity, alternatively at least about 85 ~ nucleic acid sequence identity, alternatively at least about 86 ~ nucleic acid sequence identity, alternatively at least about 87 nucleic acid sequence identity, alternatively at least about 88~ nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91 ~ nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93 ~ nucleic acid sequence identity, alternatively at least about 94 k nucleic acid sequence identity, alternatively at least about 95 ~ nucleic acid sequence identity, alternatively at least about 96fo nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO polypeptide cDNA
as disclosed herein, the coding sequence of a PRO polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane PRO
polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA
molecule of (a).
In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81 % nucleic acid sequence identity, alternatively at least about 82 % nucleic acid sequence identity, alternatively at least about 83 '.~
nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at I O least about 85 % nucleic acid sequence identity, alternatively at least about 86 % nucleic acid sequence identity, alternatively at least about 87 ~ nucleic acid sequence identity, alternatively at least about 88 % nucleic acid sequence identity, alternatively at least about 89 % nucleic acid sequence identity, alternatively at least about 90 nucleic acid sequence identity, alternatively at least about 91 % nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94 % nucleic acid sequence identity, alternatively at least about 95 % nucleic acid sequence identity, alternatively at least about 96 % nucleic acid sequence identity, alternatively at least about 97 nucleic acid sequence identity, alternatively at least about 9830 nucleic acid sequence identity and alternatively at least about 9996 nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs deposited with the ATCC
as disclosed herein, or (b) the complement of the DNA molecule of (a).
Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the uansmembrane domains) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO
polypeptides are contemplated.
Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes. Such nucleic acid fragments are usually at least about 20 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at Least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, altennatively at least about 60 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 130 nucleotides in length, alternatively at least about 140 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 160 nucleotides in length, alternatively at least about 170 nucleotides in length, alternatively at least about 180 nucleotides in length, WO 00/56889 PC'fNS00/05601 alternatively at least about 190 nucleotides in length, alternatively at least about 200 nucleotides in length, alternatively at least about 250 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 350 nucleotides in length, alternatively at least about 400 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 500 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 700 nucleotides in length, alternatively at least about 800 nucleotides in length, alternatively at least about 900 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragments) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO polypeptide fragments that comprise a binding site for an anti-PRO
antibody.
In another embodiment, the invention provides isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identifed.
In a certain aspect, the invention concerns an isolated PRO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81 % amino acid sequence identity, alternatively at least about 82 % amino acid sequence identity, alternatively at least about 83 %
amino acid sequence identity, alternatively at least about 84 '~ amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 899b amino acid sequence identity, alternatively at least about 9096 amino acid sequence identity, alternatively at least about 919b amino acid sequence identity, alternatively at least about 92 % amino acid sequence identity, alternatively at least about 93 %
amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96 % amino acid sequence identity, alternatively at least about 97%
amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 9996 amino acid sequence identity to a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.
In a further aspect, the invention concerns an isolated PRO polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81 % amino acid sequence identity, alternatively at least about 8296 amino acid sequence identity, alternatively at least about 83 %
amino acid sequence identity, alternatively at least about 84 % amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87 % amino acid sequence identity, alternatively at least about 88 % amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90%
amino acid sequence identity, alternatively at least about 91 % amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 959b amino acid sequence identity, alternatively at least about 96 % amino acid sequence identity, alternatively at least about 97 %
amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to an amino acid sequence encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein.
In a further aspect, the invention concerns an isolated PRO polypeptide comprising an amino acid sequence scoring at least about 80% positives, alternatively at least about 81 % positives, alternatively at least about 82 % positives, alternatively at least about 83 % positives, alternatively at least about 84 % positives, alternatively at least about 85 % positives, alternatively at Ieast about 86 %
positives, alternatively at least about 87 % positives, alternatively at least about 88 ~ positives, alternatively at least about 89 % positives, alternatively at least about 90% positives, alternatively at least about 91 % positives, alternatively at least about 92% positives, alternatively al least about 93 % positives, alternatively at least about 94 %
positives, alternatively at least about 95 % positives, alternatively at least about 96% positives, alternatively at least about 97 % positives, alternatively at least about 98% positives and alternatively at least about 99% positives when compared with the amino acid sequence of a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.
In a specific aspect, the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO
polypeptide and recovering the PRO
polypeptide from the cell culture.
Another aspect the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.
In yet another embodiment, the invention concerns agonists and antagonists of a native PRO polypeptide as defined herein. In a particular embodiment, the agonist or antagonist is an anti-PRO antibody or a small molecule.
In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide. Preferably, the PRO
polypeptide is a native PRO
polypeptide.
In a still further embodiment, the invention concerns a composition of matter comprising a PRO
polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.
Another embodiment of the present invention is directed to the use of a PRO
polypeptide, or an agorust or antagonist thereof as hereinbefore described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO
polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PR01484 cDNA, wherein SEQ ID NO:I is a clone designated herein as "DNA44686-1653".
Figure 2 shows the amino acid sequence (SEQ ID N0:2) derived from the coding sequence of SEQ ID
NO:1 shown in Figure 1.
Figure 3 shows a nucleotide sequence (SEQ ID N0:8) of a native sequence PR04334 cDNA, wherein SEQ ID N0:8 is a clone designated herein as "DNA59b08-2577".
Figure 4 shows the amino acid sequence (SEQ ID N0:9) derived from the coding sequence of SEQ ID
N0:8 shown in Figure 3.
Figure 5 shows a nucleotide sequence (SEQ ID NO:10) of a native sequence PROl I22 cDNA, wherein SEQ ID NO:10 is a clone designated herein as "DNA62377-I381 ~.
Figure 6 shows the amino acid sequence (SEQ ID NO:11) derived from the coding sequence of SEQ
ID NO:10 shown in Figure 5.
Figure 7 shows a nucleotide sequence (SEQ ID NO:15) of a native sequence PR01889 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA77623-2524".
Figure 8 shows the amino acid sequence (SEQ ID NO:16) derived from the coding sequence of SEQ
ID NO:15 shown in Figure 7.
Figure 9 shows a nucleotide sequence (SEQ ID N0:17) of a native sequence PR01890 cDNA, wherein SEQ ID N0:17 is a clone designated herein as "DNA79230-2525".
Figure 10 shows the amino acid sequence (SEQ ID N0:18) derived from the coding sequence of SEQ
ID N0:17 shown in Figure 9.
Figure 11 shows a nucleotide sequence (SEQ ID N0:22) of a native sequence PR01887 cDNA, wherein SEQ ID N0:22 is a clone designated herein as "DNA79862-2522".
Figure 12 shows the amino acid sequence (SEQ ID N0:23) derived from the coding sequence of SEQ
ID N0:22 shown in Figure 11.
Figure 13 shows a nucleotide sequence (SEQ ID N0:28) of a native sequence PRO
1785 cDNA, wherein SEQ ID N0:28 is a clone designated herein as "DNA80136-2503".

Figure 14 shows the amino acid sequence (SEQ ID N0:29) derived from the coding sequence of SEQ
ID N0:28 shown in Figure I3.
Figure 15 shows a nucleotide sequence (SEQ ID N0:34) of a native sequence PR04353 cDNA, wherein SEQ ID N0:34 is a clone designated herein as "DNA80145-2594".
Figure 16 shows the amino acid sequence (SEQ ID N0:35) derived from the coding sequence of SEQ
ID N0:34 shown in Figure 15.
Figure 17 shows a nucleotide sequence (SEQ ID N0:39) of a native sequence PR04357 cDNA, wherein SEQ ID N0:39 is a clone designated herein as "DNA84917-2597".
Figure 18 shows the amino acid sequence (SEQ ID N0:40) derived from the coding sequence of SEQ
ID N0:39 shown in Figure 17.
Figure 19 shows a nucleotide sequence (SEQ ID N0:44) of a native sequence PR04405 cDNA, wherein SEQ ID N0:44 is a clone designated herein as "DNA84920-2614".
Figure 20 shows the amino acid sequence (SEQ ID N0:45) derived from the coding sequence of SEQ
ID N0:44 shown in Figure 19.
Figure 21 shows a nucleotide sequence (SEQ ID N0:49) of a native sequence PR04356 cDNA, wherein IS SEQ ID N0:49 is a clone designated herein as "DNA86576-2595".
Figure 22 shows the amino acid sequence (SEQ ID NO:50) derived from the coding sequence of SEQ
ID N0:49 shown in Figure 21.
Figure 23 shows a nucleotide sequence (SEQ ID NO:51 ) of a native sequence PR04352 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA87976-2593~.
Figure 24 shows the amino acid sequence (SEQ ID N0:52) derived from the coding sequence of SEQ
ID NO:51 shown in Figure 23.
Figure 25 shows a nucleotide sequence (SEQ ID N0:56) of a native sequence PR04380 cDNA, wherein SEQ ID N0:56 is a clone designated herein as "DNA92234-2602~.
Figure 26 shows the amino acid sequence (SEQ ID N0:57) derived from the coding sequence of SEQ
ID N0:56 shown in Figure Z5.
Figure 27 shows a nucleotide sequence (SEQ ID N0:58) of a native sequence PR04354 cDNA, wherein SEQ ID N0:58 is a clone designated herein as "DNA92256-2596".
Figure 28 shows the amino acid sequence (SEQ ID N0:59) derived from the coding sequeace of SEQ
ID N0:58 shown in Figure 27.
Figure 29 shows a nucleotide sequence (SEQ ID N0:60) of a native sequence PR04408 cDNA, wherein SEQ ID N0:60 is a clone designated herein as "DNA92274-2617".
Figure 30 shows the amino acid sequence (SEQ ID N0:61) derived from the coding sequence of SEQ
ID N0:60 shown in Figure 29.
Figure 31 shows a nucleotide sequence (SEQ ID N0:62) of a native sequence PR05737 cDNA, wherein SEQ ID N0:62 is a clone designated herein as "DNA92929-2534~.
Figure 32 shows the amino acid sequence (SEQ ID N0:63) derived from the coding sequence of SEQ
ID N0:62 shown in Figure 31.

Figure 33 shows a nucleotide sequence (SEQ ID N0:64) of a native sequence PR04425 cDNA, wherein SEQ ID N0:64 is a clone designated herein as "DNA93011-2637".
Figure 34 shows the amino acid sequence (SEQ ID N0:65) derived from the coding sequence of SEQ
ID N0:64 shown in Figure 33.
Figure 35 shows a nucleotide sequence (SEQ ID N0:66) of a native sequence PR05990 cDNA, wherein SEQ ID N0:66 is a clone designated herein as "DNA96042-2682".
Figure 36 shows the amino acid sequence (SEQ ID N0:67) derived from the coding sequence of SEQ
ID N0:66 shown in Figure 35.
Figure 37 shows a nucleotide sequence (SEQ ID N0:71) of a native sequence PR06030 cDNA, wherein SEQ ID N0:71 is a clone designated herein as "DNA96850-2705".
Figure 38 shows the amino acid sequence (SEQ ID N0:72) derived from the coding sequence of SEQ
ID N0:71 shown in Figure 37.
Figure 39 shows a nucleotide sequence (SEQ ID N0:73) of a native sequence PR04424 cDNA, wherein SEQ ID N0:73 is a clone designated herein as "DNA968S7-2636".
Figure 40 shows the.amino acid sequence (SEQ ID N0:74) derived from the coding sequence of SEQ
ID N0:73 shown in Figure 39.
Figure 41 shows a nucleotide sequence (SEQ ID N0:75) of a native sequence PR04422 cDNA, wherein SEQ ID N0:75 is a clone designated herein as "DNA96867-2620".
Figure 42 shows the amino acid sequence (SEQ ID N0:76) derived from the coding sequence of SEQ
ID N0:75 shown in Figure 41.
Figure 43 shows a nucleotide sequence (SEQ ID N0:77) of a native sequence PR04430 cDNA, wherein SEQ ID N0:77 is a clone designated herein as "DNA96878-2626".
Figure 44 shows the amino acid sequence (SEQ ID N0:78) derived from the coding sequence of SEQ
ID N0:77 shown in Figure 43.
Figure 45 shows a nucleotide sequence (SEQ ID N0:79) of a native sequence PR04499 cDNA, wherein SEQ ID N0:79 is a clone designated herein as "DNA96889-2641".
Figure 46 shows the amino acid sequence (SEQ ID N0:80) derived from the coding sequence of SEQ
ID N0:79 shown in Figure 4S.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
I. pefinitions The terms "PRO polypeptide" and "PRO" as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PROlnumber) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO
polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods.

A ~native sequence PRO polypeptide~ comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO
polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO
polypeptide (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In various embodiments of the invention, the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides, The PRO polypeptide "extracellular domain" or "ECD" refers to a form of the PRO polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide ECD will have less than 196 of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5 % of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are comtemplated by the present invention.
The approximate location of the "signal peptides" of the various PRO
polypeptides disclosed herein are shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot. . 10:1-6 (1997) and von Heinje et al., Nucl. Acids.
Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cask cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.
"PRO polypeptide variant" means an active PRO polypeptide as defined above or below having at least about 80 % amino acid sequence identity with a full-length native sequence PRO
polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO pokypeptide sequence as disclosed herein. Such PRO
polypeptide variants include, for instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a PRO
polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82 % amino acid sequence identity, alternatively at least about 83 % amino acid sequence identity, alternatively at least about 84 % amino acid sequence identity, alternatively at least about 85 %
amino acid sequence identity, alternatively at least about 86 % amino acid sequence identity, akternatively at least about 87 % amino acid sequence identity, alternatively at least about 88 %
amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91 % amino acid sequence identity, alternatively at least about 92 %
amino acid sequence identity, alternatively at least about 93 % amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98 % amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a full-length native sequence PRO
polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO
polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, PRO
variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at Least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.
"Percent (~o) amino acid sequence identity" with respect to the PRO
polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequatce identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTARY software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, 96 amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Tabie 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc.
and the source code shown *-trademark 73 in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.OD. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
IO
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the %
amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "PRO", wherein "PRO" represents the amino acid sequence of a hypothetical PRO polypeptide of interest, "Comparison Protein"
represents the amino acid sequence of a polypeptide against which the "PRO" polypeptide of interest is being compared, and "X, "Y" and "Z" each represent different hypothetical amino acid residues.
Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % amino acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzylnol~ 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a °~ amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acid residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (i.e., the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest. For example, in the statement "a polypeptide comprising an the amino acid sequence A which has or having at least 80% amino acid sequence identity to the amino acid sequence B", the amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.

Percent amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded.from http://www.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask =
yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, mufti-pass e-value =
0.01, constant for mufti-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.
In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B
(which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the ~ amino acid sequence identity of A to B will not equal the % amino acid sequence identity ofBtoA.
"PRO variant polynucleotide" or "PRO variant nucleic acid sequence" means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80 ~ nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO poiypeptide sequence as disclosed herein.
Ordinarily, a PRO variant polynucleotide will have at least about 80~ nucleic acid sequence identity, alternatively at least about 8196 nucleic acid sequence identity, alternatively at least about 8251; nucleic acid sequence identity, alternatively at least about 83 96 nucleic acid sequence identity, alternatively at least about 84 ~
nucleic acid sequence identity, alternatively at least about 85 ~ nucleic acid sequence identity, alternatively at least about 866 nucleic acid sequence identity, alternatively at least about 8796 nucleic acid sequence identity, alternatively at least about 8896 nucleic acid sequence identity, alternatively at least about 89~ nucleic acid sequence identity, alternatively at least about 9096 nucleic acid sequence identity, alternatively at least about 91 ~
nucleic acid sequence identity, alternatively at least about 929b nucleic acid sequence identity, alternatively at least about 93 Y nucleic acid sequence identity, alternatively at least about 94 ~ nucleic acid sequence identity, alternatively at least about 95'% nucleic acid sequence identity, alternatively at least about 9696 nucleic acid sequence identity, alternatively at least about 97 ~ nucleic acid sequence identity, alternatively at least about 98 '~
nucleic acid sequence identity and alternatively at least about 9990 nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal sequence, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.
Ordinarily, PRO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.
"Percent (%) nucleic acid sequence identity" with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent 1S nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S.
Copyright Office, Washington D.C., 20559, where it is registered under U.S.
Copyright Registration No.
TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below.
The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.OD.
All sequence comparison 2S parameters are set by the ALIGN-2 program and do not vary.
In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the 96 nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:
100 times the fraction W/Z
where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be 3S appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the 96 nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5, demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "PRO-DNA", wherein "PRO-DNA" represents a hypothetical PRO-encoding nucleic acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule against which the "PRO-DNA" nucleic acid molecule of interest is being compared, and "N", "L" and "V" each represent different hypothetical nucleotides.
Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, nucleic acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in En~mology 266:460-480 (1996)).
Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % nucleic acid sequence identity value is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e., the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides of the PRO polypeptide-encoding nucleic acid molecule of interest. For example, in the statement "an isolated nucleic acid molecule comprising a nucleic acid sequence A which has or having at least 80~ nucleic acid sequence identity to the nucleic acid sequence B", the nucleic acid sequence A
is the comparison nucleic acid molecule of interest and the nucleic acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.
Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from http://www.ncbi.nlm.nih.gov or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask =
yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, mufti-pass e-value =
0.01, constant for mufti-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.
In situations where NCBI-BLAST2 is employed for sequence comparisons, the %
nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain 96 nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:
100 times the fraction W/Z
where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C.
In other embodiments, PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash S conditions, to nucleotide sequences encoding a full-length PRO polypeptide as disclosed herein. PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.
The term "positives", in the context of sequence comparison performed as described above, includes residues in the sequences compared that are not identical but have similar properties (e.g. as a result of conservative substitutions, see Table 6 below). For purposes herein, the %
value of positives is determined by dividing (a) the number of amino acid residues scoring a positive value between the PRO polypeptide amino acid sequence of interest having a sequence derived from the native PRO polypeptide sequence and the comparison amino acid sequence of interest (i.e., the amino acid sequence against which the PRO polypeptide sequence is being compared) as determined in the BLOSUM62 matrix of WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest.
Unless specifically stated otherwise, the % value of positives is calculated as described in the immediately preceding paragraph. However, in the context of the amino acid sequence identity comparisons performed as described for ALIGN-2 and NCB1-BLAST-2 above, includes amino acid residues in the sequences compared that are not only identical, but also those that have similar properties. Amino acid residues that score a positive value to an amino acid residue of interest are those that are either identical to the amino acid residue of interest or are a preferred substitution (as defined in Table 6 below) of the amino acid residue of interest.
For amino acid sequence comparisons using ALIGN-2 or NCBI-BLAST2, the % value of positives of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain %
positives to, with, or against a given amino acid sequence B) is calculated as follows:
100 times the fraction X/Y
where X is the number of amino acid residues scoring a positive value as defined above by the sequence alignment program ALIGN-2 or NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the 96 positives of A
to B will not equal the % positives of B to A.
"Isolated, " when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide in situ within recombinant cells, since at least one component of the PRO polypeptide natural environment wilt not be present.
Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.
An "isolated" PRO polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at Least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature.
Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide-encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-PRO
monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO antibody compositions with polyepitopic specificity, single chain anti-PRO antibodies, and fragments of anti-PRO
antibodies (see below). The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.
"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration.
In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA
to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular BioloQV, Wiley Interscience Publishers, (1995).
S "Stringent conditions" or "high stringency conditions~, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1 % sodium dodecyl sulfate at 50°C;
(2) employ during hybridization a denaturing agent, such as formamide, for example, 50~ (v/v) fotmamide with 0.1% bovine serum albumin/0.1 ~ Ficoll/0.1 ~ polyvinylpyrrolidone/SOmM sodium phosphate buffer at pH 6.5 with 7S0 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCI, 0.075 M
sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1 % sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 wg/ml), 0.1 ~ SDS, and 10~ dextran sulfate at 42°C, with washes at 42°C
in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55 °C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.
"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Clonine: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20~ fotmamide, 5 x SSC (I50 mM NaCI, 15 mM trisodium citrate), SO
mM sodium phosphate (pH
7.6), 5 x Denhardt's solution, 10 ~ dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
The term ~epitope tagged" when used herein refers to a chimeric polypeptide comprising a PRO
polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypepdde to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).
As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heteroIogous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD
*-trademark or IgM.
"Active" or "activity" for the purposes herein refers to forms) of a PRO
polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring PRO, wherein "biological" activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PRO
other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO and an "immunological" activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO.
The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO
polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological IO activity of a native PRO polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonise antibodies or antibody fragments, fragments or amino acid sequence variants of native PRO polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a PRO polypeptide may comprise contacting a PRO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the PRO polypeptide.
"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.
"Chronic" administration refers to administration of the agents) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time.
"Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.
"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.
Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.
"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution.
Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide;
proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENr", polyethylene glycol (PEG), and PLURONICS'".
"Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')Z, and Fv fragments; diabodies; linear antibodies (Zapata et al., Protein EnE. 8(10):
1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab"
fragments, each with a single antigen-binding site, and a residual "Fc"
fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab')Z fragment that has two antigen-combining sites and is still capable of cross-linking antigen.
"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the VH-V~ dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHl domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residues) of the constant domains bear a free thiol group. F(ab')2 antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.
Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immtutoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGI, IgG2, IgG3, IgG4, IgA, and IgA2.
"Single-chain Fv" or "sFv" antibody fragments comprise the V" and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the VH and V~ domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharcnacologv of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (V") connected to a light-chain variable domain (VJ in the same polypeptide chain (VH-VJ. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).
An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95 % by weight of antibody as determined by the Lowry method, and most preferably more than 99~ by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain.
Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody.
The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones, In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.
A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO polypeptide or antibody thereto) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.
A "small molecule" is defined herein to have a molecular weight below about 500 Daltons.

Table 1 /*
* C-C increased from 12 to IS
* Z is average of EQ
$ * B is average of ND
* match with stop is M; stop-stop = 0; J (joker) match = 0 *%
lldefine M -8 /* value of a match with a stop *!
10int day[26][26] _ {

/* _ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
*/

/* { 2, 0,-2, 0, 0,-4, 1,-1,-1, 0,-1,-2,-I, 0, M, 1, 0,-2, A 1, I, 0, 0,-6, 0,-3, 0}, */

/* { 0, 3,-4, 3, 2,-5, 0, 1,-2, 0, 0,-3,-2, 2,_M,-1, 1, B 0, 0, 0. 0,-2,-5, 0,-3, 1}, */

l* {-2,-4, I5,-5,-5,-4,-3,-3,-2, 0,-5,-6,-5,-4,_M,-3,-5,-4, C 0,-2, 0,-2,-8, 0, 0,-5}, *!

1$1* { 0, 3,-5, 4, 3,-6, 1, 1,-2, 0, 0,-4,-3, 2,_M,-1, 2,-1, D 0, 0, 0,-2,-7, 0,-4, 2}, */

/* { 0, 2,-5. 3, 4; 5, 0, 1,-2, 0, 0,-3,-2, I,_M,-1, 2,-1, E 0, 0, 0,-2,-7, 0,-4, 3}, */

/* {-4,-5,-4,-6,-5, 9,-5,-2, 1, 0,-5, 2, 0,-4,_M,-S,-5,-4,-3,-3, F 0,-1, 0, 0, 7,-5}, */

/* { 1, 0,-3, 1, 0,-5, 5,-2,-3, 0,-2,-4,-3, 0,_M,-1,-1,-3, G 1, 0, 0,-1,-7, 0,-5, 0}, */

/* {-1, I,-3, I, 1,-2,-2, 6,-2, 0, 0,-2,-2, 2, M, 0, 3, H 2,-1,-1, 0,-2,-3, 0, 0, 2}, */

20/* {-1,-2,-2,-2,-2, 1,-3,-2, 5, 0,-2, 2, 2,-2, M,-2,-2,-2,-1, I 0, 0, 4; 5, 0,-1,-2}, */

/* { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0. M, 0, 0, J 0, 0, 0, 0, 0, 0, 0, 0, 0}, */

/* {-1, 0,-5, 0, 0,-5,-2, 0,-2, 0, 5,-3, 0, 1, M,-1, 1, K 3, 0, 0, 0,-2,-3, 0,-4, 0}, */

/* {-2,-3,-6,-4,-3, 2,-4,-2, 2, 0,-3, 6, 4,-3,_M,-3,-2,-3,-3,-1, L 0, 2,-2, 0,-1.-2}, */

/* {-1,-2,-5,-3,-2, 0,-3,-2, 2, 0, 0, 4, 6,-2, M,-2,-1, M 0,-2,-I, 0, 2,-4, 0,-2,-1}, */

2S/* { 0, 2,-4, 2, I,-4, 0, 2,-2, 0, 1,-3,-2, 2, M,-1, 1, N 0, 1, 0, 0,-2,-4, 0,-2, I}, */

/* M, M,_M,_M,_M, M, 0, M. M, M,_M, M =M, M =M, M, M =M}, O M, M, M, M, M, */ M, M, { M, 1* _ P _ */ _ { I,-1,-3; 1,-I,-5; 1, 0,-2, 0,-1,-3.-2.-1, M, 6, 0, 0, 1, 0, 0,-1,-6, 0,-5, 0}, 1* { 0, 1,-5, 2, 2,-5,-1, 3, 2, 0, 1,-2,-I, I,_M, 0, 4, Q I,-1,-1. 0,-2,-5, 0,-4, 3}, */

/* {-2, 0,-4,-1,-1,-4,-3, 2,-2, 0, 3,-3, 0, 0, M, 0, 1, R 6, 0,-1, 0,-2, 2, 0,-4. 0}, */

30/* { 1, 0, 0, 0, 0; 3, 1,-I,-1, 0, 0,-3,-2, 1, M, I,-1, S 0, 2, 1, 0,-1,-2, 0,-3, 0}, *I

/* { 1, 0,-2, 0, 0,-3, 0,-1, 0, 0, 0,-I,-1, O, M, 0,-1,-1, T 1, 3, 0, 0,-5, 0,-3, 0}, */

/* { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, O, M, 0, 0, U 0, 0, 0, 0, 0, 0, 0, 0, 0}.
*/

/* { 0,-2,-2,-2,-2; 1,-I,-2, 4, 0,-2, 2, 2,-2, M,-1,-2,-2,-1, V 0, 0, 4,-6, 0,-2,-2}, */

/* {-6,-5,-8,-7,-7, 0,-7,-3; 5, 0,-3,-2,-4,-4, M,-6,-5, W 2,-2,-5, 0,-6,17, 0, 0,-6}, */

35/* { o, o, o, o, o, o, o, o, o, o, o, o, o, o._M, o, o, x o, o, o, o, o, o, o, o, o}, */

/* {-3,-3, 0,-4,-4, 7,-5, 0,-I, 0,-4,-1,-2,-2,_M,-5,-4,-4,-3,-3, Y 0,-2, 0, 0,10,-4}, */

/* { 0, I,-5, 2, 3,-5, 0, 2,-2, 0, 0,-2,-1, 1 -M, 0, 3, Z 0, 0, 0, 0,-2,-6, 0,-4, 4}
*/

};

Table 1 (cony) /*

*/

#include h >
<
stdio.

#include .h >
<
ctype #defineMAXJMP /* max jumps in a diag */

#defineMAXGAP /* don't continue to penalize 24 gaps larger than this */

#defineJMPS 1024 /* max jmps in an path */

#defineMX 4 /* save if there's at least MX-I bases since last jmp */

#defineDMAT 3 /* value of matching bases */

#defineDMIS 0 /* penalty for mismatched bases */

#de6neDINSO8 /* penalty for a gap */

#defineDINS11 /* penalty per base */

i$ #del"mePINSO8 /* penalty for a gap */ ' #det'mePINSI4 /* penalty per residue */

struct jmp {

shortn[MAXJMP];
/* size of jmp (neg for dely) */

unsigned short x[MAXJMP];
/*
base no.
of jmp in seq x */

}; /* limits seq to 2" 16 -1 */

struct diag {

int score; /* score at last jmp */

2$ long offset; /* offset of prev block */

shortijmp; /* current jmp index *!

struct I* list of jmps *!
jmp jp;

};

struct path {

int spc; /* number of leading spaces */

shortn[JMPS];of jmp (gap) */
/* size int x[JMPS];
/* loc of jmp (last elem before gap) */

};

char *ofile; /* output file name */

char *namex[2];/* seq names: getseqs0 */

char *prog; /* prog name for err msgs */

char *seqx[2];/* seqs: getseqsQ */

int dmax; /* best diag: nwQ */

int dmax0; /* final diag */

int dna; /* sec if dna: main() */

int endgaps;/* set if penalizing end gaps */

int gapx, /* total gaps in seas */
gapy;

tnt len0, /* seq lens */
lent;

Int ngapx, /* total size of gaps */
ngapy;

int smax; /* max score: rtw(7 */

int *xbm; /* bitmap for matching */

long offset; /* current offset in jmp file */

5~ structdiag *dx; /* holds diagonals */

Pad PP[21; /* holds path for seqs */

char *callocQ, *mallocQ, *index(), *strcpyQ;

char *getseq0, *g callocQ;

$$

8$

Table 1 (cony) /* Needleman-Wunsch alignment program * usage: progs file! filet * where file! and 61e2 are two dna or two protein sequences.
$ * The sequences can be in upper- or lower-case an may contain ambiguity * Any lines beginning with ';' ' >' or ' <' are ignored * Max file length is 65535 (limited by unsigned short x in the jmp struct) * A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
* Output is in the file "align.out"
* The program may create a tmp file in /tmp to hold info about traceback.
* Original version developed under 13SD 4.3 on a vax 8650 */
J/include "nw.h"
!/include "day.h"
static _dbval[26] _ {
1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0 }:
static ~bval[26] _ {
I, 2J(1 < <('D'-'A'))J(I < <('N'-'A')), 4, 8, 16, 32, 64, 128, 256, OxFFFFFFF, 1 < < 10, 1 < < 11, 1 < < 12, I < < 13, 1 < < 14, 1«15, 1«16, 1«17, 1«18, 1«19, I«20, 1«21, 1«22, 1 < <23, 1 < <24, 1 < <25J(1 < <('E'-'A'))J(I < <('Q'-'A')) main(ac, av) main int ac;
char *av~;
{
prog = av[0];
if(ac!=3){
fprintf(stderr,"usage: 96s file! filet\n", prog);
3S fprintf(stderr,"where file! and filet are two dna or two protein sequences.\n");
fprintf(stderr,"The sequences can be in upper- or lower-case\n");
fprintf(stderr,"Any lines beginning with ';' or ' <' are ignored\n~);
fprintf(stderr,"Output is in the file \"align.out\"\n");
exit(1);
namez[0] = av[1];
namex[1] = av[2];
seqx(0] = getseq(namez[0], &IenO);
seqx[I] = getseq(namex[I], &lenl);
4J~ xbm = (dna)? dbval : ~bval;
endgaps = 0; 1* 1 to penalize endgaps */
ofile = "align.out"; /* output file */
nwQ; /* fill in the matrix, get the possible jmps */
readjmps0; /* get the actual jmps */
printQ; /* print stats, alignment */
SS }
cleanup(0); /* unlink any tmp files */

Table I (conk']
/* do the alignment, return best score: main() * dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983 * pro: PAM 250 values * When scores are equal, we prefer mismatches to any gap, prefer * a new gap to extending an ongoing gap, and prefer a gap in seqx * to a gap in seq y.
*/
nwn nW
{
char *px, *py; /* seqs and ptrs */
int *ndely, *dely; /* keep track of defy */
int ndelx, delx; /* keep track of delx */
int *tmp; 1* for swapping row0, rowl */
int mis; /* score for each type */
1S int ins0, insl; /* insertion penalties */
register id; /* diagonal index */
register ij; /* jmp index */
register *col0, *coll; /* score for curr, last row */
register xx, yy; /* index into seqs */
dx = (struct diag *)g calloc("to get diags", len0+lenl + 1, sizeof(struct diag));
ndely = (int *)g calloc("to get ndely", ienl+1, sizeof(int));
defy = (int *)g calloc("to get defy", lenl+1, sizeof(int));
col0 = (int *)g calloc("to get col0", lent+1, sizeof(int));
coil = (int *)g calloc("to get coil", lenl+1, sizeof(int));
ins0 = (dna)? DINSO : PINSO;
insl = (dna)? DINS1 : PINS1;
smax = -10000;
if (endgaps) {
for (col0[0] = defy[0] _ -ins0, yy = 1; yy < = lent; yy++) {
col0[yy] = dely(yy] = col0[yy-lj -insl;
ndely[yy] = yy;
col0[O] = 0; /* Waterman Bull Math Biol 84 */
else for (yy = 1; yy < = lent; yy++) defy[yy] _ -ins0;
/* fill in match matrix */
for (px = seqx[0], xx = 1; xx < = IenO; px++, zx++) {
/* initialize first entry in col */
if (endgaps) {
~(~ _= 1) coll(0] = delx = -(ins0+insl);
else colt [0] = delx = col0[0] - insl;
ndelx = zx;
else {
coil[O] = o;
delx = -ins0;
ndelx = 0;

Table 1 (cony) for (py = seqx(1], yy = 1; yy < = lenl; py++, yy++) {

mis = col0[yy-1];

if (dna) mis + _ (xbm[*px-'A']&xbm[*py-'A'])? DMAT
: DMIS;

else mis += day[*px-'A'j[*py-'A']>

/* update penalty for del in x seq;

* favor new del over ongong del * ignore MAXGAP if weighting endgaps */

if (endgaps ~ ~ ndely[yy] < MAXGAP) {

if (col0[yy] - ins0 > = dely[yyj) {

dely(yy] = col0[yy] - (ins0+insl);

ndely[yy] = I;

} else {

dely[yyj -= insl;

ndely[yy]++;

) } else {

if (col0[yy] - (ins0+insl) > = dely[yy]) {

dely[yy] = col0[yy] - (ins0+insl);

ndely[yy] = 1;

} else ndely[yyJ++;

}

/* update penalty for del in y seq;

3~ * favor new del over ongong del */

if (endgaps ~ ~ ndelx < MAXGAP) {

if (collfYY-I] - ins0 > = deli) {

delx = coil[yy-I] - (ins0+insl);

ndelx = 1;

} else {

delx -= insl;

ndelX+ +;

) } eye {

if (coll[yy-1] - (ins0+insl) > = delx) {

deIx = toll[yy-lJ - (ins0+insl);

ndelx = 1;

else ndelx++;

}

/* pick the maximum score; we're favoring * mis over any del and delx over dely */

...nw WO 00/56889 PC'f/US00/05601 T;~ble 1 (cont'1 id = xx - yy + lent - 1;
if (mis > = deli && mis > = dely[yy]) col l [yy] = mis;
$ else if (deli > = dely[yy]) {
coll(yy] = delx;
ij = dx[id].ijmp;
if (dx[id].jp.n[0] && (!dna ~ ~ (ndelx > = MAXJMP
&& xx > dx[id].jp.x[ij]+MX) ~ ~ mis > dx[id].score+DINSO)) {
dx[id].ijmp++;
if (++ij >= MAXJMP) {
writejmps(id);
ij = dx[idj.ijmp = 0;
dx[id].offset = offset;
1$ offset += sizeof(struct jmp) + sizeof(offset);
dx[id].jp.n[ij] = ndelx;
dx[id].jp.x[ij] = xx;
dx[id].score = delx;
j else {
toll[yy] = defy[yy];
ij = dx[id].ijmp;
2$ if (dx(id].jp.n[0] && (!dna ~ ~ (ndely(yy] > = MAXJMP
&& xx > dx[id].jp.x[ij]+MX) ~ ~ mis > dx[id].score+DINSO)) {
dx[id].ijmp++;
if (++ij >= MAXJMP) {
writejmps(id);
ij = dx[id].ijmp = 0;
dx[id].offset = offset;
offset += sizeof(struct jmp) + sizeof(offset);
3$ dx[id].jp.n[ij] _ -ndeiy[yyJ;
dx[id] ;jp.x[ij] = xx;
dx(id].score = dely(yy];
if (xx == len0 && yy < lent) {
/* last coI
*I
if (endgaps) toll[yy] -= ins0+insl*(lenl-yy);
if (toll[yy] > smax) {
4$ smax = coil[yy];
dmax = id;
$0 if (endgaps && xx < len0) coll(yy-1] -= ins0+insl*(len0-xx);
if (coll(yy-1] > smaz) {
smax = toll[yy-I];
dmax ~ id;
$$
tmp = col0; colo = colt; toll = tmp;
(void) free((char *)ndely);
(void) free((char *)dely);
60 (void) free((char *)col0);
(void) free((char *)coll);
j ...nw Table 1 cony) /*
* print() -- only routine visible outside this module * static:
* getmatp -- trace back best path, count matches: print() * pr align0 -- print alignment of described in array p[]: print() * dumpblock() -- dump a block of lines with numbers, stars: pr aligu0 * nums0 -- put out a number line: dumpblock() * putlinep -- put out a line (name, [num], seq, [num]): dumpblock() * stars() - -put a line of stars: dumpblock() * stripname() - strip any path and prefix from a seqname */
t/include "nw.h"
!/det'me SPC 3 Hdet-me P_LINE 256 /* maximum output line */
!/define P_SPC 3 /* space between name or num and seq */
extern day[26](26];
in! olen; /* set output line length */
FILE *fx; /* output file */
print() print {
int Ix, 1y, firstgap, lastgap; /* overlap */
if ((fx = fopen(otile, "w")) _ = 0) {
fprintf(stderr,"~s: can't write 96s\n", grog, ofile);
cleanup(I);
}
fprintf(fx, " < first sequence: % s (length = Y&d)\n", namex(0], len0);
fprintf(fx, "<second sequence: ~s (length = 96d)\n", namex(1], lenl);
olen = 60;
Ix = len0;
1y = lenl;
firstgap = lastgap = 0;
if (dmax < lenl - I) { /* leading gap in x */
4~ pp[0].spc = firstgap = lent - dmax - 1;
1y _= pPlOl.sPc;
}
else if (dmax > lenl - 1) { /* leading gap in y */
pp(1].spc = firstgap = dmax - (lenl - 1);
ix -= pp[1].spc;
}
if (dmax0 < len0 - 1) { /* trailing gap in x */
lastgap = len0 - dmax0 -1;
ix -= iastgap;
}
else if (dmax0 > len0 - 1) { /* trailing gap in y */
lastgap = dmax0 - (len0 - 1);
1y _ _ (a~gap;
}
getmat(lx, 1y, firstgap, lastgap);
pr align0;

Tale 1 (cony) /.
* trace back the best path, count matches */
static $ getmat(lx, ly, firstgap, lastgap) getlilat int lx, ly; /* "core" (minus endgaps) */
int firstgap, lastgap; /* leading trailing overlap *I
{
int nm, i0, i 1, siz0, siz 1;
1~ c6ar outx[32];
doable pct;
register n0, nl;
register char *p0, *pl;
1$ /* get total matches, score */
i0 = it = siz0 = sizl = 0;
p0 = seqx(0] + pp[l].spc;
pt = seqx[I] + pp[0].spc;
20 n0 = pp[1].spc + l;
nl = pp[0].spc + 1;
nm = 0;
while ( *p0 && *pl ) {

25 if (siza) {
pl++;
nl++;
siz0.;
30 else if (sizl) {
p0++;
n0++;
Sizl-;
35 ~e {
if (xbm[*p0-'A']&xbm[*pl-'A']) nm+ +;
if (n0++ _= pp[0].x[i0]) siz0 = pp[U].n[i0++J;
4d if(nl++ _=pp[Ij.x[iI]) sizl = pp[l].n[il++J;
p0+ +;
pl++;
/* pct homology:
* if penalizing endgaps, base is the shorter seq * else, knock off overhangs and take shorter core $0 */
if (endgaps) Ix = (IenO < lent)? IenO : lent;
else ' (x = (Ix < ly)? lx : ly;
$$ pct = 100.*(double)nm/(double)Ix;
fprintf(fx, "\n");
fprituf(fx, " < ~d matches in an overlap of ~d: 9~.2f percent similarity\n", ~' (~ .-_ 1)? "" . "es", lx, pct);

T b[a a 1 (cony) fprintf(fx, "<gaps in first sequence: 96d", gapx): ...gCtlllat if (gapx) {
(void) sprintf(outx, " (%d ~OS~s)", S ngapx, (dna)? "base":"residue", (ngapx = = I)? "":"s");
fprintf(fx," fos", outx);
fprintf(fx, ", gaps in second sequence: %d", gapy);
(gaPY) {
(void) sprintf(outx, " (%d 96s~s)", ngapy, (dna)? "base":"residue", (rtgapy == 1)? "":"s );
fprintf(fx," 35s", outx);

if (dna) fprintf(fx, "\n<score: 96d (match = ~d, mismatch = ~d, gap penalty = fod + %d per base)\n", smax, DMAT, DMIS, DINSO, DINSI);
else Cprintf(fz, "\n<score: ~d (Dayhoff PAM 250 matrix, gap penalty = %d + ~Od per residue)\n", smax, PINSO, PINSk);
if (endgaps) fprintf(fx, "<endgaps penalized. left endgap: ~d ~s:6s, right endgap: &d %sq6s\n", firstgap, (dna)? "base" : "residue", (firstgap == 1)? "" : "s", lastgap, (dna)? "base" : "residue". (lastgap =~ 1)? "" : "s");
else fprintf(fx, " < endgaps not penalizedln");
static nor; /* matches in core -- for checking */
static Imax; /* lengths of stripped file mores */
static ij[2]; /* jmp index for a path */
static nc[2]; /* number at start of current line */
static ni[2]; /* current efem number - for gapping */
static siz(2]:
static char *ps[2]; /* ptr to current element */
static char *po[2]; /* pa to next output char slot */
static char out[2][P~LINE]; /* output line */
static char star[P LINE]; /* set by stars() x/
/*
* print aligttment of described in struct path pp[J
*/
4$ static pr-align0 pr ~Igll {
int nn; /* char count */
int more;
register i;
for (i = 0. ltnax = 0; i < 2; i++) {
nn = stripname(namex[i]);
if (tut > Imax) 5$ Imax = nn;
nc[i) = I;
ni[i] = 1;
s~(il = ij[il = 0:
ps(i] = seqx[i];
po[ij = out[i]:

Table 1 (cony) for (ttn -= tun = 0, mare = 1; more; ) { .:.pr align for (i = more = 0; i < 2; i++) {
/*
* do we have more of this sequence?
*/
if (!*ps[i]) continue;
more++;
if (pp[iJ.spc) { /* leading space */
*po[il++ _ , PP[iJ.spc__:
else if (siz(i]) { I * in a gap *I
*po(i]++ _ , siz[i]__;
else { /* we're putting a seq element */
*po(i] _ *Ps(il:
if (islower(*ps[i])) *ps[i] = toupper(*ps[i]);
po[i]+ +;
ps[i]++;
/*
* are we at next gap for this seq?
*/
if (ni[i] _= pPfi].x[ii(ill) {
/*
* we treed to merge all gaps * at this location */
siz(i] = pP(i].n[ij(ij++];
while (tti[i] _= pp[i].x[ij[i]D
siz[iJ += pp(i].n(ij(i]++]:
to[i]++;
) if (++nn == olen ~ ~ !more && nn) {
dumpblock();
for (i = 0; i < 2; i++) po[i] = out(iJ:
nn=o;
) /*
* dump a block of litres, including numbers, stars: pr align() */
$5 static attmpblock0 dumpblock {
register i;
for (i = 0: i < 2; i++) *po[;]__ -_ '\0';

Table I (cony) ...dumpblock (void) putt('\n', fx);
for (i = 0; i < 2; i++) {
$ if (*out[i] && (*out[i] ! _ ' ' I I *(po[i]) ! _ ' ')) {
if (i == 0) nums(i);
if (i == 0&& *out[1]) starsp;
putline(i);
if (i == 0 && *out[1]) fprintf(fx, star);
== 1) nums(i);
1$ }
}
}
/.
* put out a number line: dumpblockp *I
static nums(ix) nums int ix; I * index in out[] holding seq line *I
{
char mine[P LINEj;
register i, j;
register char *pn, *px, *py;
for (pa = mine, i = 0; i < lmax+P SPC; i++, pn++) *Pn = , for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
if (*py =- ' I I *PY =- '-~) *pn = , 3$ else {
if (i9~ to == o I I (i =_= 1 8c8c nc[ix] ~= 1)) {
j=(i <0)?-i:i;
for (px = pn; j; j /= 10, px--) *px = j~10 + '0';
40 if (i < 0) *px =
else *Pn =
4$ i++;
) *Pn ~ ~~0~;
nc[ix] = i:
$0 for (pn = Nine; *pn; pn++) (void) putt(*pn, fx);
(void) putt('\n', fx);
}
$$ /*
* put out a tine (name. [num], seq, [num]): dumpblock() */
static putline(ix) putline 60 int ix;

Table 1 (cony) int i;
register char *px;
for (px = ttamex[ix], i = 0; *px 8c& *px !_ ':'; px++, i++) (void) putc(*px, fx);
for (; i < Imax+P SPC; i++) (void) putc(' ', fx);
/* these count from I:
* tti[] is current element (from I) * nc(] is number at start of current line */
for (px = out[ix]; *px; px++) (void) putc(*px&Ox7F, fx);
(void) putt('\n', fx);
...putline /*
* put a Iine of scars (seqs always in outj0], out[1]): dumpblock0 */
static stars() StaTS
{
int i;

register char *p0, *pl, cx, *px;

if (!*out(0] I I (*out[0] _ _ ' && *(po[0]) _- ' ') I I

!*out(11 I I (*out[1] _-_ ' &&
*(PotlD =- ' ')) return;

px = star;

for (i = lmax+P SPC; i; i--) *px++ _ , for (p0 = out[0], p1 = out[1];
*p0 && *pl; p0++, p1 ++) {

if (isalpha(*p0) && isalpha(*pl)) {

if (xbm[*p0-'A']&xbm[*pl-'A']) {

cx = '*';

nm++;

else if (!dna && day(*p0-'A'][*pl-'A']
> 0) cx = ' , else cx = , l else cx = , *px++ = cx;

) *px++ _ '\n';

*px = '\0';

Table 1 (cont'1 /*
* strip path or prefix from pn, return len: pr align() */
static S stripname(pn) stripname char *pn; !* file name (may be path)'/
register char *px, *py;
IO py = 0;
for (px = pn; *px; px++) if (*px =_ ~/~) py=px+1;
(PY) l$ (void) strcpy(pn, py);
return(strlen(pn));

Table 1 Lcont') /*
* cleanup() -- cleanup any tmp file * getseq() -- read in seq. set dna, lea, maxlen * g calloc() -- calloc() with error checkin * rradjmpsQ -- get the good jmps, from imp file if necessary * writejmps0 -- write a filled array of jmps to a imp file: nwQ
*/
l/include "nw.h"
kinclude <sys/file.h>
char *jname = "/tmp/homgXXXXXX"; I * imp file for jmps *I
FILE *fj;
int cleanupQ; /* cleanup imp file */
1 S tong (seek();
/*
* remove any imp file if we blow */
ZO cleanup(i) Cleanup int i;
{
if (fj) (void) unlink(jname);
25 exit(i):
/.*
* read, retucn ptr to seq, set dna, len, maxlen 30 * skip lines starting with ';', ' <', or ' >' * seq in upper or tower case */
char getseq(file, len) getseq 35 char *file; /* file name */
int *len; /* seq len */
char Line[1024], *pseq;
register char *px, *py;
40 int natgc, teen;
FILE *fp;
if ((fp = fopen(file. "r")) _ = U) {
fprintf(stderr."'Jbs: can't read 96s\n", prog, file);
45 exit(I);
lien = natgc = 0;
while (fgets(line, 1024, fp)) {
if (*linc =_ ';' ~ ~ *line =- ' <' ! ~ *line =_ ' >') 50 continue;
for (px = line; *px ! _ '\n'; px++) if (isupper(*px) ~ ~ islower(*px)) tlen+ +;
55 if ((pseq = malloc((unsigned)(tlen-I-6))) == 0) {
fprimf(stderr,"9bs: mallocQ failed to get q6d bytes for :Ks\n", prog, lien+6, file);
exit( I );
PseqI01 = Pseq[Il = P~q[21 = P~q[3) _ '\0':

Tablgl i(,cont') ... getseq py = pseq + 4;
*len = tlen;
rewind(fp);
while (fgets(line, 1024, fp)) {
if (*line =- ' ~ ~ *line =- ' <' ~ ~ *line =- ' >') continue;
for (px = line; *px ! _ '\n'; px++) {
if (isupper(*px)) *py++ _ *px;
else if (islower(*px)) *py++ = toupper(*px);
if (index("ATGCL7",*(py-I))) natgc++;
*py++ _ '\0';
*PY ° ~\0.;
(void) fclose(fp);
dna = natgc > (tleN3);
return(pseq+4);
j char g calloc(msg, nx, sz) ~callOC
char *msg; /* program, calling routine */
int nx, sz; /* number and size of elements */
{
char *px, *callocQ;
i f ((Px = ~loc((unsigned)nx, (ansigned)sz)) _ = Oj {
if (*msg) {
fprintf(stderr, ":6s: g caliocQ failed :~s (n=?bd, sz=~d)\n", prog, msg, nx, sz);
exit(1);

j return(px):
/*
* get final jmps from dx[j or tmp file, set pp[], reset dmax: main() */
readjmpsQ readjmps {
int fd = -1;
int siz, i0, i1;
register i, j, xx;
if (fj) {
(void) fclose(fjj;
if ((fd = open(jname, O_RDONLY. 0)) < 0) {
fprintf(stdert, "'~s: can't open() '~s\n", prog, jnarae);
cleanup(1);
fur (i = i0 = il = 0, dmo~0 = dmaz, xx = IenO; ; i++) {
while (l) {
for (j = dx(dmaz].ijmp; j > = 0 8c& dx(dmaxj.jp.x[jj > = zx; j--) , Table 1 (cony) ... readj mps if (j < 0 && dx[dmax].offset && fj) {
(void) Iseek(fd, dx[dmax].offset. 0);
(void) read(fd. (char *)&dx[dmax].jp, sizeof(struct jmp));
$ (void) read(fd. (char *)&dx[dmax].offset, sizeof(dx[umax].offset));
dx[dmaxj.ijmp = MAXJMP-1;
}
else break;
}
if (i > = JMPS) {
fprintf(stderr, "~s: too many gaps in alignment\n", prug);
cleanup(1);
}
if (j > = 0) {
siz = dx(dmax].jp.n[j]:
xx = dx[dmax].jp.x(jj;
dmax += siz;
if (siz < 0) { /* gap in second seq */
pp[I].n[il] _ -siz;
xx += siz;
/*id=xx-yy+lenl-1 */
pp[1].x[il] = xx - dmax + lenl - 1;
2$ gapy++;
ngapy -= siz;
1* ignore MAXGAP when doing endgaps */
siz = (-siz < MAXGAP ~ ~ endgaps)? -siz : MAXGAP;
i1++;
}
else if (siz > 0) { /* gap in fast seq */
pp[0].n[i0] = siz;
PP[Oj-x[~1 = xx:
gapx++;
ngapx += siz;
/* ignore MAXGAP when doing endgaps */
siz = (siz < MAXGAP ~ ~ endgapsf! siz : MAXGAP;
i0++;
}
}
else break;
}
4$ /* reverse the order of jmps */
for (j = 0. i0--: j < i0: j+'~. i0--) {
1 - PP[Oj~n[Ij: PP[Oj~~11 ° PP[Oj~nhOj: PP[Oj~nUOj 6 1:
$0 1 ° PPIOj.xIll; PP[Ol~xUj = PP[Ol-x[~j: PPI01~x(i0] = i:
}
for (j = 0, i1--; j < i1: j++, i1--) {
i = PP[lj~nUj: PP[ll~hUj = PP(Ij.n[ilJ: PP[l1~n[ilj = i:
i ' PP[1j~xUj: PP[ll.xG1 = PP[lj.x[ilj: PP[lj.xfilj = i;
$5 'tf (fd > = 0) (void) close(fd);
if (fj) {
(void) unlink(jname);
fj = 0;
f)0 offset = 0;
}
}

Table 1 (cont.
,.
* write a filled jmp struct offset of the prey one (if any): nw0 *!
writejmps(ix) wCItejIllpS
int ix;
{
char *mktemp0;
If (!fj) {
if (mktemp(jnamc~) < 0) {
fprintf(stderr, "96s: can't mktemp0 9~s\n", prog, jname);
cleanup( I );
1$ if ((fj = fopen(jname, "w")) _= 0) {
fprintf(stdetr, "~s: can't write ~sln", prog, jname);
exit(I);
(void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), I, fj);
!void) fwrite((char *)&dx[ix].offset, sizeof(dx[iz].offset), I, fj);

T_ able 2 PRO XXXXXXXXXXXXXXX (Length = 15 amino acids) Comparison Protein XXXXXYYYYYYY (Length = 12 amino acids) S % amino acid sequence identity =
(the number of identically matching amino acid residues between the two polypeptide sequences as determined uy ALIGN-2) divided by (the total number of amino acid residues of the PRC~
polypeptide) _ 5 divided by IS = 33.3'0 Table 3 PRO XXXXXXXXXX (Length = 10 amino acids) Comparison Protein XXXXXYYYYYYZZYZ (Length = 15 amino acids) % amino acid sequence identity =
(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO
polypeptide) _ 5 divided by 10 = 50 %

Table 4 PRO-DNA NNNNNNNNNNNNNN (Length = 14 nucleotides) Comparison DNA NNNNNNLLLLLLLLLL (Length = 16 nucleotides) % nucleic acid sequence identity =
(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) _ 6 divided by 14 = 42.9%

Table 5 PRO-DNA NNNNNNNNNNNN (Length = 12 nucleotides) Comparison DNA NNNNLLLVV (Length = 9 nucleotides) % nucleic acid sequence identity =
(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) _ 4 divided by 12 = 33.3 '~

II. Compc~itions and Methods of the Invention A. Full-Leneth PRO Polypentides The present invention provides newly identified and isolated nucleotide sequ~:nces encoding polypeptides referred to in the present application as PRO polypeptides. In particular, cDNAs encoding various PRO
polypeptides have been identified and isolated, as disclosed in further detail in the Examples below. It is noted that proteins produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed.
However, for sake of simplicity, in the present specification the protein encoded by the full length native nucleic acid molecules disclosed herein as well as all further native homologues and variants included in the foregoing definition of PRO, will be referred to as "PRO/number", regardless of their origin or mode of preparation.
As disclosed in the Examples below, various cDNA clones have been deposited with the ATCC. The actual nucleotide sequences of those clones can readily be determined by the skilled artisan by sequencing of the deposited clone using routine methods a the art. The predicted amino acid sequence can be determined from the nucleotide sequence using routine skill. For the PRO polypeptides and encoding nucleic acids described herein, Applicants have identified what is believed to be the reading frame best identifiable with the sequence information available at the time.
1. Full-length PR01484 Polvpeptides Using the WU-BLAST2 sequence alignment computer program, it has been found that a full-length native sequence PR01484 (shown in Figure Z and SEQ ID N0:2) has certain amino acid sequence identity with a portion of the mouse adipocyte complement related protein (ACR3 MOUSE).
Accordingly, it is presently believed that PR01484 disclosed in the present application is a newly identified adipocyte complement-related protein homolog and may possess activity typical of that protein.
2. Full-leneth PR04334 Polv~ntides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR04334 (shown in Figure 4 and SEQ ID N0:9) has certain amino acid sequence identity with PC-1.
Accordingly, it is presently believed that PR04334 disclosed in the present application is a newly identified member of the PC-1 family and shares similar mechanisms.
3. Full-length PR01122 Poly~enti~es The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PR01122. In particular, Applicants have identified and isolated eDNA
encoding a PR01122 polypeptide, as disclosed in further detail in the Examples below. Using BLAST and FastA sequence alignment computer programs, Applicants found that the PR01122 polypeptide has sequence identity with CTLA-8. The amino acid sequence shows a region having sequence identity with iL-17.
Acco.lingly, it is presently believed that PR01122 polypeptide disclosed in.
the present application is a novel cytokine and thus may be involved in inflammation responses.

4. Full-length PR01889 Polypeptides Using the WU-BLAST2 sequence alignment computer program, it has been found that a portion of the full-length native sequence PR01889 (shown in Figure 8 and SEQ ID N0:16) has certain amino acid sequence identity with a portion of the human E48 antigen protein (HSE48ATGN_1).
Accordingly, it is presently believed that PR01889 disclosed in the present application is a newly identified E48 homolog and may possess activity or properties typical of the E48 protein.
5. Full-len~,th PR01890 Polypeptides Using the WU-BLAST2 sequence alignment computer program, it has been found that a portion of the full-length native sequence PR01890 (shown in Figure LO and SEQ ID NO:18~ has certain amino acid sequence identity with a portion of the layilin protein (AF093673_I).
6. Full-length PR01887 Po~peptides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR01887 (Figure 12; SEQ ID N0:23) has certain amino acid sequence identity with a mouse liver carboxylesterase precursor identified on the Dayhoff database as "ESTM MOUSE".
Accordingly, it is presently believed that PR01887 disclosed in the present application is a newly identified member of the carboxylesterase family and may possess enzymatic activity typical of carboxylesterases.
7. Full-length PR01785 Polypeptides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR01785 (shown in Figure 14 and SEQ ID N0:29) has certain amino acid sequence identity with glutathione peroxidase. Accordingly, it is presently believed that PR01785 disclosed in the present application is a newly identified member of the peroxidase family and may possess antioxidant enzyme activity: Regulation of antioxidant activity is of interest in the treatment of cancer and aging.
8. Full-length PR04353 Polypeptides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR04353 (shown in Figure 16 and SEQ ID N0:35) has certain amino acid sequence identity with semaphorin Z. Accordingly, it is presently believed that PR04353 disclosed in the present application is a newly identified member of the semaphorin Z family and is involved in inhibition of nerve growth. PR04353 can be used in assays to identify modulators of semaphorin Z, particularly inhibitors to promote central nerve regeneration.
9. Full-IenEth PR04357 Polypeptides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PF04357 (shown in Figure 18 and SEQ ID N0:40) has certain amino acid sequence identity with 289 amino acids in accession number P W48804. However, PR043S7 has an additional 213 amino acids at the N-terminus.
10. Full-IenEth PR04405 P~~eotides As far as is known, the DNA84920-2614 sequence encodes a novel fa~tor designated herein as PR04405; using WU-BLAST2 sequence alignment computer programs, limited sequence identities to known proteins were revealed.
1I. Full-length PR043S6 Polv~etides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR04356 (shown in Figure 22 and SEQ ID NO:50) has certain amino acid sequence identity with metastasis associated GPI-anchored protein. Accordingly, it is presently believed that PR04356 disclosed in the present application is a newly identified member of this family and shares similar mechanisms.
12. Full-length PR04352 PoiyBeptides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR04352 (shown in Figure 24 and SEQ 1D N0:52) has certain amino acid sequence identity with protocadherin pc3 and protocadherin pe4. Accordingly, it is believed that PR04352 is involved in cell adhesin and can be used in treatments regarding differentiation disorders, cell adhesin, neural receptor or skin disorders.
Moreover, it can be used in screens to identify agonists and antagonists to treat such disorders.
13. Fall-tenEth PR04380 Poly~eptldes As far as is known, the DNA92234-2602 sequence encodes a novel factor designated herein as PR04380; using WU-BLAST2 sequence alignment computer programs, limited sequence identities to proteins with known functions were revealed.
14. Full-length PR04354 Polvoentides As far as is known, the DNA92256-2596 sequence encodes a novel factor designated herein as PR04354; using WU-BLAST2 sequence alignment computer programs, limited sequence identities to proteins with known functions were revealed.
1S. Full-length PR04408 P~ly~g tp ides As far as is known, the DNA92274-2617 sequence encodes a novel factor designated herein as PR04408; using WU-BLAST2 sequence alignment computer programs, limited sequence identities to known proteins were revealed.
16. Full-lenEth PR05737 Polvpeutides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR05737 (shown in Figure 32 and SEQ ID N0:63) has certain amino acid sequence identity with IL-I

and/or IL-IRa. Accordingly, it is presently believed that PR05737 disclosed in the present application is a newly identified member of this family and shares similar mechanisms.
17. Full-le~th PR04425 Polyue~tides As far as is known, the DNA93011-2637 sequence encodes a novel factor designated herein as PR04425; using WU-BLAST2 sequence alignment computer programs, PR04425 showed homology to a protein in GenBank, accession number HGS RE295, but is not identical.
18. Full-length PR05990 Polype~tides Using the ALIGN-2 sequence alignment computer program referenced above, it has been found that the full-length native sequence PR05990 (shown in Figure 36 and SEQ ID N0:67) has certain amino acid sequence identity with Secretogranin II (Dayhoff No. GEN14673). Accordingly, it is presently believed that the PR05990 polypeptide disclosed in the present application is a newly identified member of the secretogranin protein family and may possess one or more biological and/or immunotogical activities or properties typical of that protein family.
19. Full-length PR06030 Polypeptides The DNA96850-2705 clone was isolated from a htunan library as described in the Examples below.
As far as is known, the DNA96850-2705 nucleotide sequence encodes a novel factor designated herein as PR06030; using the ALIGN-2 sequence alignment computer program, no significant sequence identities to any known proteins were revealed.
20. Full-length PR04424 Polvpeptides As far as is known, the DNA96857-2636 sequence encodes a novel factor designated herein as PR04424; using WU-BLAST2 sequence alignment computer programs, PR04424 showed homology to a protein in GenBank, accession number HGS A135, but is not identical thereto.
21. Full-leneth PR04422 Polvue~tides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR04422 (shown in Figure 42 and SEQ ID N0:76) has certain amino acid sequence identity with lysozyme g. Accordingly, it is presently believed that PR04422 disclosed in the present application is a newly identified member of the tysozyme family and may have lysozyme activy.
22. Full-length PR04430 Polypentides Using WU-BLAST2 sequence alignment computer programs, it has been found that a full-length native sequence PR04430 (shown in Figure 44 and SEQ ID N0:78) has certain amino acid sequence identity with the protein in GenBank accession number MMHC213L3 9. Accordingly, it is presently believed that PR04430 disclosed in the present application is related to the GenBank protein and may share at least one similar *-trademark 108 mechanism.
23. Full-lenEth PR04499 Folygeptides As far as is known, the DNA96889-2641 sequence encodes a novel factor designated herein as PR04499; using WU-BLAST2 sequence alignment computer programs, limited sequence identities to known proteins were revealed.
B. PRO Polypentide Variants In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated that PRO variants can be prepared. PRO variants can be prepared by introducing appropriate nucleotide changes into IO the PRO DNA, andJor by synthesis of the desired PRO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.
Variations in the native full-length sequence PRO or in various domains of the PRO described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative IS mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO that results in a change in the amino acid sequence of the PRO as compared with the native sequence PRO. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO.
Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may 20 be found by comparing the sequence of the PRO with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural, and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions ar deletions may optionally be in the range of about I to 5 amino acids. The variation 25 allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
PRO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein.
Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PRO
30 pofypeptide.
FRO fragments may be prepared by any of a number of conventional techniques.
Desired peptide fragments may be chemically synthesized. An alternative approach involves generating FRO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the 35 desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerise chain reaction (PCR).
Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR.
Preferably, PRO poiypeptide fragments share at least one biological and/or immunological activity with the native PRO polypeptide disclosed herein.
In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exartplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.
Table 6 Original Exemvlary Preferred Residue Substitutions Substitutions Ala (A) val; leu; ile val Arg (R) lys; gln; asn lys Asn (N gln; his; lys; arg gln j Asp (D) glu glu Cys (C) ser ser Gln (Q) asn asn Glu (E) asp asp Gly (G) pro; ala ala His (H) asn; gln; lys; arg arg Ile (I) leu; val; met; ala;
phe;

norleucine leu Leu (L) norleucine; ile; val;

met; ala; phe ile Lys (K) arg; gln; asn arg Met (M) leu; phe; ile Ieu Phe (F) leu; val; ile; ala; leu tyr Pro (P) ala ala Ser (S) thr thr Thr (T) ser ser Ttp (W) tyr; phe tyr Tyr (Y) trp; phe; thr; ser phe Val (V) ile; leu; met; phe;

ala; norleucine leu Substantial modifications in function or immunological identity of the PRO
polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobiciry of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side~hain properties:
(1) hydrophobic: norleucine, met, ala, val, leu, ile;
(2) neutral hydrophilic: cys, ser, thr;
(3) acidic: asp, glu;
(4) basic: asn, gln, his, lys, arg;
(5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, p6e.

WO 00/56889 PC'f/US00/05601 Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.
The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (Carter et al., Nucl.
Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA
to produce the PRO variant DNA.
Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scarming amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and IS exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.);
Chothia, 1. Mol. Biol., 150:1 (I976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.
C. Modifications of PRO
Covalent modifications of PRO are included within the scope of this invention.
One type of covalent modification includes reacting targeted amino acid residues of a PRO
polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of the PRO.
Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,I-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccittimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunetional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate.
Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspattyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of Beryl or threonyl residues, methylation of the a-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, Protgins: Structure and MQecular Properties, W.H.
Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.
Another type of covalent modification of the PRO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.
Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, oT
substitution by, one or more serine or threonine residues to the native sequence PRO (for O-linked glycosylation sites). The PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA
encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.
Another means of increasing the number of carbohydrate moieties ~n the PRO
polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the an, e.g., in WO 87/05330 published 1 I September I987, and in Aplin and Wriston, CRC
Crit. Rev. Biochem., pp. 259-306 (1981).
Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Bioohvs., 259:52 (1987) and by Edge et al., Anal. Biochem,, 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth.
Enzymol., 138:350 (1987).
Another type of covalent modification of PRO comprises linking the PRO
polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144;
4,670,417; 4,791,192 or 4,179,337.
The PRO of the present invention may also be modified in a way to form a chimeric molecule comprising PRO fused to another, heterologous polypeptide or amino acid sequence.
In one embodiment, such a chimeric molecule comprises a fusion of the PRO with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind.
The epitope tag is generally placed at the amid- or carboxyl- terminus of the PRO. The presence of such epitope-tagged forms of the PRO can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., _8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., lvfolecular and Cellular Biolggv, ~:3610-3616 ( 1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Ene_ineering, ~(6):547-553 (/990)]. Other tag polypeptides include the Flag-peptide (Hopp et al., BioTechnoloQV, 6_:1204-1210 (1988)]; the ICT3 epitope peptide [Mattin et al., fence, 255:192-194 (1992)];
an a-tubutin epitope peptide (Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

wo ooissss9 PcTiIlsooros6ol In an akemative embodiment, the chimeric molecule tnay comprise a fusion of the PRO with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an °immunoadhesin"), such a fusion could be to the Fc region of an Ig(~ molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO
polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CHI, CH2 and CH3 regions of an IgG 1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.
D. Preparation of PRO
The description below relates primarily to production of PRO by culturing cells transformed or transfected with a vector containing PRO nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare PRO. For instance, the PRO sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA
(1969); Merrifield, J. Am. Chem.
Soc., 85:2149-2154 (1963)]. In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO.
1. Isolation of DNA Encod;ne PRO
DNA encoding PRO may be obtained from a cDNA library prepared from tissue believed to possess the PRO mRNA and to express it at a detectable level. Accordingly, human PRO
DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples. The PRO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).
Libraries can be screened with probes (such as antibodies to the PRO or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA
or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Clonine: A ~aborator~Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding PRO is to use PCR
methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: A Laboratory! Manual (Cold Spring Harbor Laboratory Press, 1995)].
The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized.
The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being careened. Methods of labeling are well known in the art, and include the use of radiolabels like '2P-labeled ATP, biotinytation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.
Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases.
Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.
Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.
2. Selection and Transformation of Host Cells Host cells are transfected or transformed with expression or cloning vectors described herein for PRO
production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., su r .
Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example, CaClz, CaPO,, liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with Agrobacterium nUnefaciens is used for transformation of certain plant cells, as described by Shaw et al. , Gene, 23:315 ( 1983) and WO 89/05859 published 291une 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virolotw 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., . Bact , ~Q:946 (1977) and Hsiao et al., Proc.
Natl. Acad. Sci. (USA), x:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithirte, may also be used. For various techniques for transforming mammalian cells, see Keown et al., v(_tethods in EnzvmoloQV, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).
Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as E. coli.
Various E, coli swains are publicly available, such as E. coli K12 strain MM294 (ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain W311~ (ATCC 27,325) and KS 772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacter iaceae such as Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g., Serratia marcescans, and Shigella, as well as Bacilli such as B.
subtilis and B, licheniformis (e.g., B. licheniformis 41P disclosed in DD
266,710 published 12 April 1989), Pseudomonas such as P. aeruginosa, and Streptomyces. These examples are illustrative rather than limiting.
Strain W3I 10 is one particularly preferred host or parent host because it is a common hzst strain for recombinant DNA product fermentations, Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including E. coli W3110 strain 1A2, which has the complete genotype tonA ; E, coli W3110 strain 9E4, which has the complete genotype tonA l~trS;
E. coli W3110 strain 27C7 (ATCC 55,244), which has the complete genotype toM ptr3 phoA El S (argF
lac)169 degP ompT kan'; E, coli W3110 strain 37D6, which has the complete genotype tonA ptr3 phoA ElS (argF
lac)169 degP ompT rbs7 ilvG kan'; E. coli W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant degP deletion mutation; and an E. coli strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, in vitro methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PRO-encoding vectors. Saccharomyces cerevisiae is a commonly used lower eukaryotic host microorganism. Others include Schizosaccharomyces pombe (Beach and Nurse, Nature, 290: 140 [1981];
EP 139,383 published 2 May 1985); Kluyveromyces hosts (U.S. Patent No.
4,943,529; Fleer et al., Bio/Technoloav, 9:968-975 (1991)) such as, e.g., K. lactis (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacteriol., 154(2):737-742 [1983]), K. fragilis (ATCC 12,424), K.
bulgaricus (ATCC 16,045), K.
wickeramii (ATCC 24,178), K. waltii (ATCC 56,500), K. drosophilarurn (ATCC
36,906; Van den Berg et al., Bio/Technolo~y, 8:135 (1990)), K. thermotolerans, and K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28:265-278 [1988]);
Candida; Trichoderma reesia (EP
244,234); Neurospora crassa (Case et al., Proc. Natl. Aced. Sci. USA, 76:5259-5263 (1979]); Schwanniomyces such as Schwanniomyces occidentalis (EP 394,538 published 31 October 1990);
and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium(W091/00357 published lOlanuary 1991), andAspergillushosts such as A. nidulans (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 (1983]; Tilburn et al., Gene, 26:205-221 [1983]; Yeltonet al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) andA. niger(Kelly and Hynes, B 1., 4:475-479 [1985]). Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of Nansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis, and Rhodotorula. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylotroph_s, 269 (1982).
Suitable host cells for the expression of glycosylated PRO are derived from multicellular organisms.
Examples of invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells.
More specific examples include monkey kidney CVI line transformed by SV40 (COS-7, ATCC CRL 1651);
human embryonic kidney tine (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J_.
Gen Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Nat!. Acad.

WO 00156889 Pl:'T/US00/05601 ti. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT
060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.
3. Selection and Use of a Replicable Vector S The nucleic acid (e.g., eDNA or genomic DNA) encoding PRO tnay be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease sites) using techniques known in the art.
Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these componems employs standard ligation techniques which are known to the skilled artisan.
The PRO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a pan of the PRO-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader. (including Saccharomyces and Kluyveromyces a-factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the C. albicans glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO
90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral 2S secretory leaders.
Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses.
The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2p, plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.
Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker.
Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.
An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci.
USA, 77:4216 (1980). A suitable selection gene for use in yeast is the trill gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., ~gne, 7:141 (1979); Tschemper et at., Gene, 10:157 !1980)]. The trill gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, n ti , 85:12 (1977)].
Expression and cloning vectors usually contain a promoter operably linked to the PRO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the (3-lactamase and lactose promoter systems [(:hang et al., atu e, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (trp) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980);
EP 36,776], and hybrid promoters such as the tac promoter [de$oer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA
encoding PRO.
Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 ( 1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.
Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.
PRO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK
2,211,504 published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.
Transcription of a DNA encoding the PRO by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, a-fetoprotein, and insulin).
Tvvpicaliy, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or eDNAs.
These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO.
S Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantel et al., Nature, 281:406 (1979); EP 117,060; and EP 117,058.
4. Detectine Gene Amnlification/Ex~ression Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of tnRNA [Thomas, Proc. Natl.
Acad. Set. USA, 77:5201-5205 (1980)), dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein.
Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.
Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO
DNA and encoding a specific antibody epitope.
5. Purification of Polypeptide Forms of PRO may be recovered from collate medium or from host cell lysates.
if membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g.
Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.
It may be desired to purify PRO from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange cohunn;
ethanol precipitation; reverse phase HPLC; chromatography on silica or on a canon-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG;
and metal chelating columns to bind epitope-tagged forms of the PRO. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzvmoloev, 182 (1990);
*-trademark 118 Scopes, Protein Purification: Principles and Prg_ctice, Springer-Verlag, New York (198?). The purification steps) selected will depend, for example, on the nature of the production process used and the particular PRO
produced.
E. Uses for PRO
Nucleotide sequences (or their complement) encoding PRO have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. PRO nucleic acid will also be useful for the preparation of PRO
polypeptides by the recombinant techniques described herein.
The full-length native sequence PRO gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length PRO cDNA or to isolate still other cDNAs (for instance, those encoding naturally-occurring variants of PRO or PRO from other species) which have a desired sequence identity to the native PRO sequence disclosed herein. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the full length native nucleotide sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and introns of native sequence PRO. By way of example, a screening method will comprise isolating the coding region of the PRO gene using the known DNA sequence to synttesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as "P or'sS, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the PRO
gene of the present invention can be used to sct~een libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to.
Hybridization techniques are described in further detail in the Examples below.
Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.
Other useful fragments of the PRO nucleic acids include antisense or sense oligonucleotides comprising a singe-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target PRO mRNA (sense) or PRO DNA (antisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of PRO DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein astd Cohen (Cancer Res. 48:2659, 1988) and van der Krol et al. (BioTechnigues 6:958, 1988).
Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means.
The antisense oligonucleotides thus may be used to block expression of PRO
proteins. Antisense or sense oiigonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable in vivo (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.
Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/
100:8, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.
Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example, CaPO; mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Ban virus.
In a preferred procedure, an antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either in vivo or ex vivo. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCTSA, DCTSB and DCTSC (sce WO
90/13641).
Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.
Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.
Antisense or sense RNA or DNA molecules are generally at least about 5 bases in length, about 10 bases in length, about 15 bases in length, about 20 bases in length, about 25 bases in length, about 30 bases in length, about 35 bases in length, about 40 bases in length, about 45 bases in length, about 50 bases in length, about 55 bases in Length, about 60 bases in length, about 65 bases in length, about 70 bases in length, about 75 bases in length, about 80 bases in length, about 85 bases in length, about 90 bases in length, about 95 bases in length, about 100 bases in length, or more.
The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related PRO coding sequences.
Nucleotide sequences encoding a PRO can also be used to construct hybridization probes for mapping the gene which encodes that PRO and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as in situ hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

When the coding sequences for PRO encode a protein which binds to another protein (example, where the PRO is a receptor), the PRO can be used in assays to identify the other proteins or molecules.involved in the binding interaction. By such methods, inhibitors of the receptor/ligand binding interaction can be identified.
Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor PRO can be used to isolate correlative ligand(s).
Screening assays can be designed to find lead compounds that mimic the biological activity of a native PRO or a receptor for PRO. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be perfotTrted in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.
Nucleic acids which encode PRO or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding PRO. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for PRO transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding PRO introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding PRO. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression.
In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.
Altennatively, non-human homologues of PRO can be used to construct a PRO
"knock out" animal which has a defective or altered gene encoding PRO as a result of homologous recombination between the endogenous gene encoding PRO and altered genomic DNA encoding PRO introduced into an embryonic stem cell of the animal. For example, cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques. A portion of the genomic DNA encoding PRO can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., Ce]_l, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras (see e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologousIy recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the PRO polypeptide.
Nucleic acid encoding the PRO polypeptides may also be used in gene therapy.
In gene therapy applications, genes are introduced into cells in order to achieve in vivo synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA.
Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes in vivo. It has already been shown that short antisense oligonucIeotides can b~
impoi red into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik et al. , Proc. Natl. Acad. Sci. USA 83:4143-414b [1986]).
The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.
There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or in vivo in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAF-dextran, the calcium phosphate precipitation method, etc. The currently preferred in vivo gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al., ends in Biotechnoloev 11, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life.
The technique of receptor-mediated endocytosis is described, for example, by Wu et al., 1. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson et at., c'ence 256, 808-813 (1992).
The PRO polypeptides described herein may also be employed as molecular weight markers for protein electrophoresis purposes and the isolated nucleic acid sequences may be used for recombinantly expressing those markers.

wo oo/ssss9 PcT/usoo/os6o1 The nucleic acid molecules encoding the PRO polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each PRO nucleic acid molecule of the present invention can be used as a chromosome marker.
The PRO polypeptidec and nucleic acid molecules of the present invention may also be used for tissue typing, wherein the PRO polypeptides of the present invention may be differentially expressed in one tissue as compared to another. PRO nucleic acid molecules will find use for gener4ting probes for PCR, Northern ar~.alysis, Southern analysis and Western analysis.
The PRO polypepades described herein tnay also be employed as therapeutic agents. The PRO
polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the PRO product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle. Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remin~ton's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids;
antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine;
monosaccharides, disaccharides and other carbohydrates including glucose, tnannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN''~"', PLURONICST"' or PEG.
The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.
Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
The route of administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems.
Dosages and desirod dntg concentrations of pharmaceutical compositions of the present invention may vary depending on the particuiar use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the pritxiples laid down by Mordenti, J. and Chappell, W.
"The use of interspecies scaling in toxicokinetics" In Toxiookinetics and New Drug Development, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96.
When in vivo administration of a PRO polypeptide or agonist or antagonist thereof is employed, not~tttal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1 /eg/kg/day to 10 mg/kg/day, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos.
4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue, for example, may necessitate delivery in a manner different from that to another organ or tissue.
Where sustained-release administration of a PRO polypeptide is desired in a formulation with release characteristics suitable for the treatment of any disease or disorder requiring administration of the PRO
polypept de, microencapsuiation of the PRO polypeptide is contemplated.
Microencapsulation of recombinant proteins for sustained release has been successfully performed with human growth hormone (rhGH), interferon-(rhIFN- ), interleukin-2, and MN rgp120. Johnson et al., Nat. Med., 2:795-799 (1996); Yasuda, Biomed.
Ther., 27:1221-1223 (1993); Hora et al., Bio/Technologv. 8:755-758 (1990);
Cleland, "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in Vaccine Desien:
Tote Subunit and Adjuvant Approach, Powell and Newman, eds, (Plenum Press: New York, 1995), pp. 439-462;
WO 97/03692, WO 96/40072, WO 96/07399; and U.S. Pat. No. 5,654,010.
The sustained-release formulations of these proteins were developed using poly-lactic-coglyeolic acid (PLGA) polymer due to its biocompatibility and wide range of biodegradable properties. The degradation products of PLGA, lactic and glycolic acids, can be cleared quickly within the human body. Moreover, the degradability of this polymer can be adjusted from months to years depending on its molecular weight and composition. Lewis, "Controlled release of bioactive agents from lactide/glycotide polymer," in: M. Chasin and R. Langer (Eds.), Biode rg adable Polymers as Drug Delivery S stems (Marcel Dekker: New York, 1990), pp.l-41.
This invention encompasses methods of screening compounds to identify those that,mimic the PRO
polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the PRO polypeptides encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.
The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.
All assays for antagonists are common in that they call for contacting the drug candidate with a PRO
polypeptide erxoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.
In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the PRO polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a mierotiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the PRO polypeptide and drying. Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the PRO polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes anchored on die solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.
If the candidate compound interacts with but does not bind to a particular PRO
polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-finking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature Ice. ndon), 340:245-246 (1989); Chien et al., Proc.
Natl. Ac~l. Sci. tjSA, 88:9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DIVA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GALL-IacZ reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction.
Colonies containing interacting polypeptides are detected with a chromogenie substrate for ~i-galactosidase. A
complete kit (MATCHMAKERT"') for identifying protein-protein interactions between two specific proteins using the two hybrid technique is commercially available from Clontech. This system can also be extended to map protein domains involved in sp~ific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.
Compounds that interfere with the interaction of a gene encoding a PRO
polypeptide identified herein and other infra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the infra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the infra- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reactions) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.
To assay for antagonists, the PRO polypeptide may be added lo a cell along with the compound to be screened for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the PRO polypeptide indicates that the compound is an antagonist to the PRO
polypeptide. Alternatively, antagonists may be detected by combining the PRO polypeptide and a potential antagonist with membrane-bound PRO polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The PRO polypeptide can be labeled, such as by radioactivity, such that the number of PRO polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FAGS sorting. Coligan et al., Current Protocols in Immun., 1(2): Chapter 5 (1991).
Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the PRO polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS
cells or other cells that are not responsive to the PRO polypeptide.
Transfected cells that are grown on glass slides are exposed to labeled PRO polypeptide. The PRO polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.
As an alternative approach for receptor identification, labeled PRO
polypeptide can be photoaffinity linked with cell membrane or extract preparatiotu that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing.
The amino acid sequence obtained from micro- sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA
library to identify the gene encoding the putative receptor.
In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled PRO polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.
More specific examples of potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with PRO polypeptide, and, in particular antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments.
Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the PRO
polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the PRO polypeptide.
Another potential PRO polypeptide antagonist is an antisense RNA or DNA
construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation.
Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature PRO polypeptides herein, is used to design an antisense RNA
oligonucleotide of from about 10 to 40 base pairs in length. A DNA
oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix -see Lee et al., Nucl. Acids Res., 6:3073 (/979); Cooney et al., Science, 241: 456 (/988); Dervan et al., Science, 251:1360 (1991)), thereby preventing transcription and the production of the PRO polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into the PRO polypeptide (antisense - Okano, ~leurochem., 56:560 (1991); O~godeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed in vivo to inhibit production of the PRO
polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +1U positions of the target gene nucleotide sequence, are preferred.
Potential antagonists include small molecules that bind to the active site, the receptor binding site, or IO growth factor or other relevant binding site of the PRO polypeptide, thereby blocking the normal biological activity of the PRO polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.
Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA.
Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by lrnown techniques. For furtherdetails see, e.g., Rossi, Current Biology, 4:469-471 (1994), and PCT publication No. WO 97/33551 (published September 18, 1997).
Nucleic acid molecules in triple-helix fotination used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, e.g., PCT publication No. WO
97/33551,sup~a.
These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.
Uses of the herein disclosed molecules may also be based upon the positive functional assay hits disclosed and described below.
F. Anti-PRO Antibodies The present invention further provides anti-PRO antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.
1. Polyclonal Antibodies The anti-PRO antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mamrrtal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant.
Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the PRO polypeptide or a fusion protein thereof.
It may he useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which ::lay be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).
The immunization protocol may be selected by one skilled in the art without undue experimentation.
2. Monoclonal Antibodies The anti-PRO antibodies may, alternatively, be monoclonal antibodies.
Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975).
In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Atternatively, the lymphocytes may be immunized in vitro.
The immunizing agent will typically include the PRO polypeptide or a fusion protein thereof.
Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desire.
The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [coding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103].
Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and htunan origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridotnas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell litres are marine myeloma litres, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Typo Culture Collection, Mantissas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, ,],, Immunol., x:3001 (1984); Brodeur et al., ]Monoclonal Antibody Pr~oduct~on Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].
The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., X7:220 (1980).

After the desired hybridoma cells are identified, the clones may be subclened by limiting dilution procedures and grown by standard methods [coding, su ra . Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Altetnan vely, the hybridoma cells may be grown in vivo as ascites in a mammal.
The monoclonal antibodies secreted by the subclotxs may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of marine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modifed, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous marine sequences [U.S. Patent No. 4,816,567; Morrison et al., s ra or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-itnmunoglobulin polypeptide can be substituted for ;he constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
The antibodies tray be monovalent antibodies. Methods for preparing monovalent antibodies are welt Irnown in the art. For example, one method involves recombinant expression of ittununoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinlcing.
In vitro methods are also suitable for preparing monovalent antibodies.
Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques lrnown in the art.
3. Htunan and Humanized Antibodies The anti-PRO antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., marine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')Z or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR
regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. 0o.
Struct. Biol.,, 2_:593-596 (1992)].
Methods for humanizing non-human antibodies are well known in the art.
Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import"
variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riectunann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, x:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., x:581 (1991)J. The techniques of Cole et al. and Boertter et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Ther_apv, Alan R. Liss, p. 77 ( 1985) and Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous itnmtmoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806;
5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology ~Q, 779-783 ( 1992); Lonberg er al., Nature 368 856-859 ( 1994); Morrison, Nature ~ø8, 812-13 (1994); Fishwild e1 al., Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Imm~ol. 1_~ 65-93 (1995).
4. Bispecific Antibodies Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.
Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chainshave different specificities [Milstein and Cuello, Natma, 305:537-539 ( 1983)].
Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific stricture. The purification of the correct molecule is usually accomplished by affinity chromatography steps.
Sinular procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO
J., 10:3655-3659 (1991).
Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH 1 ) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the itnmunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzvmolotrv, 121:210 (1986).
According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant celi culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain.
In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chains) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.
Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')Z
bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared can be prepared using chemical linkage. Brennan et al. , Science 229:81 ( 1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')i fragtttettts. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenate to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives.
One of the Fab'-TNB
derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.
Fab' fragments may be directly recovered from E. cola and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')2 molecule. Each Fab' fragment was separately secreted from E. cola and subjected to directed chemical coupling in vitro to forth the bispecific antibody. The bispeciftc antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T
cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.
Various technique for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispeciftc antibodies have been produced using leucine zippers.
Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' port ions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers.
This method can also be utilized for the production of antibody homodimers.
The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody frabments. The fragments comprise a heavy-chain variable domain (V") connected to a light-chain variable domain (V~) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V" and V~ domains of one fragment are forced to pair with the complementary V~ and VH domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Itturtunol. 152:5368 (1994).
Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared.
Tutt et al. , J. hnmunol. 147:60 ( 1991 ).
Exemplary bispecific antibodies may bind to two different epitopes on a given PRO polypeptide herein.
Alternatively, an anti-PRO polypeptide arm tray be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CDZ, CD3, CD28, or B7), or Fc receptors for IgG
(FcyR), such as FcyRI (CD64), FcyRII (CD32) and FcyRIII (CDl6) so as to focus cellular defense mechanisms to the cell expressing the particular PRO polypeptide. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a particular PRO polypeptide. These antibodies possess a PRO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the PRO polypeptide and further binds tissue factor (TF).
IleteroconLgate An~yodies Heteroconjugate antibodies are also within the scope of the present invention.
Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [tl.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 921200373; EP 03089]. It is contemplated that the antibodies may be prepared in vitro using kaown methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disul fide exchange reaction or by forming a thioether bond.
Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

6. Effector Function En ineering It may be desirable to modify the antibody of the inventioti with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residues) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated rnay have improved internalization capability and/or increased complement-s mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC).
See Caron et al. , J. Exp Med., 176:
1191-1195 (1992) and Shopes, J. lmmunol., _l~: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff et al.
Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Dru Desigj 3: 219-230 (1989).
7. Immunoconiugates The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g. , an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above.
Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Psetulomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, croon, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include Z'ZBi, '3'I, '3'In, ~°Y, and'~Re.
Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifuneoonal derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6 diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobetuxne). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., Science, X38: 1098 (1987). Carbon-14-labeled 1 isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See W094/11026.
In another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., .avidin) that is conjugated to a cytotoxic agent (e.g., a radionucleotide).

8. Immunoli sp2mes The antibodies disclosed herein may also be formulated as immunoliposomes.
Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad.
Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos.
4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No.
5,013,556.
Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter.
Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al ., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).
9. Pharmaceutical Compositions of Antibodies Antibodies specifically binding a PRO polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders in the form of pharmaceutical compositions.
If the PRO polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred.
For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA
technology. See, e.g., Marasco et al., P_roc. Natl. Acad. Sci. USA, ~0: 7889-7893 (1993). The fpm herein may also contain more than one active compound as rPcessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.
Such techniques are disclosed in Remington's Pharmaceutical Sciences, supra.
The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S.
Pat. No. 3,773,919), copolymers of L-glutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON
DEPOT T"' (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.
G. Uses for anti-PRO Antibodies The anti-PRO antibodies of the invention have various utilities. For example, anti-PRO antibodies may be used in diagnostic assays for PRO, e.g., detecting its expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases (Zola, Monoclonal Antibodies: A Manual of Techniques, CRC Press, Inc. ( 1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as'H, '°C,'~P, "S, or'~51, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, x:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981);
and Nygren, J. Histochem. and Cvtochem., 30:407 (1982).
Anti-PRO antibodies also are useful for the affinity purification of PRO from recombinant cell culture or natural sources. In this process, the antibodies against PRO are immobilized on a suitable support, such a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample containing the PRO to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PRO, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the PRO from the antibody.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
S EXAMPLES
Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Mana~aas, VA.
EXAMPLE 1: Extracellular Domain Homology Screening to Identif~Novel Polypeptides and cDNA Encoding Therefor The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases. The EST
databases included public databases (e.g., Dayhoff, GenBank), and proprietary databases (e.g. LIFESEQT"', Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST-2 (Altschul et al., Methods in Enzvmology 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA
sequences with the program "phrap" (Phil Green, University of Washington, Seattle, WA).
Using this extracellular domain homology screen, consensus DNA sequences were assembled relative to the other identified EST sequences using phrap. In addition, the consensus DNA sequences obtained were often (but not always) extended using repeated cycles of BLAST or BLAST-2 and phrap to extend the consensus sequence as far as possible using the sources of EST sequences discussed above.
Based upon the consensus sequences obtained as described above, oligonucleotides were then synthesized and used to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for a PRO
polypeptide. Forward and reverse PCR
primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 by in length. The probe sequences are typically 40-55 by in length. In some cases, additional oligonucleotides are synthesized when the consensus sequence is greater than about I-I.Skbp. In order to screen several libraries for a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel et al., Current Protocols in Molecular Biology, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs.
The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA.
The cDNA was primed with oligo dT containing a NotI site, linked with blunt to SaII hemikinased adaptors, cleaved with Notl, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as *-trademark 136 pRKB or pRKD; pRKSB is a precursor of pRKSD that does not contain the SfiI
site; see, Holmes et al., Science, 253:1278-1280 (1991)) in the unique Xhol and NotI sites.
EXAMPLE 2: Isolation of cDNA clones by Amylase Screening Preparation of oligo dT primed cDNA library mRNA was isolated from a human tissue of interest using reagents and protocols from Invitrogen, San Diego, CA (Fast Track 2). This RNA was used to generate an oligo dT primed cDNA library in the vector pRKSD using reagents and protocols from Life Technologies, Gaithersburg, MD
(Super Script Plasmid System).
In this procedure, the double stranded .:DNA was sized to greater than 1000 by and the SaII/NotI Tinkered cDNA
was cloned into Xhol/NotI cleaved vector. pRKSD is a cloning vector that has an sp6 transcription initiation site followed by an SfiI restriction enzyme site preceding the XhoI/Notl cDNA
cloning sites.
2. Preparation of random primed cDNA library A secondary cDNA library was generated in order to preferentially represent the 5' ends of the primary cDNA clones. Sp6 RNA was generated from the primary library (described above), and this RNA was used to generate a random primed cDNA library in the vector pSST-AMY.O using reagents and protocols from Life Technologies (Super Script Plasmid System, referenced above). In this procedure the double stranded cDNA
was sized to 500-1000 bp, Tinkered with blunt to NotI adaptors, cleaved with SfiI, and cloned into Sfil/Notl cleaved vector. pSST-AMY.O is a cloning vector that has a yeast alcohol dehydrogenase promoter preceding the cDNA cloning sites and the mouse amylase sequence (the mature sequence without the secretion signal) followed by the yeast alcohol dehydrogenase terminator, afrer the cloning sites. Thus, cDNAs cloned into this vector that are fused in frame with amylase sequence will lead to the secretion of amylase from appropriately transfected yeast colonies.
3. Transformation and Detection DNA from the library described in paragraph 2 above was chilled on ice to which was added electrocompetent DHIOB bacteria (Life Technologies, 20 ml). The bacteria and vector mixture was then electroporated as recommended by the manufacturer. Subsequently, SOC media (Life Technologies, 1 ml) was added and the mixture was incubated at 37°C for 30 minutes. The transformants were then plated onto 20 standard 150 mm LB plates containing ampicillin and incubated for 16 hours (37°C). Positive colonies were scraped off the plates and the DNA was isolated from the bacterial pellet using standard protocols, e.g. CsCI-gradient. The purified DNA was then carried on to the yeast protocols below.
The yeast methods were divided into three categories: (1) Transformation of yeast with the plasmid/cDNA combined vector; (2) Detection and isolation of yeast clones secreting amylase; and (3) PCR
amplification of the insert directly from the yeast colony and purification of the DNA for sequencing and further analysis.
The yeast strain used was HD56-SA (ATCC-90785). This strain has the following genotype: MAT
alpha, ura3-52, leu2-3, leu2-112, his3-I I, his3-I5, MAL', SUC*, GALr.
Preferably, yeast mutants can be *-trademark 137 employed that have deficient post-translational pathways. Such mutants may have translocation deficient alleles in sec71, sec72, sec62, with truncated sec71 being most preferred.
Alternatively, antagonists (including antisense nucleotides and/or ligands) which interfere with the normal operation of these genes, other proteins implicated in this post translation pathway (e.g., SEC6lp, SEC72p, SEC62p, SEC63p, TDJIp or SSAIp-4p) or the complex formation of these proteins may also be preferably employed in combination with the amylase-expressing yeast.
Transformation was performed based on the protocol outlined by Gietz et al., Nucl. Acid. Res., 20:1425 (1992). Transformed cells were then inoculated from agar into YEPD
complex media broth (100 ml) and grown overnight at 30°C. The YEPD broth was prepared as described in Kaiser et al., Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 207 (1994). The overnight culture was then diluted to about 2 x 106 cells/ml (approx. ODD=0.1) into fresh YEPD broth (500 ml) and regrown to 1 x 10' cellsJml (approx. ODD=0.4-0.5).
The cells were then harvested and prepared for transformation by transfer into GS3 rotor bottles in a Sorval GS3 rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and then resuspended into sterile water, and centrifuged again in 50 ml falcon tubes at 3,500 rpm in a BecIQrtart GS-6KR centrifuge. The supernatant was discarded and the cells were subsequently washed with LiAc/1'E (10 ml, 10 mM Tris-HCI, 1 mM EDTA
pH 7.5, 100 mM Li200CCH~), and resuspended into LiAc/TE 12.5 ml).
Transformation took place by mixing the prepared cells ( 100 ~d) with freshly denatured single stranded salmon testes DNA (Lofstrand Labs, Gaithersburg, MD) and transforming DNA (1 pg, vol. < 10 ~d) in microfuge tubes. The mixture was mixed briefly by vortexing, then 409 PEG/TE
(600 ~d, 40~ polyethylene glycol-4000, 10 mM Tris-HCI, 1 mM EDTA, 100 mM Li200CCH3, pH 7.5) was added.
This mixture was gently mixed and incubated at 30°C while agitating for 30 minutes. The cells were then heat shocked at 42°C
for 15 minutes, and the reaction vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds, decanted and resuspended into TE (500 p1, 10 mM Tris-HCI, 1 mM EDTA pH 7.5) followed by recentrifugation. The cells were then diluted into TE (1 ml) and aliquots (200 ~.1) were spread onto the selective media previously prepared in I50 mm growth plates (VWR).
Alternatively, instead of multiple small reactions, the transformation was performed using a single, large scale reaction, wherein reagent amounts were scaled up accordingly.
The selective media used was a synthetic complete dextrose agar lacking uracil (SCD-Ura) prepared as described in Kaiser et al., Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p.
208-210 (1994). Transfonmants wcre grown at 30°C for 2-3 days.
The detection of colonies secreting amylase was performed by including red starch in the selective growth media. Starch was coupled to the red dye (Reactive Red-120, Sigma) as per the procedure described by Biely et al., Anal. Biochem., x:176-179 (1988). The coupled starch was incorporated into the SCD-Ura agar plates at a final concentration of 0. I ~ ~6 (w/v), and was buffered with potassium phosphate to a pH of 7.0 (50-100 mM final concentration).
The positive colonies were picked and streaked across fresh selective media (onto 150 mm plates) in order to obtain well isolated and identifiable single colonies. Welt isolated single colonies positive for amylase *-trademark 138 secretion were detected by direct incorporation of red starch into buffered SCD-Ura agar. Positive colonies were determined by their ability to break down starch resulting in a clear halo around the positive colony visualized directly.
4. Isolation of DNA by PCR Amplification When a positive colony was isolated, a portion of it was picked by a toothpick and diluted into sterile wai er (30 u() in a 96 well plate. At this time, the positive colonies were either f~ ozen and stored for subsequent analysis or immediately amplified. An aliquot of cells (5 ~.1) was used as a template for the PCR reaction in a 25 ~1 volume containing: 0.5 ~1 Klentaq (Clontech, Palo Alto, CA); 4.0 ~1 10 mM dNTP's (Perkin Elmer Cetus); 2.5 ~I Kentaq buffer (Clontech); 0.25 ~1 forward oligo I ; 0.25 ~1 reverse oligo 2; 12.5 /d distilled water.
The sequence of the forward oligonucleotide 1 was:
5'-TGTAAAACGACGGCCAGTTAAATAGACCTGCAATTATTAATCT-3' (SEQ ID N0:3) The sequence of reverse oligonucleotide 2 was:
5'-CAGGAAACAGCTATGACCACCTGCACACCTGCAAATCCATT-3' (SEQ ID N0:4) PCR was then performed as follows:
a. Denature 92°C, 5 minutes b. 3 cycles of: Denature 92°C, 30 seconds Anneal 59°C, 30 seconds Extend 72°C, 60 seconds c. 3 cycles of: Denature 92°C, 30 seconds Anneal 57°C, 30 seconds Extend n°C, 60 seconds d. 25 cycles of: Denature 92°C, 30 seconds Anneal 55°C, 30 seconds Extend 72°C, 60 seconds e. Hold 4°C
The underlined regions of the oligonucleotides annealed to the ADH promoter region and the amylase region, respectively, and amplified a 307 by region from vector pSST-AMY.O
when no insert was present.
Typically, the first 18 nucleotides of the 5' end of these oligonucleotides contained annealing sites for the sequencing primers. Thus, the total product of the PCR reaction from an empty vector was 343 bp. However, signal sequence-fused cDNA resulted in considerably longer nucleotide sequences.
Following the PCR, an aliquot of the reaction (5 ~l) was examined by agarose gel electrophoresis in a 1 ~6 agarose gel using a Tris-Borate-EDTA (TBE) buffering system as described by Sambrook et al., ~.
Clones resulting in a single strong PCR product larger titan 400 by were further analyzed by DNA sequencing after purification with a 96 Qiaquick PCR clean-up column (Qiagen Inc., Chatsworth, CA).
*-trademark EXAMPLE 3: Isolation of cDNA Clones Usin~~nal Algorithm Analysis Various polypeptide-encoding nucleic acid sequences were identified by applying a proprietary signal sequence finding algorithm developed by Genentech, Inc. (South San Francisco, CA) upon ESTs as well as clustered and assembled EST fragments from public (e.g., GenBank) and/or private (LIFESEQ~, Incyte Pharmaceuticals, Inc., Palo Alto, CA) databases. The signal sequence algorithm computes a secretion signal score based on the character of the DNA nucleotides surrounding the first and optionally the second methionine codon(s) (ATG) at the 5'-end of the sequence or sequence fragment under c<~nsideration. The nucleotides following ,he first ATG must code for at least 35 unambiguous amino acids without any stop codons. If the first ATG has the required amino acids, the second is not examined. If neither meets the requirement, the candidate sequence is not scored. 1n order to determine whether the EST sequence contains an authentic signal sequence, the DNA and corresponding amino acid sequences surrounding the ATG codon are scored using a set of seven sensors (evaluation parameters) known to be associated with secretion signals.
Use of this algorithm resulted in the identification of numerous polypeptide-encoding nucleic acid sequences.
EXAMPLE 4: Isolation of cDNA clones Encoding Human PR01484 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA39616.
Based on the DNA39616 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR01484.
PCR primers (forward and reverse) were synthesized:
forward PCR primer (39616. f1) 5'-GCAACAATGGAGCCACTGGTCATG-3' (SEQ ID NO:S) reverse PCR primer (39616.r1) 5'-GCAAAGGTGGAGAAGCGTTGGTGG-3' (SEQ 1D N0:6) Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA39616 sequence which had the following nucleotide sequence 2$ hybridization probe (39616.p1) 5'-CCCACTTCAGCAATCAGAACAGTGGGATTATCTTTCAGCAGTGTTTGAGACC-3' (SEQ ID N0:7) In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened by PCR amplification with the PCR primer pair identified above. A
positive library was then used to isolate clones encoding the PR01484 gene using the probe oligonucleotide and one of the PCR primers. RNA
for construction of the cDNA libraries was isolated from human fetal kidney tissue.
DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PRO 1484 (designated herein as DNA44686-1653 [Figure 1, SEQ ID NO: 1 j;
(UNQ753) and the derived protein sequence for PR01484.
The entire nucleotide sequence of DNA44686-1653 is shown in Figure 1 (SEQ ID
NO:1). Clone DNA44686-1653 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 77-79 and ending at the stop codon at nucleotide positions 815-817 (Figure 1). The predicted polypeptide precursor is 246 amino acids long (Figure 2). The full-length PR01484 protein shown in Figure 2 has an estimated molecular weight of about 26,994 daltons and a pI of about 6.43. Analysis of the full-length PR01484 sequence shown in Figure 2 (SEQ ID N0:2) evidences the presence of the following: a signal peptide from about amino acid 1 to about amino acid 22, a Clq domain signature sequence from about amino acid 137 to about amino acid 167 and various amino acid sequence blocks having homology to Clq domain-containing proteins as shown in Figure 2. Clone DNA44686-1653 has been deposited with ATCC on January 12, 1999 and is assigned ATCC deposit no. 203581.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST:'. sequence alignment analysis of the full-length sequence shown in Figure 2 (SEQ ID
N0:2), evidenced significant homology between the PR01484 amino acid sequence and the following Dayhoff sequences: P W09108, CAIA_HUMAN, CIQC HUMAN, HUMC1QB2-1, COLE_LEPMA, MMU32107_l, CAS4 EPHMU, A57131, A41207 and CERL RAT.
EXAMPLE 5: Isolation of cDNA clones Encoding Human PR04334 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST
cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLASTZ
(Altshul et al., Methods in Enzvmolo>ry 266:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Green, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA56421.
In light of an observed sequence homology between the DNA56421 sequence and an EST sequence contained within the Incyte EST clone no. 3347532, the Incyte clone was purchased and the cDNA insert was obtained and sequenced. The sequence of this cDNA insert is shown in Figure 3 and is herein designated as DNA59608-2577.
The full length clone shown in Figure 3 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 83-85 and ending at the stop colon found at nucleotide positions 1404-1406 (Figure 3; SEQ ID N0:8). The predicted polypeptide precursor (Figure 4, SEQ ID N0:9) is 440 amino acids long. P804334 has a calculated molecular weight of approximately 50,211 daltons and an estimated pI of approximately 8.29.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 4 (SEQ ID
N0:9), revealed homology between the PR04334 amino acid sequence and the following Dayhoff sequences incorporated herein: AB020686-1, PC1 HUMAN, P 879148, PCl MOUSE, RNU78788-1, RATPDIB-1, P W75859, AC005587_1, P

and PPD1 BOVIN.
Clone DNA59608-2577 was deposited with the ATCC on March 23, 1999 and is assigned ATCC
deposit no. 203870.
*-trademark 141 EXAMPLE 6: Isolation of cDNA clones Encodine Human PR01122 An expressed sequence tag (EST) DNA database (LIFESEQT"', Incyte Pharmaceuticals, Palo Alto, CA) was searched and an EST was identified. The EST was Incyte 1347523 which is also called herein DNA49665.
Based on the DNA49665 sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR01122.
PCR primers (forward and reverse) were synthesized:
forward PCR primer 5'-ATCCACAGAAGCTGGCCTTCGCCG-3' (SEQ ID N0:12); and reverse PCR primer 5'-GGGACGTGGATGAACTCGGTGTGG-3' (SEQ ID N0:13).
Additionally, a synthetic oligonucleotide hybridization probe was constructed which had the following nucleotide sequence:
hybridization probe 5'-TATCCACAGAAGCTGGCCTTCGCCGAGTGCCTGTGCAGAG-3' (SEQ ID N0:14) In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened by PCR amplification with the PCR primer pair identified above. A
positive library was then used to isolate clones encoding the PROl 122 gene using the probe oligonucleotide and one of the PCR primers. RNA
for construction of the eDNA libraries was isolated from human fetal kidney tissue (LIB228).
DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PR01122 [herein designated as DNA62377-1381] (SEQ ID NO:10) and the derived protein sequence for PR01122.
The entire nucleotide sequence of DNA62377-1381 is shown in Figure 5 (SEQ ID
NO:10). Clone DNA62377-1381 contains a single open reading frame with an apparent translational initiation site at nucleotide positions SO-52 and ending at the stop colon at nucleotide positions 641-643 of SEQ ID NO:10 (Figure 5). The predicted polypeptide precursor is 197 amino acids long (Figure 6). The full-length PR01122 protein shown in Figure 6 has an estimated molecular weight of about 21,765 daltons and a pI
of about 8.53. Clone DNA62377-1381 has been deposited with ATCC on Decen.ber 22, 1998. It is understood that the deposited clone has the actual nucleic acid sequence and that the sequences provided herein are based on known sequencing techniques.
Analysis of the amino acid sequence of the full-length PR01122 polypeptide suggests that it possesses similarity with CTLA-8 and IL-17, thereby indicating that PR01122 may be a novel cytokine. More specifically , an analysis of the Dayhoff database (version 35.45 SwissProt 35) evidenced significant homology between the PR01122 amino acid sequence and the following Dayhoff sequences, P-W 13651, VG13 HSVSA
and CEF25DI 1.
EXAMPLE 7: Isolation of cDNA clones Encoding Human PR01889 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA49310.
Based up an observed homology between the DNA49310 consensus sequence and an EST contained within the Incyte EST clone no.

2779436, Incyte EST clone no. 2779436 was purchased and its insert obtained and sequenced. The sequence of that insert is shown in Figure 7 and is herein designated DNA77623-2524.
The entire nucleotide sequence of DNA77623-2524 is shown in Figure 7 (SEQ ID
NO:IS). Clone DNA77623-2524 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 39-41 and ending at the stop codon at nucleotide positions 330-332 (Figure 7). The predicted polypeptide precursor is 97 amino acids long (Figure 8). The full-Iength PR01889 protein shown in Figure 8 has an estimated molecular weight of about I0, I60 daltons and a pI of about 6.56. Analysis of the full-length PR01889 sequence shown in Figure 8 (SEQ ID N0:16) evidences the presence of the following: a signal peptide from about amino acid 1 to about amino acid 20, potential N-myristolation sites from about amino acid 6 to about amino acid 11 and from about amino acid 33 to about amino acid 38 and prokaryotic membrane lipoprotein Iipid attachment sites from about amino acid 24 to about amino acid 34 and from about amino acid 78 to about amino acid 88. Clone DNA77623-2524 has been deposited with ATCC on December 22, 1998 and is assigned ATCC
deposit no. 203546.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 8 (SEQ ID
N0:16), evidenced significant homology between the PR01889 amino acid sequence and the following Dayhoff sequences: HSE48ATGN_1, P W06292, AB012293_l, THYB MOUSE, P 870984, CHKSCA2A I, P W61628, I48639, BMBUNGKP4_1 and UPA.~. HUMAN.
EXAMPLE 8: Isolation of cDNA clones Encodina~Hutttan PR01890 A consensus DNA sequence was assembled relative to other EST sequences using repeated cycles of BLAST and phrap as described in Example 1 above. This consensus sequence is herein designated DNA52I62.
Based on the DNA52162 consensus sequence, oligonucleotides were synthesized: 1 ) to identify by PCR a cDNA
library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR01890.
PCR primers (forward and reverse) were synthesized:
forward PCR primer (52162.f11 5'-CACCAACCAACTGCCAATCCTGGC-3' (SEQ ID !10:19) reverse PCR primer (52162.r11 5'-ACCACATTCTGATGGGTGTCTCCTGG-3' (SEQ ID N0:20) Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA52162 sequence which had the following nucleotide sequence hybridization.probe (52162.v1) 5'-GGGTCCCTACCTTTACCAGTGGAATGATGACAGGTGTAACATGAAGCAC-3' (SEQ ID N0:21) RNA for construction of the cDNA libraries was isolated from human fetal kidney tissue.
DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PR01890 mesignated herein as DNA79230-2525 [Figure 9, SEQ ID N0:17j; (UNQ872) and the derived protein sequence for PROI890.
The entire nucleotide sequence of DNA79230-2525 is shown in Figure 9 (SEQ ID
N0:17). Clone DNA79230-2525 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 378-380 and ending at the stop codon at nucleotide positions I I97-1199 (Figure 9). The predicted polypeptide precursor is 273 amino acids long (Figure 10). The full-length PR01890 protein shown in Figure has an estimated molecular weight of about 30,431 daltons and a pI of about 6.79. Analysis of the full-length PR01890 sequence shown in Figure 10 (SEQ ID N0:18) evidences the presence of the following: a signal peptide from about amino acid I to about amino acid 21, a transmembrane domain from about amino acid 214 5 to about amino acid 235, potential N-glycosylation sites from about amino acid 86 to about amino acid 89 and from about amino acid 255 to about amino acid 258, a CAMP- and cGMP-dependent protein kinase phosphorylation site from about amino acid 266 to about amino acid 269 and potential N-myristolation sites from about amino acid 27 to about amino acid 32, from about amino acid 66 to about amino acid 71, from al,~ut amino acid 9I to about amino acid 96, from about amino acid 93 to about amino acid 98, from about amino acid 10 102 to about amino acid 107, from about amino acid 109 to about amino acid 114, from about amino acid I40 to about amino acid 145 and from about amino acid 2I2 to about amino acid 2I7.
Clone DNA79230-2525 has been deposited with ATCC on December 22, 1998 and is assigned ATCC deposit no.
203549.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 10 (SEQ ID
N0:18), evidenced significant homology between the PROI890 amino acid sequence and the following Dayhoif sequences: AF093673_I, P W44118, AB014609 1, AC005254_l, AF026547_l, LEC2,MEGRO, PGCV_HUMAN, GEN12667, P 806331 and CELF52E1 9.
EXAMPLE 9: Isolation of cDNA clones Encodine Human PR01887 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein "DNA43041 ".
Based on this consensus sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA
library that contained the sequence of interest, and 2) for use as probes to isotate a clone of the full-length coding sequence for PR01887.
PCR primers (forward and reverse) were synthesized:
forward PCR urimer: 5'-GCAAAGCTCTGCCTCCTTGGCC-3' (SEQ ID N0:24); and reverse PCR primers: 5'-GGGTGGACTGTGCTCTAATGGACGC-3' (SEQ ID N0:25), and 5'-CGTGGCACTGGGTTGATC-3' (SEQ ID N0:26).
Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA43041 sequence which had the following nucleotide sequence:
hybridization rn obe: 5'-GATGCAGTTCTGGTCAGAGACGCTCCCCAGCAAGATACAACAGTG-3' (SEQ
ID N0:27).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened by PCR amplification with the PCR primer pair identified above. A
positive library was then used to isolate clones encoding the PR0188~ gene using the probe oligonucleotide and one of ~he PCR prim~~s. RNA
for construction of the cDNA libraries was isolated from human bone marrow.
DNA sequencing of the clones isolated as described above gave the full-Length DNA sequence for PRO1887, designated herein as "DNA79862-2522" (Figure 11; SEQ ID N0:22), and the derived protein sequence for PR01887.
DNA79862-2522 is shown in Figure 11 (SEQ ID N0:22). Clone DNA79862-2522 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 6-8, and an apparent stop codon at nucleotide positions 1719-1721. The predicted polypeptide precursor is 571 amino acids long. The full-length PR01887 protein shown in Figure 12 has an estimated molecular weight of about 62,282 daltons and a pI of about 5.56. Additional features of the PROI887 protein include a signal peptide at about amino acids I-27; a transmembrane domain at about amino acids 226-245; a potential N-gly:.osylation site at about amino acids 105-108; N-myristoylation sites at about amino acids 10-15, 49-54, 62-67, 86-91, 150-155, 155-160, 162-167, 217-222, 227-232, 228-23~, 232-237,262-267, 257-362, and 461-466; a prokaryotic membrane lipoprotein lipid attachment site at about amino acids 12-22; and a carboxylesterases type-B serine active site at about amino acids 216-231.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 12 (SEQ ID
N0:23), revealed significant homology between the PRO 1887 amino acid sequence and Dayhoff sequence ESTM
MOUSE. Homology was also found between the PR01887 amino acid sequence and the following additions! Dayhoff sequences:
IS D50579 I, I61085, ESTI HUMAN, GEN12405, P W39078, GEN13248, P 858980, A31800 1, and P 845189.
Clone DNA79862-2522 was deposited with the ATCC on December 22, 1998, and is assigned ATCC
deposit no. 203550.
EXAMPLE 10: Isolation of cDNA clones Encodin& Human PR01785 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein "DNA35718".
Based on the DNA35718 consensus sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA library that contained the sequence of interest, and Z) for use as probes to isolate a clone of the full-length coding sequence for PR01785.
PCR primers (forward and reverse) were synthesized:
forward PCR grime,: 5'-ATCCTCCAACATGGAGCCTCTTGC-3' (SEQ ID N0:30); forward P~primer:
S'-GTATCTTGTCAACCCTGAGG-3' (SEQ ID N0:31); and reverse PCR primer: S'-TAACCAGAGCTGCTATGTCAGGCC-3' (SEQ ID N0:32);
Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA35718 sequence which had the following nucleotide sequence:
~tybridization probe: S'-AGGCAAAGTTTCACTAGTTGTAAACGTGGCCAGTGACTGCCAACTCACAG-3' (SEQ ID N0:33).
In order to screen se;~;,ral libraries for a source of a foil-length clone, DNA from the libraries was screened by PCR amplification with the PCR primer pair identified above. A
positive library was then used to isolate clones encoding the PR01785 gene using the probe oligonuchtide and one of the PCR primers. RNA
for construction of the cDNA libraries was isoiated from human aortic endothelial cells.

DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PR01785 (designated herein as DNA80136-2503 [Figure 13, SEQ ID N0:28]; and the derived protein sequence for PR01785.
The entire coding sequence of PR01785 is shown in Figure 13 (SEQ ID N0:28).
Clone DNA80136-2503 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 2-4 and an apparent stop codon at nucleotide positions 629-631 of SEQ ID
N0:28. The predicted polypeptide precursor is 209 amino acids long. There is a signal peptide at about amino acids I-31, a transmembrane domain at about amino acids 18-37 and a glutathione peroaidase signature at about amino acids 104-111 of SEQ ID
N0:29. Clone DNA80136-2503 has been deposited with the ATCC and is assigned ATCC deposit no. 203541.
The full-length PR01785 protein shown in Figure 14 has an estimated molecular weight of about 23, 909 daltons and a pI of about 9.68.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 14 (SEQ ID
N0:29), revealed sequence identity between the PR0I785 amino acid sequence and the following Dayhoff sequences:
GSHC SCHMA, P 844988, A8012395 1, GSHH HUMAN, AC004151 3, BTUE ECOLI, GSHC HUMAN, P 889910, PWU88907 and D37916 I.
EXAMPLE I I : Isolation of cDNA clones Encodine Human PR04353 A consensus DNA sequence was assembled relative to other EST sequences using repeated cycles of BLAST and phrap as described in Example 1 above. This consensus sequence is designated herein "DNA39482°. Based on the DNA39482 cot>settsus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR04353.
PCR primers (forward and reverse) were synthesized:
forward PCR ~r_imer: 5'-GAGGACCTACCGGCCGGACAG-3' (SEQ ID N0:36) and reverse PCR primer: 5'-ATACACCCCGAGTACTGCTGGCAG-3' (SEQ ID N0:37).
Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA39482 sequence which had the following nucleotide sequence:
~,vbridization probe: S'-AGACAGGGCAGCGGCTGCTGAGCTTGGAGCTGGACGCAGCTT-3' (SEQ ID
N0;38).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened by PCR amplification with the PCR primer pair identified above. A
positive library was then used to isolate clones encoding the PR04353 gene using the probe oligonucleotide and one of the PCR primers. RNA
for construction of the eDNA libraries was isolated from human aortic endothelial cells.
DNA sequencing of the cle :es isolated as described above gave the full-length DNA sequence for PR04353 (designated herein as DNA80145-2594 [Figure 15, SEQ ID N0:34J: and the derived protein sequence for PR04353.

The entire coding sequence of PR04353 is shown in Figure 15 (SEQ ID N0:34).
Clone DNA80145-2594 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 19-21, and an apparent stop codon at nucleotide positions 2683-2685. The predicted polypeptide precursor is 888 amino acids long. Clone DNA80145-2594 has been deposited with ATCC and is assigned ATCC deposit no. 204-PTA. The full-length PR04353 protein shown in Figure 16 has an estimated molecular weight of about 95,285 daltons and a pI of about 8.89.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence aligtunent analysis of the full-length sequence shown in Figure 16 (SEQ ID
N0:34), revealed homology between the PR04353 amino acid sequence and the following Dayhoff sequences (sequences and related text incorporated herein): P W19857, AB000776 1, P W57260, JH0798, P 871382, CEY54ESB 1, I48747, MUSC1 1, P 871383 and P W63748.
EXAMPLE 12: Isolation of cDNA clones~ncoding Human PR04357 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein "DNA80155".
Based on the DNA80155 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-Length coding sequence for PR04357.
PCR primers (forward and reverse) were synthesized:
forward PCR~rimer: 5'-GAAGGTGGAAATTAAATTCCAAGGGC-3' (SEQ ID N0:41) and reverse PCR primer: 5'-CGATAAGCTGCTACAGTGCCATCG-3' (SEQ ID N0:42).
Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA80155 sequence which had the following nucleotide sequence:
hybridization probe: 5'-GTGACTGTCCTCTGCAAGATAGTGCAGCCTGGCTACGGGA-3' (SEQ ID
N0:43).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened by PCR amplification with the PCR primer pair identified above. A
positive library was then used to isolate clones encoding the PR04357 gene using the probe oligonucleotide and one of the PCR primers. RNA
for construction of the cDNA libraries was isolated from human aortic endothelial cells.
DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PR04357; and the derived protein sequence for PR04357.
The entire coding sequence of PR04357 is shown in Figure 17 (SEQ ID N0:39).
Clone DNA84917-2597 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 286-288, and an apparent stop codon at nucleotide positions 1792-1794. The predicted polypeptide precursor is 502 amino acids long. Clone DNA84917-2597 has been deposited with ATCC and is assigned ATCC deposit no. 203863. The full-length PR04357 protein shown in Figure 18 has an estimated molecular weight of about 58,043 daltons and a pI of about 7.94.

An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 18 (SEQ ID
N0:40), revealed homology between the PR04357 amino acid sequence and the following Dayhoff sequences: P W48804, AF003534 66, ATAC00466519, LPSA BACNO, GELA DICDI, EHU70560 1, AF089841_1, ABP2 HMAN, P

and A49551.
EXAMPLr 13: Isolation of cDNA clones Encoding Human PR04405 A consensus DNA sequence was assembled relative to other EST sequences using repeated cycles of BLAST and phrap. This consensus sequence is designated herein "DNA80170".
Based on the DNA80170 consensus sequence, oligonucleotides were synthesized: I) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR04405.
PCR primers (forward and reverse) were synthesized:
forward PCR primer: 5'-CGGGACTTTCGCTACCTGTTGC-3' (SEQ :D N0:46) and reverse PCR primer: 5'-CATCATATTCCACAAAATGCTTTGGG-3' (SEQ ID N0:47).
Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus sequence which had the following nucleotide sequence:
hybridization probe: 5'-CCTTCGGGGATTCTTCCCGGCTCCCGTTCGTTCCTCTG-3' (SEQ ID
N0:48).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened by PCR amplification with the PCR primer pair identified above. A
positive library was then used to isolate clones encoding the PR04405 gene using the probe oligonucleotide and one of the PCR primers. RNA
for construction of the cDNA libraries was isolated from human fetal kidney.
DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PR04405 (designated herein as DNA84920-2614 [Figure 19, SEQ ID N0:441; and the derived protein sequence for PR04405.
The entire coding sequence of PR04405 is shown in Figure 19 (SEQ ID N0:44).
Clone DNA84920 2614 contains a single open reading frame with an apparent translationat initiation site at nucleotide positions 79-81, and an apparent stop colon at nucleotide positions 1009-101 I . The predicted polypepade precursor is 310 amino acids long. Clone DNA84920-2614 has been deposited with ATCC and is assigned ATCC deposit no. 203966. The full-length PR04405 protein shown in Figure 20 has an estimated molecular weight of about 33,875 daltons and a pI of about 7.08.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 20 (SEQ ID
N0:45), revealed homology between the PR04405 amino acid sequence and the following Dayhoff sequences (sequences and related text incorporated herein): YA93 SCHPO, 562432, YJG2 YEAST, AC004472 3, AB004539 7, 564782, CELC27A12 8, AFI09219_1, AF086791_I0, and P W75859.

EXAMPLE 14: Isolation of cDNA clones Encodine Human PR04356 A consensus DNA sequence was assembled relative to other EST sequences using phrap. asdescribed in Example 1 above. This consensus sequence is designated herein "DNA80200".
Based upon an observed homology between the DNA80200 consensus sequence and an EST sequence contained within Merck EST clone 248287, Merck EST clone 248287 was purchased and its insert obtained and sequenced, thereby providing DNA86576-2595.
The entire codiag sequence of PR04356 is shown in Figure 21 (SEQ ID N0:49).
Clone D.'~IA86576-2595 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 55-57, and an apparent stop codon at nucleotide positions 808-810. The predicted polypeptide precursor is 251 amino acids long. Clone DNA86576-2595 has been deposited with ATCC and is assigned ATCC deposit no.
203868. The full-length PR04356 protein shown in Figure 22 has an estimated molecular weight of about 26,935 daltons and a pI of about 7.42.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 22 (SEQ ID
NO:50), revealed homology between the PR04356 amino acid sequence and the following Dayhoff sequences incorporated herein: RNMAGPIAN_1, UPAR BOVIN, S42152, AF007789-1, UPAR RAT, UPAR MOUSE, P W31165, P W31168, P
844423 and P W26359.
EXAMPLE 15: Isolation of cDNA clones Encoding Human PR04352 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is designated herein "DNA83397".
Based on the DNA83397 consensus sequence, oligonucleotides were synthesized: 1) to identify by PCR a cDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR04352.
PCR primers (forward and reverse) were synthesized:
forward PCRprimer: 5'-CTGGGGAGTGTCCTTGGCAGGTTC-3' (SEQ ID N0:53) and reverse PCR priqter: 5'-CAGCATACAGGGCTCTTTAGGGCACAC-3' (SEQ ID N0:54).
Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA83397 sequence which had the following nucleotide sequence:
hybridization probe: 5'-CGGTGACTGAGGAAACAGAGAAAGGATCCTTfGTGGTCAATCTGGC-3' (SEQ
ID NO:55).
In order to screen several libraries for a source of a full-length clone, DNA
from the libraries was screened by PCR amplification with the PCR primer pair identified above. A
positive library was then used to isolate clones encoding the PR04352 gene using the probe oligonucleotide and one of the PCR primers. RNA
for construction of the cDNA libraries was isolated from human fetal brain.
DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for PR04352 (designated herein as DNA87976-2593 tFigure 23, SEQ ID NO:51 ); and the derived protein sequence for PR04352.

The entire coding sequence of PR04352 is shown in Figure 23 (SEQ ID NO:51).
Clone DNA87976-2593 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 179-181, and an apparent stop colon at nucleotide positions 2579-2581 of SEQ
ID NO:51. The predicted polypeptide precursor is 800 amino acids long. Clone DNA87976-2593 has been deposited with ATCC and is assigned ATCC deposit no. 203888. The full-length PR04352 protein shown in Figure 24 has an estimated molecular weight of about 87,621 daltons and a pI of about 4.77.
An analysis of thr, Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 24 (SEQ ID
N0:52), revealed homology between the PR04352 amino acid sequence and the following Dayhoff sequences: P 886865, P 886866, RATPCDH_ 1, AB011160_l, MMU88549 1, D86917_l, AB008179_l, P 858907, HSHFATPRO 1, and AF031572 1.
EXAMPLE 16: Isolation of cDNA clones Encodin~~Human PR04380 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST
cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al., Me in Enzvmoloev 266:460-480 ( 1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Green, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA79132. In light of DNA79I32, DNA92234-2602 was identified.
The full length clone shown in Figure 25 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 201-203 and ending at the stop colon found at nucleotide positions 1722-1724 (Figure 25; SEQ ID N0:56). The predicted polypeptide precursor (Figure 26, SEQ ID
N0:57) is 507 amino acids long. P804380 has a calculated molecular weight of approximately 56,692 daltons and an estimated pI of approximately 5.22.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 26 (SEQ ID
N0:57), revealed homology between the PR04380 amino acid sequence and the following Dayhoff sequences (sequences and related text incorporated herein): CER11H6 1, 556299, D89150 1, 670870, 543914, LM034616~5, LLU78036_1, AF055904_2, P W79066 and ARGE ECOLI.
Clone DNA92234-2602 was deposited with the ATCC and is assigned ATCC deposit no. 203948.
EXAMPLE 17: isolation of cDNA clones Encoding-Human PR04354 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST
cluster (92909) sequence designated herein as DNA10195. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST
databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST
or BLASTZ (Altshul et al., Methods in Enzvmoloey 266:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode lrnown proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Gt~een, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated as DNA56063. In light of DNA56063, DNA92256-2596 was identified.
The full length clone shown in Figure 27 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 108-110 and ending at the stop codon found at nucleotide positions 852-854 (Figure 27; SEQ ID N0:58). The predicted polypeptide precursor (Figure 28, SEQ ID
N0:59) is 248 amino acids long. P804354 has a calculated molecular weight of approximately 28,310 daltons and an estimated pI of approximately 4.63.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 28 (SEQ ID
N0:59), revealed homology between the PR04354 amino acid sequence and the following Dayhoff sequences incorporated herein: HGS RF300, CEVK04G11 2, CEC11H1 7, HSU80744_1, CEF09E8 2, RNAJ2967~1, DDICOI-1, AB020648 1, P W33887 and A64319.
Clone DNA92256-2596 was deposited with the ATCC on March 30, 1999 and is assigned ATCC
deposit no.203891.
EXAMPLE 18: Isolation of cDNA clones Encoding Human PR04408 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST
cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g. , GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Pato Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzvmolo_gv 266:460-480 ( 1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode (mown proteins were clustered and assembled into a consensus DN.1 sequ~ce with the program "phrap° (Phil Green, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA79298. In light of DNA79298, DNA92274-2617 was identified and sequenced in full.
The full length clone shown in Figure 29 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 89-91 and ending at the stop codon found at nucleotide positions 758-760 (Figure 29; SEQ ID N0:60). The predicted polypeptide precursor (Figure 30, SEQ ID N0:61) is 223 amino acids long. P804408 has a calculated molecular weight of approximately 25,402 daltons and an estimated ~t of apprc°~mately 8.14.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 30 (SEQ ID
N0:6I ), revealed homology between the PR04408 amino acid sequence and the following Dayhoff sequences: P 827897, P 849942, PBP RAT, CELF40A3 3, D10NCV0, PC4214, OV 16 ONCVO, P 827718, GEN 10789, and OBAS_DROME.
Clone DNA92274-2617 was deposited with the ATCC and is assigned ATCC deposit no. 203971.
EXAMPLE 19: Isolation of eDNA clones Encoding Human PR05737 An expressed sequence tag (EST) DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) was searched with a human interleukin-1 receptor antagonist (hIL-1Ra) sequence, and an EST sequence, designated herein as 1433156 was identified, which showed homology with the hIL-1 Ra known protein. EST
clone 1433156 was purchased from Incyte Pharmaceuticals (Palo Alto, CA) and the cDNA insert was obtained and sequenced in its entirety, giving the DNA92929-2534 sequence..
The entire nucleotide sequence of DNA92929-2534 is shown in Figure 31 (SEQ ID
N0:62). Clone DNA92929-2534 contains a single open reading frame with an apparent translational initiation site at nucieotide positions 96-98 and a stop codon at nucleotide positions 498-500 (Figure 31;
SEQ ID N0:62). The predicted polypeptide precursor (hIL-1 Ra2) is 134 amino acids long. The putative signal sequence extends from amino acid positions 1-17. Clone DNA92929-2534 was deposited with ATCC and was assigned ATCC deposit no. 203586.
The full-length hIL-lra2 protein shown in Figure 32 has an estimated molecular weight of about 14,927 daltons and a pI of about 4.8.
Based on a BLAST and FastA sequence alignment analysis (using the ALIGN-2 ~mputer program) of the full-length sequence, hIL-IRa2 (Figure 32, SEQ ID N0:63) shows significant amino acid sequence identity to hIL-lRap protein. hIL-lRa2 is believed to be a splice variant of hIL-lRa~.
EXAMPLE 20: Isolation Qf cDNA clones Encodin~,e Human PR04425 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST
cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.
g. , GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Aitshul et al., Methods in EnzymoloQV xøø:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Green, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA81099.
In light of an observed sequence homology between the DNA81099 sequence and an EST sequence contained within the EST clone no. AA448744, the EST clone AA448744 was purchased from Merck and the cDNA insert was obtained and sequenced. The sequence of this cDNA insert is shown in Figure 33 and is herein designated as DNA93011-2637.
The full length clone shown in Figure 33 contained a single open reading frame with ar apparent translational initiation site at nucleotide positions 27-29 and ending at the stop codon found at nucleotide positions 435-437 (Figure 33; SEQ ID N0:64). The predicted polypeptide precursor (Figure 34, SEQ ID N0:65) is 136 amino acids long. P804425 has a calculated molecular weight of approximately 15.577 daltons and an estimated *-trademark 152 WO 00!56889 PCT/US00/05601 pI of approximately 8.88.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 34 (SEQ ID
N0:65), revealed homology between the PR04425 amino acid sequence and the following Dayhoff sequences: HGS
RE295, S44655, YO18 CAEEL, VBRI CLVK, P 839520, P 865332, P 839388, TGL4 HUMAN, YKAB CAEEL, and S71105.
Clone DNA9301 I-2637 was deposited with the ATCC and is assigned ATCC deposit no. 20-PTA.
EXAMPLE 21: Isolation of cDNA clones Encoding_Human PR05990 A consensus DNA sequence was assembled relative to other EST sequences using phrap as described in Example 1 above. This consensus sequence is herein designated DNA86602.
Based on the DNA86602 consensus sequence, oligonucleotides were synthesized: I) to identify by PCR a eDNA library that contained the sequence of interest, and 2) for use as probes to isolate a clone of the full-length coding sequence for PR05990.
PCR primers (forward and reverse) were synthesized:
forward PCP primer: 5'-CGTCACAGGAACTTCAGCACCC-3' (SEQ ID N0:68) reverse PCR primer: 5'-GTCTTGGCTTCCTCCAGGTTTGG-3' (SEQ ID N0:69) Additionally, a synthetic oligonucleotide hybridization probe was constructed from the consensus DNA86602 sequence which had the following nucleotide sequence hybridization probe:
5'-GGACAGCGCTCCCCTCTACCTGGAGACTTGACTCCCGC-3' (SEQ ID N0:70) RNA for construction of the cDNA libraries was isolated from human fetal brain tissue.
DNA sequencing of the clones isolated as described above gave the full-length DNA sequence for a full-length PR05990 polypeptide (designated herein as DNA96042-2682 [Figure 35, SEQ
ID N0:66]) and the derived protein sequence for that PR05990 polypeptide.
The full length clone identified above contained a single open reading frame with an apparent translational initiation site at nucleotide positions 265-267 and a stop signal at nucleotide positions 1669-I671 (Figure 35, SEQ ID N0:66). The predicted polypeptide precursor is 468 amino acids long, has a calculated molecular weight of approximately 53,005 daltons and an estimated pI of approximately 4.98. Analysis of the full-length PR05990 sequence shown in Figure 36 (SEQ ID N0:67) evidences the presence of a variety of important polypeptide domains as shown in Figure 36, wherein the locations given for those important polypeptide domains are approximate as described above. Clone DNA96042-2682 has been deposited with ATCC on July 20, 1999 and is assigned ATCC deposit no. 382-PTA.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using the ALIGN-2 sequence alignment analysis of the full-length sequence shown in Figure 36 (SEQ ID
N0:67), evidenced sequence identity between the PR(~5990 amino aril sequence and the following Dayhoff sequences:
SG3 MOUSE; SG3~RAT;
GEN14673; ENHMHCAX 1; MYS2 DICDI; NFU43192_I; USO1 YEAST; A56577; PFLSA13_1;
CELF12F3 3.

EXAMPLE 22: Isolation of cDNA clones Encoding Human PR06030 Use of the signal sequence algorithm described in Example 3 above allowed identificatipn of an EST
cluster sequence from the LIFESEQ~ (Incyte Pharmaceuticals, Palo Alto, CA) database, designated herein as CLU20900. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g., Genbank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzymoloav 266:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode latown proteins were clustered and assembled into a consensus DNA
sequence with the program "phrap"
(Phil Green, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA81229.
In light of an observed sequence homology between the DNA81229 sequence and an EST sequence encompassed within clone no. 4020130H1 from the Incyte (Incyte Pharmaceuticals, Palo Alto, CA) database, clone no.4020130H 1 was purchased and the cDNA insert was obtained and sequenced. It was found herein that that cDNA insert encoded a full-length protein. The sequence of this cDNA
insert is shown in Figure 37 and is herein designated as DNA96850-2705.
Clone DNA96850-2705 contains a single open reading frame with an apparent translational initiation site at nucleotide positions 60-62 and ending at the stop codon at nucleotide positions 1026-1028 (Figure 37).
The predicted polypeptide precursor is 322 amino acids long (Figure 38). The full-length PR06030 protein shown in Figure 38 has an estimated molecular weight of about 34,793 daltons anal a pI of about 6.34. Analysis of the full-length PR06030 sequence shown in Figure 38 (SEQ ID N0:72) evidences the presence of a variety of important polypeptide domains as shown in Figure 38, wherein the locations given for those important polypeptide domains are approximate as described above. Clone DNA96850-2705 has been deposited with ATCC on August 3, 1999 and is assigned ATCC Deposit No. 479-PTA.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using the ALIGN-2 sequence alignment analysis of the full-length sequence shown in Figure 38 (SEQ ID
N0:72), evidenced sequence identity between the PR06030 amino acid sequence and the following Dayhoff sequences:
AF059571_l; I38346;
AF035835_I; P W83138; P 854714; P 865166; P P93995; BGPI HUMAN; P W06873;
A43165_l.
EXAMPLE 23: Isolation o~cDNA clones Encodine Human PR04424 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST
cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g.. GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al., M th s i Enzymology 266:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode lrnown proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Green, University of Washington, Seattle, Washington). The extended consensus sequence obtained therefrom is designated DNA80820. In light of DNA80820, DNA96857-2636 was identified and sequenced.
The full length clone shown in Figure 39 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 52-54 and ending at the stop codon found at nucleotide positions 715-717 (Figure 39; SEQ ID N0:73). The predicted polypeptide precursor (Figure ~0, SEQ ID N0:74) is 221 S amino acids long. P804424 has a calculated molecular weight of approximately 23,598 daltons and an estimated pI o1 approximately 6.96.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), us_ng a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 40 (SEQ ID
N0:74), revealed homology between the PR04424 amino acid sequence and the following Dayhoff sequences: HGS A135, JC5105, P 888555, JC5106, P 888556, CELR12E2 13, DMC34F3 8, ATG13D4 7, HGS A204, S58331.
Clone DNA96857-2636 was deposited with the ATCC and is assigned ATCC deposit no. 17-PTA.
EXAMPLE 24: Isolation of cDNA clones Encodine Human PR04422 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST
cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzvmoloev 266:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode Irnown proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Green, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA80134. In light of DNA80134, DNA96867-2620 was identified and sequenced in full.
The full length clone shown in Figure 41 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 318-320 and ending at the stop codon found at nucleotide positions 900-902 (Figure 41; SEQ ID N0:75). The predicted polypeptide precursor (Figure 42, SEQ ID
N0:76) is 194 amino acids long. P804422 has a calculated molecular weight of approximately 21,431 daltons and an estimated pI of approximately 8.57.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 42 (SEQ ID
N0:76), revealed homology between the PR04422 amino acid sequence and the following Dayhoff sequences: LYG
CHICK, LYG CYGAT, LYG ANSAN, LYG STRCA, P W69515, ATAC003680 7, ACCA HAEIN, I64065, A70853 and AF074611 71.
Clone DNA96867-2620 was deposited with the ATCC and is assigned ATCC deposit no. 203972.

EXAMPLE 25: Isolation of cDNA clones Encoding H~ uman PR04430 Use of the signal sequence algorithm described in Example 3 above allowed identificatiop of an EST
cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enzymologv_ 266:460-480 ( 1996)). Those comparisons resulting in a BLAST scor a of 70 (or io some cases 90) or greater that did not encode latown proteins were clustered and assembled in.o a consensus DNA sequence with the program "phrap" (Phil Green, University of Washington, Seattle, Washington). The extended consensus sequence obtained therefrom is herein designated DNA82380. In light of DNA82380, DNA96878-2626 was identified and sequenced.
The full length clone shown in Figure 43 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 56-58 and ending at the stop codon found at nucleotide positions 431-433 (Figure 43; SEQ ID N0:77). The predicted polypeptide precursor (Figure 44, SEQ ID N0:78) is 125 amino acids long. PR04430 has a calculated molecular weight of approximately 13,821 daltons and an estimated pI of approximately 8.6.
An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 44 (SEQ ID
N0:78), revealed homology between the PR04430 amino acid sequence and the following Dayhoff sequences: MMHC2I3L3 9, A45835, D45835, UPAR MOUSE, AF043498 1, P W62066, LY6C MOUSE, LY6A MOUSE, P R587I0, and P
R863I5.
Clone DNA96878-2626 was deposited with the ATCC and is assigned ATCC deposit no. 23-PTA.
EXAMPLE 26: Isolation of cDNA clones Encoding_Hu n~an PR04499 Use of the signal sequence algorithm described in Example 3 above allowed identification of an EST
cluster sequence from the Incyte database. This EST cluster sequence was then compared to a variety of expressed sequence tag (EST) databases which included public EST databases (e.g., GenBank) and a proprietary EST DNA database (LIFESEQ~, Incyte Pharmaceuticals, Palo Alto, CA) to identify existing homologies. The homology search was performed using the computer program BLAST or BLAST2 (Altshul et al., Methods in Enz oloev 2,x:460-480 (1996)). Those comparisons resulting in a BLAST score of 70 (or in some cases 90) or greater that did not encode lrnown proteins were clustered and assembled into a consensus DNA sequence with the program "phrap" (Phil Green, University of Washington, Seattle, Washington). The consensus sequence obtained therefrom is herein designated DNA81I55. In light of DNA81155, DNA96889-2641 was identified and sequenced.
'The full length clone shown in Figure 45 contained a single open reading frame with an apparent translational initiation site at nucleotide positions 185-187 and ending at the stop codon found at nucleotide positions 1202-1204 (Figure 45; SEQ ID N0:79). The predicted polypeptide precursor (Figure 46, SEQ ID
N0:80) is 339 amino acids long. PR04499 has a calculated molecular weight of approximately 36,975 daltons and an estimated p1 of approximately 7.85.

An analysis of the Dayhoff database (version 35.45 SwissProt 35), using a WU-BLAST2 sequence alignment analysis of the full-length sequence shown in Figure 46 (SEQ ID
N0:80), revealed homology between the PR04499 amino acid sequence and the following Dayhoff sequences: CEF38B7 4, D70575, AF073993_l, PNAPA_l, AF098967_1, AF007140-1, ROA3 HUMAN, E70969, CEY53C12B 5 and CEY53C12B
6.
Clone DNA96889-2641 was deposited with the ATCC and is assigned ATCC deposit no. 119-PTA.
EXAMPLE 27: Use of FRO as a hybridization probe The following method describes use of a nucleotide sequence encoding PRO as a hybridization probe.
DNA comprising the coding sequence of full-length or mature PRO as disclosed herein is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO) in human tissue cDNA libraries or human tissue genomic libraries.
Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled PRO-derived probe to the filters is performed in a solution of 50% formamide, Sx SSC, 0.196 SDS, 0.1 % sodium pyrophosphate, 50 mM sodium phosphate, pH
6.8, 2x Denhardt's solution, and 10 % dextran sulfate at 42°C for 20 hours. Washing of the filters is performed in an aqueous solution of 0. lx SSC and 0.1 % SDS at 42°C.
DNAs having a desired sequence identity with the DNA encoding full-length native sequence PRO can then be identified using standard techniques known in the art.
EXAMPLE 28: Expression of PRO in E. coli This example illustrates preparation of an unglycosyiated form of PRO by recombinant expression in E. coli.
The DNA sequence encoding PRO is initially amplified using selected PCR
primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is pBR322 (derived from E. coli; see Bolivar et al., Gene, 2_:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR
amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO coding region, lambda transcriptional terminator, and an argU gene.
The ligation mixture is then used to uansform a selected E, coli strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA
sequencing.
Selected clones can be grown overnight in liquid culture medium such as LB
broth supplemented with antibiotics. The overnight culture may subsequ~r.~ly be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.
PRO may be expressed in E. colt in a poly-His tagged form, using the following procedure. The DNA
encoding PRO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other usef.tl sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an E. colt host based on strain 52 (W3110 fuhA(to:~A) Ion galE rpoHts(htpRts) clpP(lacIq). Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 is reached.
Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH,)ZSO,, 0.71 g sodium citrate~2H20, 1.07 g KCI, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM
MPOS, pH 7.3, 0.55°6 (w/v) glucose and 7 mM MgSO,) and grown for approximately 20-30 hours at 30°C
with shaking. Samples are removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.
E. colt paste from 0.5 to 1 L fetmentations (6-10 g pellets) is resuspenaed in 10 volumes (w/v) in 7 M
guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1 M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step results in a denatured protein with all cysteine residues blocked by sulfitolization.
The solution is centrifuged at 40,000 rpm in a Beckman Ultracentifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal cheIate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM
imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containi~~g 250 mM
imidazole. Fractions containing the desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 ttm using the calculated extinction coefficient based on its amino acid sequence.
The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCI, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA.
Refolding volumes are chosen so that the final protein concentration is between SO to 100 micrograms/ml. The refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4 ~ (pH of approximately 3). Before further purification of the protein, the solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10~ final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column tvzg a mobile buffer of 0.196 TfA with elution with a gradient of acetonitriie from 10 to 80~. Aliquots of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled.
Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile *-trademark 158 since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.
Fractions containing the desired folded PRO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4'~ mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.
Many of the PRO polypeptides disclosed herein were successfully expressed as described above.
EXAMPLE 29: Expression of PRO in mammalian cells This example illustrates preparation of a potentially glycosylated form of PRO
by recombinant expression in mammalian cells.
The vector, ARKS (see EP 307,247, published March 15, 1989), is employed as the expression vector.
Optionally, the PRO DNA is ligated into pRKS with selected restriction enzymes to allow insertion of the PRO
DNA using ligation methods such as described in Sambrook et al., supra. The resulting vector is called pRKS-PRO.
In one embodiment, the selected host cells may be 293 cells. Htunan 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM
supplemented with fetal calf senun and optionally, nutrient components and/or antibiotics. About 10 /cg pRICS-PRO DNA
is mixed with about 1 beg DNA encoding the VA RNA gene [Thimtnappaya et al., Cell, 31:543 (1982)] and dissolved in 500 Nel of I mM
Tris-HCI, 0.1 mM EDTA, 0.227 M CaClz. To this mixture is added, dropwise, 500 p1 of 50 mM HEPES (pH
7.35), 280 mM NaCI, 1.5 mM NaPO,, and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20~ glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.
Approximately 24 hours after the transfections, the culture medium is removed and t~epla:,ed with culture medium (alone) or culture medium containing 200 ~cCi/ml'~S-cysteine and 200 ~cCi/ml uS-methiortine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 1596 SDS gel. The prod gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO polypeptide. The cultures containing transfected cells may undergo fitrther incubation (in serum free medium) and the medium is tested in selected bioassays.
In an alternative technique, PRO may be introduced into 293 cells transiently using the dextran sulfate method described by Somparyrac et al., Proc. Natl. Acad. Sci., 12:7575 (1981).
293 cells are grown to maximal dc-:~ity in a spinner flask and 700 Pg pRKS-PRO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are ueated with 2096 glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, S /cg/ml bovine insulin and *-trademark 159 0.1 /cg/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO can then be concentrated and purified by.any selected method, such as dialysis and/or column chromatography.
In another embodiment, PRO can be expressed in CHO cells. The pRKS-PRO can be transfected into CHO cells using known reagents such as CaPO, or DEAF-dextran. As described above, the cell cultures can S be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as 'SS-methionine. After determining the presence of PRO polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed PRO can then be concentrated and purified by any selec";d method.
Epitope-tagged PRO tray also be expressed in host CHO cells. The PRO may be subcloned out of the pRKS vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged PRO insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described 1S above, to verify expression. The culture medium containing the expressed poly-his tagged PRO can then be concentrated and purified by any selected method, such as by NiZ+-chetate affinity chromatography.
PRO may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO
cells by another stable expression procedure.
Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgGI constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.
Following PCR amplification, the respective DNAs are subcloned in a CHO
expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology, Unit 3.16, John 2S Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR
expression permits selection for stable maintenance of the plasmid following uansfection.
Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect' (Quiagen), Dosper~ or Fugene' (Boehringer Mannheim). The cells are grown as described in Lucas et al., ssuora.
Approximately 3 x 10'' cells are frozen in an ampule for further growth and production as described below.
The ampules containing the plasmid DNA are thawed by placement into v-~~er bath and -fixed by 3S vortexing. The contents are pipetted into a centrifuge tube containing 10 mLs of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2 ~cm filtered PS20 with 5% 0.2 ~m diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL

spinner containing 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, 250 mL, 500 tnl, and 2000 mL spinners are seeded with 3 x lOs cells/mL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A
3L production spinner is seeded at 1.2 x 106 cells/mL. On day 0, the cell number pH ie detetmtined. On day I, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 3590 polydimethylsiloxane emulsion, Dow C.~rning 365 Medical Grade Emulsion) taken.
Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70 % , the cell culture is harvested by centrifugation and filtering through a 0.22 um filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.
For the poly-His tagged constructs, the proteins are purified using a Ni-NTA
column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCI
and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazoIe. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCI and 4~
mannitol, pH 6.8, with a 25 ml G25 Superfine (Phatmacia) column and stored at -80°C.
Itnmunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Phatmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275 ~eL of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins, The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.
Many of the PRO polypeptides disclosed herein were successfully expressed as described above.
EXAMPLE 30: Expression of PRQ in Yeast The following method describes recombinant expression of PRO in yeast.
First, yeast expression vectors are constructed for intracellular production or secretion of PRO from the ADH2/GAPDH promoter. DNA encoding PRO and the promoter is inserted into suitable restriction enzyme sites in the selected plasmid to direct intracellular expression of PRO. For secretion, DNA encoding PRO can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH
promoter, a native PRO
signal peptide or other mamma'inn signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO.
Yeast cells, such as yeast strain AB 110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by *-trademark 161 precipitation with 10~ trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.
Recombinant PRO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing PRO may further be purified using selected column chromatography resins.
Many of the PRO polypeptides disclosed herein were successfully expressed as described above.
EXAMPLE 31: Expression of PRO in Baculovirus-Infected Insect Cells The following method describes recombinant expression of PRO in Bact.~lovirus-infected insect cells.
The sequence coding for PRO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG).
A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding PRO or the desired portion of the coding sequence of PRO such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.
Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGoIdT"" virus DNA (Pharmingen) into Spodoptera frugiperda ("SP9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released «iruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).
Expressed poly-his tagged PRO can then be purified, for example, by NiZ~-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, xø2_:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl2; 0.1 mM EDTA; 10~ glycerol; 0.196 NP-40; 0.4 M
KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted SO-fold in loading buffer (50 mM phosphate, 300 mM NaC~, 1096 glycerol, pH 7.8) and filtered through a 0.45 ~cm filter. A Nip'-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer.
The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline AZ~ with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM
phosphate; 300 mM NaCI, 10 ~ glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching A2~ baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collectc~ and analyzed by SDS-PAGE and silver staining or Western blot with Nip'-NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His,o tagged PRO are pooled and dialyzed against loading buffer.
*-trademark I62 WO 00/56889 PCTlUS00/05601 Alternatively, purification of the IgG tagged (or Fc tagged) PRO can be perfotined using known chromatography techniques, including for instance, Protein A or protein G
column chromatography.
Many of the PRO polypeptides disclosed herein were successfully expressed as described above.
EXAMPLE 32: Prevaration of Antibodies that Bind PRO
This example illustrates preparation of monoclonal antibodies which can specifically bind PRO.
Techniques for producing the monoclonal antibodies are known in tl:e an and are described, for insta.~ce, in Goding, a ea. Immunogens that may be employed include purified PkO, fusion proteins containing PRO, and cells expressing recombinant PRO on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.
Mice, such as Balb/c, are immunized with the PRO immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by recro-orbital bleeding for testing in ELISA assays to detect anti-PRO
antibodies.
After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of PRO. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35~ polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.l, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT
(hypoxanthine, anvnopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.
The hybridoma cells will be screened in an ELISA for reactivity against PRO.
Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PRO is within the skill in the art.
The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PRO monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.
EXAMPLE 33: Purification of PRO Polweptides Using Specific Antibodies Native or recombinant PRO polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-PRO polypeptide, mature PRO
polypeptide, or pre-PRO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the PRO polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO polypeptide antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB
Biotechnology, Piscataway, N.J.).
Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSET"" (Phatmacia LKB
Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.
Such an immunoaffinity column is utilized in the purification of PRO
Yolypeptide by preparing a fraction from cells containing PRO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PRO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.
A soluble PRO polypeptide-containing preparation is passed over the immunoaffmity column, and the column is washed under conditions that allow the preferential absorbance of PRO polypeptide (e.g., high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/PRO polypeptide binding (e.g. , a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO polypeptide is collected.
EXAMPLE 34: Drug Screening This invention is particularly useful for screening compounds by using PRO
polypeptides or binding fragment ther~f in any of a variety of drug screening techniques. The PRO
polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method oC drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PRO
polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the PRO polypeptide and its target cell or target receptors caused by the agent being tested.
Thus, the present invention provides methods of screening for drugs or any other agents which can affect a PRO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an PRO polypeptide or fragment thereof and assaying (1) for the presence of a complex between the agent and the PRO polypeptide or fragment, or (ii) for the presetux of a complex between the PRO polypeptide or fragment and the cell, by methods well known in the art. In such competitive binding assays, the PRO polypeptide or fragment is typically labeled. After suitable incubation, free PRO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO polypeptide or to interfere with the PRO polypeptide/cell complex.
Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984.

Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a PRO polypeptide, the peptide test compounds are reacted with PRO polypeptide and washed. Bound PRO polypeptide is detected by methods well Mown in the an.
Purified PRO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.
This invention tlso contemplates the use of competitive drug screeninh assays in which nwUraiizing antibodies capable of binding PRO polypeptide specifically compete with a test compound for binding to PRO
polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO polypeptide.
EXAMPLE 35: Rational Drue Desien The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (i.e., a PRO polypeptide) or of smalt molecules with which they interact, e.g., agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the PRO potypeptide or which enhance or interfere with the function of the PRO
polypeptide in vivo (cf., Hodgson, Bio/Technoloev, 9_: 19-Z1 (1991)).
In one approach, the three-dimensional structure of the PRO polypeptide, or of an PRO
polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the PRO
polypeptide must be ascertained to elucidate the structure and to determine active sites) of the molecule.
Less often, useful information regarding the structure of the PRO polypeptide may be gained by modeling based on the structure of homologous proteins.
In both cases, relevant structural information is used to design analogous PRO
polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, x:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda et al., J. Biochem., 113:742-746 ( 1993).
It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides wouid then act as the pharmacore.
By vinue of the present invention, sufficient amounts of the PRO polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PRO polypeptide amino acid sequence provided herein will provi~ic ;uidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

EXAMPLE 36: Chondrocyte Re-differentiation Assay (Assay 110) This assay shows that certain polypeptides of the invention act to induce redifferentiation of chondrocytes, therefore, are expected to be useful for the treatment of various bone and/or cartilage disorders such as, for example, sports injuries and arthritis. The assay is performed as follows. Porcine chondrocytes are isolated by overnight collagenase digestion of articulary cartilage of metacarpophalangeal joints of 4-6 month old female pigs. The isolated cells are then seeded at 25,000 cells/em= in Ham F-12 containing !0% F$S and 4 Pg/ml gentamycin. Thu culture media is changed every third day and the cells arc then seeded in 96 well plates at 5,000 cells/well in IOOpI of the same media without serum and 100 p.1 of the test PRO polypeptide, 5 nM staurosporin (positive control) or medium alone (negative control) is added to give a final volume of 200 pl/well. After 5 days of incubation at 37°C, a picture of each well is taken and the differentiation state of the chondr~cytes is determined. A positive result in the assay occurs when the redifferentiation of the chondrocytes is determined to be more similar to the positive control than the negative control.
The following polypeptide tested positive in this assay: PR01484, PR01890, PR01887, PR04353, PR04357, PR04405, PR05737 and PR05990.
IS EXAMPLE 37: Detection of Polypeptides That Affect Glucose or FFA Uptake in Skeletal Muscle (Assay 106) This assay is designed to determine whether PRO polypeptides show the ability to aff~t glucose or FFA
uptake by skeletal muscle cells. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of disorders where either the stimulation or inhibition of glucose uptake by skeletal muscle would be beneficial including, for example, diabetes or hyper- or hypo-insulinemia.
In a 96 well format, PRO polypeptides to be assayed are added to primary rat differentiated skeletal muscle, and allowed to incubate overnight. Then fresh media with the PRO
polypeptide and +/- insulin are added to the wells. The sample media is then monitored to determine glucose and FFA uptake by the skeletal muscle cells. The insulin will stimulate glucose and FFA uptake by the skeletal muscle, and insulin in media without the PRO potypeptide is used as a positive control, and a limit for scoring. As the PRO polypeptide being tested may either stimulate or inhibit glucose and FFA uptake, results are scored as positive in the assay if greater than 1.5 times or less than 0.5 times the insulin control.
The following PRO polypeptides tested positive as either stimulators or inhibitors of glucose and/or FFA
uptake in this assay: PR01484, PR01122, PR01889, PR04357 and PR04380.
EXAMPLE 38: Detection of PRO Polypeptides That Affect Glucose or FFA Uptake by Primary Rat Adipocvtes fAss~ 94Z
This assay is designed to determine whether PRO polypeptides show the ability to affect glucose or FFA
uptake by adipocyte cells. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of disorders where either the stimulation or inhibition < ''?lucose uptake by adipocytes would be beneficial including, for example, obesity, diabetes or hyper- or hypo-insulinemia.
In a 96 well format, PRO polypeptides to be assayed are added to primary rat adipocytes, and allowed to incubate overnight. Samples are taken at 4 and 16 hours and assayed for glycerol, glucose and FFA uptake.

WO 00!56889 PCT/US00/05601 After the 16 hour incubation, insulin is added to the media and allowed to incubate for 4 hours. At this time; a sample is taken and glycerol, glucose and FFA uptake is measured. Media containing insulin without the PRO
polypeptide is used as a positive reference control. As the PRO polypeptide being tested may either stimulate or inhibit glucose and FFA uptake, results are scored as positive in the assay if greater than 1.5 times or less than 0.5 times the insulin control.
The following PRO polypeptides tested positive as stimulators of glucose and/or FFA uptake in this assay: PR01890, PR01785 and PR04422.
The following PRO potypeptides tested positive as inhibitors of glucose and/or FFA uptake in this assay: PR04334, PR04425, PR04424 and PR04430.
EXAMPLE 39: Induction of Pancreatic [3-Cell Precursor Differentiation (Assay 89) This assay shows that certain polypeptides of the invention act to induce differentiation of pancreatic (3-cell precursor cells into mature pancreatic (i-cells and, therefore, are useful for treating various insulin deficient states in mammals, including diabetes mellitus. The assay is performed as follows. The assay uses a primary culture of mouse fetal pancreatic cells and the primary readout is an alteration in the expression of markers that represent either ~3-cell precursors or mature p-cells. Marker expression is measured by real time quantitative PCR (RTQ-PCR); wherein the marker being evaluated is insulin.
7 he pancreata are dissected from EI4 embryos (CDI mice). The pancreata are then digested with collagenase/dispase in F12/DMEM at 37°C for 40 to 60 minutes (collagenase/dispase, 1.37 mg/ml, Boehringer Mannheim, N1097113). The digestion is then neutralized with an equal volume of 5~ BSA and the cells are washed once with RPMI1640. At day 1, the cells are seeded into 12-well tissue culture plates (pre-coated with laminin, 20pg/ml in PBS, Boehringer Mannheim, X124317). Cells from pancreata from 1-2 embryos are distributed per well. The culture medium for this primary cuture is 14F/1640.
At day 2, the media is removed and the attached cells washed with RPMI/1640. Two mls of minimal media are added in addition to the protein to be tested. At day 4, the media is removed and RNA prepared from the cells and marker expression analyzed by real time quantitative RT-PCR. A protein is considered to be active in the assay if it increases the expression of the relevant (i-cell marker as compared to untreated controls.
14F/1640 is RPMI1640 (Gibco) plus the following:
group A 1:1000 group B 1:1000 recombinant human insulin 10 ~g/ml Aprotinin (SOp.g/ml) I :2000 (Boehringer manheim A'981532) Bovine pituitary extract (BPE) 60pg/ml Gentamycin 100 nglml Group A : .':n lOml PBS) Transferrin, 100mg (Sigma T2252) Epidermal Growth Factor, 100~g (BRL 100004) Triiodothyronine,10~1 of 5x10'' M (Sigma T5516) Ethanolamine, 100/d of 10'' M (Sigma E0135) Phosphoethalamine, 1001 of 10' M (Sigma P0503) Selenium, 4~1 of 10-' M (Aesar //12574) Group C : (in lOml 100 ethanol) Hydrocortisone, 2P1 of 5X10'' M (Sigma IIH0135) Progesterone, 100/cl of IX10~' M (Sigma 1!P6149) Forskolin, 500.1 of 20mM (Calbiochem 11344270) Minimal media:
RPMI 1640 plus transferrin ( 10 ~g/ml), insulin ( 1 xg/ml), gentamycin ( 100 ng/ml), aprotinin (SO ug, ~nl) and BPE ( I S pg/ml).
Defined media:
RPMI 1640 plus transferrin (10 ug/ml), insulin (I Pg/ml), gentamycin (100 ng/ml) and aprotinin (50 N~g/~).
The following polypeptides were positive in this assay: PR04356.
EXAMPLE 40. Fetal Hemoelobin Induction in an Erythrablastic Cell Line (Assay 107) This assay is useful for screening PRO polypeptides for the ability to induce the switch from adult hemoglobin to fetal hemoglobin in an erythroblastic cell line. Molecules testing positive in this assay are expected to be useful for therapeutically treating various mammalian hemoglobin-associated disorders such as the various thalassemias. The assay is performed as follows. Erythroblastic cells are plated in standard growth medium at 1000 cellslwell in a 96 welt format. PRO polypeptides are added to the growth medium at a concentration of 0.2~ or 2~ and the cells are incubated for 5 days at 37°C. As a positive control, cells are treated with 100~M hemin and as a negative control, the cells are untreated.
After 5 days, cell lysates are prepared and analyzed for the expression of gamma globin (a fetal marker). A
positive in the assay is a gamma globin level at least 2-fold above the negative control.
The following polypeptides tested positive in this assay: PR04352, PR04354, PR04408, PR06030 and PR04499.
EXAMPLE 41: Mouse Kidney Mesaneial Cell Proliferation Assay (Assay 92) This assay shows that certain polypeptides of the invention act to induce proliferation of mammalian kidney mesangial cells and, therefore, are useful for treating kidney disorders associated with decreased mesangial cell function such as Berger disease or other nephropathies associated with Schonlein-Henoch purpura, celiac disease, dermatitis Iterpetiformis or Crohn disease. The assay is performed as follows. On day one, mouse kidney mesangial cells are plated on a 96 well plate in growth media (3:
. mixture of DulLecco's modified Eagle's medium and Ham's F12 medium, 95°~ fetal bovine serum, 53'o supplemented ~~vth l4 mM H'"°ES) and grown overnight. On day 2, PRO polypeptides are diluted at 2 concentrations(1 ~~ and 0.1 '~) in serum-free medium and added to the cells. Control samples are serum-free medium alone. On day 4, 20.1 of the Cell Titer 96 Aqueous one~solution reagent (Progema) was added to each well and the colormetric reaction was allowed *-trademark 168 to proceed for 2 hours. The absorbance (OD) is then measured at 490 nm. A
positive in the assay is anything that gives an absorbance reading which is at least 15% above the control reading.
The following polypeptide tested positive in this assay: PR04380, PR04408 and PR04425.
Deposit of Material The following materials have been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD, USA (ATCC):
Table 7 Material ATCC Dep. No. Deposit Date DNA44686-1653203581 January 12, 1999 DNA59608-2577203870 March 23, 1999 DNA62377-1381203552 December 22, DNA77623-2524203546 December 22, DNA?9230-2525203549 December 22, DNA79862-2522203550 December 22, DNA80136-2503203541 December 15, DNA80145-2594204-PTA June 8, 1999 DNA84917-2597203863 March 23, 1999 DNA84920-2614203966 April 27, 1999 DNA86576-2595203868 March 23, 1999 DNA87976-2593203888 March 30, 1999 DNA93234-2602203948 April 20, 1999 DNA92256-2596203891 March 30, I999 DNA92274-2617203971 April 27, 1999 DNA92929-2534203586 January 12, 1999 DNA93011-263720-PTA May 4, 1999 DNA96042-2682382-PTA July 20, 1999 DNA96850-2705479-PTA August 3, 1999 DNA96857-263617-PTA May 4, 1999 DNA96867-2620203972 April 27, 1999 DNA96878-262623-PTA May 4, 1999 DNA96899-2641119-PTA May 25, 1999 These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S.
patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny ' ~ he assignee of the presern application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to he construed as a license to practice the invention in contravention of the rights granted under the authority of any goverrunent in accordance with its patent laws.
The foregoing written specification is considered to be sufficient to enable one skilled in the att to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

Claims

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence shown in Figure 38 (SEQ
ID NO:72).

2. Isolated nucleic acid having at least 85% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence shown in Figure 38 (SEQ
ID NO:72).

3. Isolated nucleic acid having at least 90% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence shown in Figure 38 (SEQ
ID NO:72).

4. Isolated nucleic acid having at least 95% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence shown in Figure 38 (SEQ
ID NO:72).

5. Isolated nucleic acid that encodes an amino acid sequence shown in Figure (SEQ ID NO:72).

6. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence shown in Figure 37 (SEQ ID NO:71).

7. Isolated nucleic acid having at least 85% nucleic acid sequence identity to a nucleotide sequence shown in Figure 37 (SEQ ID NO:71).

8. Isolated nucleic acid having at least 90% nucleic acid sequence identity to a nucleotide sequence shown in Figure 37 (SEQ ID NO:71).

9. Isolated nucleic acid having at least 95% nucleic acid sequence identity to a nucleotide sequence shown in Figure 37 (SEQ ID NO:71).

10. Isolated nucleic acid having the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

11. Isolated nucleic acid having at least 80% nucleic acid sequence identity to the full-length coding sequence of the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

12. Isolated nucleic acid having at least 85% nucleic acid sequence identity to the full-length coding sequence of the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

13. Isolated nucleic acid having at least 90% nucleic acid sequence identity to the full-length coding sequence of the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

14. Isolated nucleic acid having at least 95% nucleic acid sequence identity to the full-length coding sequence of the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

15. Isolated nucleic acid having the full-length coding sequence of the nucleotide sequence shown in Figure 37 (SEQ ID NO:71).

16. A vector comprising the nucleic acid of any one of Claims 1 to 15.

17. The vector of Claim 16 operably linked to control sequences recognized by a host cell transformed with the vector.

18. A host cell comprising the vector of Claim 17.

19. The host cell of Claim 18, wherein said cell is a CHO cell.

20. The host cell of Claim 18, wherein said cell is an E. coli.

21. The host cell of Claim 18, wherein said cell is a yeast cell.

22. A process for producing a PRO6030 polypeptide (SEQ ID NO:72) comprising culturing the host cell of Claim 18 under conditions suitable for expression of said PRO6030 polypeptide and recovering said PRO6030 polypeptide from the cell culture.

23. An isolated polypeptide having at least 80% amino acid sequence identity to the amino acid sequence shown in Figure 38 (SEQ ID NO:72).

24. An isolated polypeptide having at least 85% amino acid sequence identity to the amino acid sequence shown in Figure 38 (SEQ ID NO:72).

25. An isolated polypeptide having at least 90% amino acid sequence identity to the amino acid sequence shown in Figure 38 (SEQ ID NO:72).

26. An isolated polypeptide having at least 95% amino acid sequence identity to the amino acid sequence shown in Figure 38 (SEQ ID NO:72).

27. An isolated polypeptide having the amino acid sequence shown in Figure 38 (SEQ ID NO:72).

28. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid encoded by the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

29. An isolated polypeptide having at least 85% amino acid sequence identity to an amino acid encoded by the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

30. An isolated polypeptide having at least 90% amino acid sequence identity to an amino acid encoded by the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

31. An isolated polypeptide having at least 95% amino acid sequence identity to an amino acid encoded by the nucleotide sequence shown in Figure 37 (SEQ ID
NO:71).

32. An isolated polypeptide having an amino acid encoded by the nucleotide sequence shown in Figure 37 (SEQ ID NO:71).

33. A chimeric molecule comprising a polypeptide according to any one of Claims 23 to 32 fused to a heterologous amino acid sequence.

34. The chimeric molecule of Claim 33, wherein said heterologous amino acid sequence is an epitope tag sequence.

35. The chimeric molecule of Claim 33, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

36. An antibody which specifically binds to a polypeptide according to any one of Claims 23 to 32.

37. The antibody of Claim 36, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

38. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:
(a) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), lacking its associated signal peptide; or (b) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), with its associated signal peptide.

39. Isolated nucleic acid having at least 85% nucleic acid sequence identity to:
(a) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), lacking its associated signal peptide; or (b) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), with its associated signal peptide.

40. Isolated nucleic acid having at least 90% nucleic acid sequence identity to:
(a) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), lacking its associated signal peptide; or (b) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), with its associated signal peptide.

41. Isolated nucleic acid having at least 95% nucleic acid sequence identity to:
(a) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID

NO:72), lacking its associated signal peptide; or (b) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), with its associated signal peptide.

42. Isolated nucleic acid having:
(a) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), lacking its associated signal peptide;or (b) a nucleotide sequence encoding the polypeptide shown in Figure 38 (SEQ ID
NO:72), with its associated signal peptide.

43. An isolated polypeptide having at least 80% amino acid sequence identity to:
(a) the polypeptide shown in Figure 38 (SEQ ID NO:72), lacking its associated signal peptide; or (b) a polypeptide shown in Figure 38 (SEQ ID NO:72), with its associated signal peptide.

44. An isolated polypeptide having at least 85% amino acid sequence identity to:
(a) the polypeptide shown in Figure 38 (SEQ ID NO:72), lacking its associated signal peptide; or (b) a polypeptide shown in Figure 38 (SEQ ID NO:72), with its associated signal peptide.

45. An isolated polypeptide having at least 90% amino acid sequence identity to:
(a) the polypeptide shown in Figure 38 (SEQ ID NO:72), lacking its associated signal peptide; or (b) a polypeptide shown in Figure 38 (SEQ ID NO:72), with its associated signal peptide.

46. An isolated polypeptide having at least 95% amino acid sequence identity to:
(a) the polypeptide shown in Figure 38 (SEQ ID NO:72), lacking its associated signal peptide; or (b) a polypeptide shown in Figure 38 (SEQ ID NO:72), with its associated signal peptide.

47. An isolated polypeptide selected from:
(a) the polypeptide shown in Figure 38 (SEQ ID NO:72), lacking its associated signal peptide; or (b) a polypeptide shown in Figure 38 (SEQ ID NO:72), with its associated signal peptide.

48. The use of a polypeptide according to any one of claims 23 to 32 or 43 to 47 for treating hemoglobin associated disorders.